Statin therapy in diabetic dyslipidemia : efficacy and mechanisms by Berk-Planken, I.I.L. (Ingrid)
Statin therapy in diabetic dyslipidemia 
Efficacy and mechanisms 
Ingrid I.L Berk-Planken 
Cover: "Dali puzzle" Ingrid Berk-Planken & Nathalie van Eijk 
Lay-out: Nathalie van Eijk, Erix- erix70@tiscali.nl, Rotterdam 
Printed by: Print Partners Ipskamp B.V: (info@ppi.nl). Enschede 
ISBN nr: 90-9016549-5- © Ingrid I.L. Berk-Planken. 
Statin therapy in diabetic dyslipidemia 
Efficacy and mechanisms 
Statine therapie bij diabetische dyslipidemie 
Efficientie en mechanismen 
Proefschrift 
ter verkrijging van de graad van doctor aan de Erasmus U niversiteit Rotterdam 
op gezag van de Rector Magnificus Prof.dr.ir. J.H. van Bemmel en 
volgens besluit van het College voor Promoties. 
De open bare verdediging zal plaatsvinden op 
Woensdag 12 februari 2003 om 15.45 uur. 
door 
Ingrid Ingeborg Louise Berk-Planken 
geboren te Brielle. 
Promotiecommissie 
Promoter : Prof.dr. H. Jansen 
Copromotoren : Dr. A. H. Bootsma 
Dr. N. Hoogerbrugge- van der Linden 
Overige !eden: Prof.dr. G.J. Bruining 
Prof.dr. H.A.P. Pols 
Prof.dr. J .A. Romijn 
Financial support by Pfizer, Novo Nordisk. MSD, Aventis Pharma, Lilly, 
Sanofi-Synthelabo, GlaxoSmithKline Beecham, AstraZeneca and the Dutch 
Diabetes Fund for the publication of this thesis is gratefully acknowledged. 
Aan Luuk 
Aan mijn ouders 
List of abbreviations: 
ApoA1 
ApoB-100 
ApoC-111 
A10 
A So 
BMI 
CETP 
CHD 
DALI 
FFA 
HbA1c 
HDL 
HL 
HMG-CoA 
IDL 
LDL 
L/PC 
LpB:CIII 
LPL 
TC 
TG 
TRL 
VLDL 
WHR 
Apolipoprotein A1 
Apolipoprotein B 
Apolipoprotein C-111 
Atorvastatin 1omg 
Atorvastatin Somg 
Body Mass Index 
Cholesterol Ester Transfer Protein 
Coronary Heart Disease 
Diabetes Atorvastatin Lipid Intervention study 
Free Fatty Acid 
Glycosylated hemoglobin 
High-density lipoprotein 
Hepatic Lipase 
Hydroxymethylglutaryl coenzyme A 
Intermediate-density lipoprotein 
Low-density lipoprotein 
Human hepatic lipase gene. 
ApoC-111 and apoB-containing lipoprotein particles 
Lipoprotein Lipase 
Total cholesterol 
Triglyceride 
Triglyceride-rich lipoproteins 
Very low-density lipoprotein 
Waist-to-Hip ratio 

Contents 
Chapter 1 Introduction 11 
l.l General introduction 12 
1.2 Diabetic dyslipidemia 13 
1.3 Treatment of lipid disorders in type 2 diabetes mellitus 14 
lA The role of hepatic lipase (HL) in the 
lipoprotein metabolism 15 
1.5 Factors influencing HL activity 17 
1.6 Lipid lowering therapy and the effect on HL activity 18 
1.7 The role of lipoprotein lipase (LPL) in the 
lipoprotein metabolism 18 
1.8 Factors influencing LPL activity 20 
1.9 Lipid lowering therapy and the effect on LPL activity 20 
1.10 The role of apolipoprotein (apo)C-III in the 
lipid metabolism 21 
1.11 Lipid lowering therapy and the effect on apoC-lll 22 
1.12 HL, LPL and apoC-III in diabetic dyslipidemia 
as target for therapy ?~ ~.:> 
1.13 Aim of the thesis 24 
1.14 Description of chapters 24 
1.15 References 25 
Chapter 2 The effect of aggressive versus standard lipid 
lowering by atorvastatin on diabetic dyslipidemia. 
The DALI study: a double blind randomized 
placebo-controlled trial in patients with 
type 2 diabetes mellitus and diabetic dyslipidemia. 35 
Chapter 3 Atorvastatin decreases hepatic lipase activity in type 2 
diabetes mellitus dose-dependently. Effect of 
gender and the LIPC promoter variant. 55 
Chapter4 Genetic variation in the lipoprotein lipase gene in 
type 2 diabetes and the effect of atorvastatin on 
lipid profiles. 71 
Chapter 5 Atorvastatin decreases atherogenic LpB: 
CIII in type 2 diabetes mellitus, a mechanism to 
lower plasma triglycerides. 89 
Chapter 6 Gender specific etiology of low HDL in diabetic 
dyslipidemia. 103 
Chapter 7 Low-density lipoprotein subfractions are reduced by 
aggressive lipid lowering in patients with type 2 
diabetes mellitus. 119 
ChapterS Effect of atonrastatin on cognitive functioning in 
hyperlipidemic patients with type 2 diabetes mellitus. 137 
Chapter 9 Discussion 151 
Chapter 10 Summary 161 
Chapter 11 Sam en vatting 165 
Chapter 12 Dankwoord 171 
Curriculum vitae 175 

Introduction 
1: introduction 
1.1 General Introduction 
It has been estimated that in the year 2010 there will be more than 220 million 
patients with diabetes mellitus worldwide (1). About 90% of these patients will have 
diabetes mellitus type 2. In the Netherlands, it is expected that the number of 
patients will have doubled to 500.000 patients (2). Type 2 diabetes is associated with 
high morbidity and mortality from macro- and microvascular complications. 
Atherosclerosis is the cause of death in 75-80% of adults with type 2 diabetes (3). At 
diagnosis, 30% of the patients have already some evidence of established coronary 
heart disease (4). Diabetes itself is a strong, independent risk factor for death from 
cardiovascular disease ( 5), and besides hyperglycemia, specific diabetic risk factors 
like endothelial dysfunction, glycation of proteins, and coa,oulation abnormalities 
may contribute (6). Several other atherosclerotic risk factors are combined in type 
2 diabetes, like dyslipidemia, hypertension and obesity (7). 
Although diabetic dyslipidemia is an established risk factor for cardiovascular 
disease, there is still a lack of information about the pathogenetic mechanism and the 
effect of hypolipidemic treatment. HMG CoA reductase inhibitors (statins) 
effectively lower total cholesterol (TC), low-density lipoprotein (LDL) and 
triglycerides (TG) in type 2 diabetes. Besides a decrease in hepatic production of 
very low-density lipoprotein (VLDL) and LDL-C, statins reduce TC and LDL-C 
through a LDL-receptor-mediated clearance. The mechanism by which statins 
lower plasma TG is still not completely understood. Regulators of TG and HDL-C 
plasma levels and of HDL and LDL subclasses composition are lipolytic enzymes, 
apolipoproteins, lipid transfer proteins, receptors and cellular transporters. Is it 
possible that these enzymes and proteins are potential targets for lipid-lowering 
therapy and if so, by which mechanism? This thesis will mainly focus on the effect 
of atorvastatin on hepatic lipase (HL), lipoprotein lipase (LPL) and apolipoprotein 
(apo)C-Ill, that may be key factors in the pathogenesis of lipoprotein abnormalities 
in type 2 diabetes. Other important aspects of the influence of statin therapy in 
patients with diabetic dyslipidemia, "'~ll be evaluated as well. The effect of 
atorvastatin on LDL subfractions will be described, since qualitative differences in 
lipoproteins may lead, besides quantitative differences, to the increased risk of 
coronary heart disease (CHD) in type 2 diabetes. The intriguing question whether 
there are gender differences in etiology of diabetic dyslipidemia that may contribute 
to the equalization of cardiovascular disease risk in men and women, will also be 
evaluated. Furthermore, if diabetic dyslipidemia indeed contributes to cognitive 
impairment, h_ypolipidemic treatment may result in improvement of cognitive 
functioning in patients with type 2 diabetes. Since most of these patients will 
eventually receive hypolipidemic treatment, studying the possible beneficial side-
effect oflipid-lowering is of clinical interest as well. 
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1.2 Diabetic dyslipidemia 
Type 2 diabetic dyslipidemia 1s characterized by elevated TG, low HDL-C, 
excessive postprandial lipemia and accumulation of remnant lipoprotein particles. 
These lipid derangements are intrinsically related to the abnormal physiology 
produced by insulin resistance or inadequate insulin action and concomitant 
metabolic disturbances. A main cause of the elevated TG concentration is 
overproduction of VLD L in the liver, provoked by an increased flow of glucose and 
free fat1y acids (FFA) to the liver. Additionally, there may be reduced catabolism of 
the triglyceride rich lipoproteins (TRLs), including VLDL and chylomicrons, due to 
the altered activity of LPL. LPL in adipose tissue is controlled by insulin and its 
activity may be reduced by prolonged insulin deficiency or decrease in insulin action 
(8). In a non-fasting state, there will be a competition between circulating VLDL 
particles and postprandially synthesized chylomicrons for the action of LPL. 
Together with the overproduction of VLDL in type 2 diabetes, this competition 
between TRLs may lead to enhanced postprandial lipemia (9,10). 
In addition to qualitative effects, quantitative changes in lipoproteins have also been 
observed. The VLDL composition may be changed, the particles are larger and TG 
enriched. The larger VLDL particles are the precursors of the atherogenic small 
dense LDL particles that are more readily engulfed by macrophages and taken into 
the arterial wall. These small dense LD L particles are more atherogenic than the 
larger, more buoyant particles by increased oxidation, increased affinity for the 
arterial wall and decreased clearance via the LDL-receptor pathway (! 1). The 
modified LDL particles bind less well to the LDL-receptor on the liver and may 
leave the circulation via the LDL scavenger receptors present on endothelial cells 
and macrophages (12). Furthermore small dense LDL particles have a tendency to 
induce free radical release (13). Taskinen et al (14) showed an association between 
LDL particle size and endothelial dysfunction suggesting increased atherogenicity, 
even at normal levels of LDL-cholesterol in type 2 diabetes. Hypertriglyceridemia 
also has important consequences for HDL metabolism, since TG metabolism is 
strongly related to HDL levels. If TG levels increase, numbers of HDL particles 
decrease. This is partly e"--plained by an increased catabolic rate of HDL. LPL, HL 
and cholesterol ester transfer protein (CETP) are the main modulators of HDL-C. 
These modulators may be affected in type 2 diabetes. The rate of cholesteryl ester 
transfer, mediated by CETP, between HDL and the apolipoprotein B-containing 
lipoproteins is enhanced during hypertriglyceridemia due to an elevated 
concentration of apolipoprotein B-containing lipoproteins (15,16). In diabetic 
dyslipidemia the HDL particles are often smaller and more dense. This is partly due 
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to the e;q>anded VLDL pool and to CETP over-activity resulting in an increased 
neutral lipid exchange. This subsequently leads to TG enrichment of both HDL and 
LDL. The smaller and denser HDL particles have altered physiological functions. 
The reverse cholesterol transfer capacity may be diminished and the antioxidant 
potential may be reduced. This will eventually interfere with the anti-atherogenic 
potential of HDL. The effect of therapeutic intervention on some aspects of these 
pathophysiological alterations in diabetes that may lead to diabetic dyslipidemia will 
be evaluated in this thesis. 
n Treatment of lipid disorders in type 2 diabetes mellitus 
Although there is controversy about how aggressively to treat cardiovascular risk 
factors in patients with diabetes, they are at high risk and it has been argued that 
diabetics should be treated as if they have established CHD (17). Besides 
hypertension, diabetic dyslipidemia has emerged as a prevalent and modifiable 
atherogenic risk factor. Optimal lipid lowering in type 2 diabetes should focus on 
lowering of LDL-C and plasma TG levels and increasing HDL-C levels, since 
increased plasma TG and LDL-C levels and decreased HDL-C levels are all 
associated with increased risk for cardiovascular morbidity and mortality (11,18). 
Statins, as well as fibrates are used for therapeutic treatment of diabetic 
dyslipidemia. Post-hoc analyses of large, clinical trials, have shown that statins 
reduce the incidence of cardiovascular events in diabetic patients with prior CHD 
(19-21). These secondary prevention trials differ in relative risk-reduction (19%-
55%). Recently, results of the Heart Protection Study (22), showed a 12% reduction 
in total mortality, a 18°/o reduction in vascular mortality, a 24% reduction in CHD 
events, a 27o/o reduction in all strokes and a 16% reduction in non-coronary 
revascularisations in more than 20.5000 patients at high risk for CHD. There were 
5963 patients with diabetes of whom 3985 had no history of CHD. Other large 
prevention trials in patients with diabetes are currently ongoing (23,24) and may 
probably raise evidence to lower target levels below those recommended in current 
treatment guidelines and whether or not aggressive treatment of dyslipidemia leads 
to primar:y prevention of cardiovascular events in patients vvith type 2 diabetes. 
Although fibrates lower plasma TG and increase HDL-C levels, intervention studies 
using fibrate therapy in patients with diabetes, did not show conclusive evidence 
with respect to reduction of cardiovascular events (25,26). 
Based on present evidence (19-21), the American Diabetes Association (ADA) and 
the National Cholesterol Education Program (NCEP) have extracted guidelines 
with target values for plasma lipid levels in patients with diabetes (27,28), LDL-C < 
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2.60 mmolJI. HDL-C >1.15 mmolJI and TG <2.3 mmolJI. To increase patient 
compliance, therapy should be simple and effective, so treatment with only one drug 
is preferred over a combination of drugs. Statins not only reduce LDL-C by 30-40%, 
but recent studies have shown that statins in adequate dosages lower TG levels and 
slightly increase HDL-C levels as well (29). These data are derived from small 
studies and most of these studies were done in subjects without diabetes. It is likely 
that newer and more potent statins and higher dosages of older statins vvith proven 
clinical efficacy, are beneficial for diabetic patients with dyslipidemia. Therefore, in 
this thesis the effect of low and high dose statin therapy on the diabetic lipid proftie 
"-ill be evaluated. 
Moreover, the mechanisms of action of statins on lipid metabolism are not fully 
understood. Insight in these mechanisms may help to better understand the 
contribution of statins to cardiovascular risk reduction in patients vvith diabetes and 
may also add to a further improvement of therapeutic interventions. It is therefore 
that the physiological roles and the pathophysiology in diabetes of some key factors 
in lipid metabolism are under study in this thesis and will be discussed in the next 
paragraphs of this introduction. 
1.4 The role of hepatic lipase CHL) in the lipoprotein metabolism 
Hepatic lipase (HL) is a glycoprotein synthesized in hepatocytes. Breedveld et a! 
(30) showed that a major portion of HL in the liver is located on luminal surfaces of 
sinusoidal endothelium and on the surfaces of hepatocytes, consistent with the 
functions of this enzyme in lipoprotein metabolism. HL is involved in the 
metabolism of several lipoproteins by catalysing the hydrolysis of lipoprotein TG 
and phospholipids (31). 
HL, a key player in HDL metabolism, is usually inversely correlated with HDL-C 
levels (32,33) (Figure 1). Hydrolysis of phospholipids and TG by HL, leads to the 
conversion of large, buoyant HDL2 to small. dense HDL3 and may induce 
cholesterol (ester) flux to the liver (34,35). In this way HL may be involved in the 
reverse cholesterol transport (32). HL promotes the uptake of HDL-C, either 
directly and! or by facilitating uptake via lipoprotein receptors, and may therefore 
lower HDL-C levels (36,37). In hypertriglyceridemic conditions, such as type 2 
diabetes, HDL is more enriched in TG, due to a transfer of cholesterol ester to apoB-
containing lipoproteins in exchange for TG. HDL-TG is a substrate for HL and 
hydrolysis of HDL-TG by HL results in delipidation of HDL, which is more prone 
to degradation than lipid-rich HDL (31.37). Therefore, the effect of HL on the 
HDL metabolism during hypertriglyceridemia is unfavorable. HL plays an 
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important role in the formation of LDL from small VLDL and atherogenic IDL 
(Figure 2). It modulates the compositional properties of LDL and contributes to the 
expression of the LDL subclass phenotype. In non-hyperttiglyceridemic conditions, 
the amount of VLDL-TG exchange may be the limiting factor, determining LDL-
size (38,39), but in hypertriglyceridemic conditions there is an excess of LDL-TG 
and small dense LDL may be formed as a result of lipolytic action of HL on TG-
enriched LDL. Finally, HL is proposed to be involved in post-prandial lipid cleating 
(40-42). HL may influence chylomicron-remnant removal via hydrolysis of the 
remnant phospholipids, thereby enhancing the binding of the particles to apoE-
recognizing receptors and by acting as a ligand protein for chylomicron-remnant 
binding to the liver. 
In conclusion, the effect of HL activity as a determinant of HDL and LDL 
metabolism and phenotype, may differ in hypertriglyceridemic situations, like in 
type 2 diabetes, compared vvith normotriglyceridemic situations. 
Figure 1 The role of hepatic lipase in HDL metabolism 
HDL3 HDL2 
LCAT HL ~o 0 Liver 
FC HL / CE 
FC/CE 
=-~ /_~ 0 0 TG HDL3 CE 
VLDL 
Small HDL3 accepts cholesterol from tissues and LCAT converts free cholesterol (FC) to 
cholesterol ester (CE). HDL becomes larger and more spherical (HDL2). This large CE-
rich HDL is a substrate for HL. HL stimulates HDL cholesterol uptake by hepatocytes. lf 
TG-rich lipoproteins are present, denoted here as VLDL, CETP transfers cholesterol from 
HDL and TG from TG-rich lipoproteins. HL then hydrolyzes HDL2 TG and 
phospholipid and converts HDL2 back to smaller HDL3. Alternatively the HDL particle 
after HL and CETP action may be eliminated. 
Figure 2 Formation and metabolism of small, dense 
LDL 
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If plasma TG exceeds levels> 1.5 mmoi!L, there is sufficient CETP mediated TG 
movement from VLDL! to LDL (poSSibly IDL) to promote hydrolysis of the LDL (or 
IDL) triglyceride core by HL. The resulting small, dense LDL bas a rela!ively slow 
clearance from plasma and will accumulate. In the absence ofhigh TG levels. LDL-TG is 
not a preferred substrnte for HL and LDL remains larger and more buoyant. Large LDL 
will be rapidly cleared via the LDL-receptors. The dotted pathway indiCa!es that TG 
transfer may occur through a HDL intermediary. 
1.5 Factors influencing H L activity 
HL activity shows large inter-individual variation. Several factors contribute to this 
variability like inheritance, sex steroid hormones, diabetes and adiposity (43-46). 
In the human hepatic lipase gene (indicated as LIPC), variants are found that affect 
the lipase activity (47-49). Besides rather rare variants leading to complete HL 
deficiency (50-52), common base substitutions in the proximal LIPC promoter affect 
HL activity up to 2 fold (46, 53-55). There are two alleles, indicated as the LIPC C 
and T allele, that are associated with high and low HL activity, respectively. 
The frequency of both alleles varies highly among different ethnic populations 
(53,56-59). The C allele is the most common allele in Caucasians, whereas the T 
allele is the major allele in black Americans. Asians contain an intermediate 
frequency. 
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Besides genetic variance, HL lipase activity is hormonally determined. In particular 
sex hormones influence LIPC e>q,ression. They are held responsible for lower HL 
activity in women than in men (43,60). Recently, Brunzell et al (61) showed that 
intra-abdominal fat is a major component of the gender difference in HL activity. 
HL activity is associated with omental fat mass, BMI, fasting insulin and fasting 
plasma triglycerides (62). These correlations are reflected in a high HL activity in 
type 2 diabetes. Baynes et al ( 63), also demonstrated that insulin resistance and 
hyperinsulinemia are both associated with higher levels of HL activity, which 
probably promotes aspects of the lipoprotein profile in patients with type 2 diabetes. 
Whether the increase in HL activity in type 2 diabetes mellitus is modulated by 
genetic factors is as yet unknown. 
1.6 Lipid lowering therapy and the effect on H L activitv 
Intervention on HL activity is a potential therapeutic tool, since it may increase 
LDL buoyancy, increase HDL-C levels and modifY HDL composition, resulting in 
amelioration of coronary risk in patients with diabetes mellitus. Some available 
hypolipidemic drugs have been shown to induce these changes in HL activity. 
Hoogerbrugge et al ( 64) found a decrease in HL activity during atorvastatin 
treatment of familial hypercholesterolemia. Zambon and coworkers (65) reported a 
drop in HL activity in participants of the FATS study, patients with documented 
coronary disease, upon treatment vvith lovastatin~colestipol and niacin~colestipol. 
Interestingly, the effect of the treatment was strongly dependent on the presence of 
the L!PC T allele. In carriers of this allele, the treatment effect on HL activity was 
less compared to non~carriers. Thus, the genotype of the LIPC promoter seems to 
determine the efficacy of the statin treatment. This is of interest as these authors also 
showed that lowering of the HL activity was accompanied by regression of the 
vascular disease. Zambon and coworkers, therefore, identified HL as a focal point 
for the development and treatment of CHD (66). Today, no data describing the 
effect of statins on HL activity in type 2 diabetes are available. In this thesis the 
effect of atorvastatin on HL activity in patients with type 2 diabetes will be 
described. 
1.7 The role of lipoprotein lipase CLPL) in the lipoprotein 
metabolism 
Lipoprotein lipase (LPL) is an enzyme bound to glycosaminoglycans on the surface 
of the endothelium in muscle and adipose tissue. The major sites of LPL synthesis 
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are the skeletal and cardiac muscle and adipose tissue, smaller amounts of LPL are 
produced in the kidney, brain, adrenals and in macrophages. LPL Is the major 
enzyme responsible for conversion of lipoprotein TG into FF A and monoglycerides 
(67). LPL hydrolyzes TG in circulating chylomicrons after stimulation of 
apolipoprotein CII. The TG-depleted remnants are then degraded by the liver. LPL 
also hydrolyzes TG in VLDL particles, that convert initially to !DL and finally to 
LDL particles by HL (68,69) (Figure 3). The hydrolytic function of LPL is essential 
for the transfer of surface free cholesterol and phosholipids to HDL particles. LPL 
activity is positively correlated with HDL-C and therefore HDL levels may reflect 
LPL activity (70). LPL also has a nonenzymatic molecular 11bridging 11 function, it 
acts as a ligand in lipoprotein-cell surface interactions, mediating cellular binding 
and uptake of lipoproteins (71-73). In summary, LPL influences both the plasma 
levels of lipoproteins and the interaction of atherogenic lipoproteins with the 
vascular wall. Factors influencing LPL activity may therefore interfere with these 
processes and thus are of clinical interest. 
Figure 3 Role ofLPL in the lipoprotein metabolism. 
=-hepatic 
""""' 
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'\.. VLDL 8 UL 
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Chylomicrons are formed post-prandially in the sro:ill intestine. Chylomicron 
metabolism requires that these lipoproteins obtain apo CII after they enter the 
bloodstream. from the thoracic duct. TG within the particles can then be hydrolysed 
by LPL. LPL is regulated by insulin. and its actions may be impaired in diabetes. 
TG-depleted remnants are primarily degraded in the liver. 
VLDL-TG are secreted from the liver and ar.4:cr TG hyd..""Olysis by LPL. converted 
initially to IDL. and finally to LDL. During these processes., surfuce lipid :md 
apoproteins dissociate from these particles and transfer to HDL. ApoC-ill interferes 
with the clearance ofTRLs through. :inh.J."bition of lipolysis by LPL. In diabetes twO 
fuctors may increase VLD L production: poor insulinization results in increased FF A 
release from fat cells and increased apoB secretion in the liver. 
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1.8 Factors influencing LPL activitv 
LPL expression in adipose tissue is controlled by insulin, so that its actiVIty is 
reduced by prolonged insulin deficiency or insulin resistance (74). In 1ype 2 diabetes 
mellitus insulin action is often decreased in spite of increased plasma insulin levels. 
Therefore LPL activity may be decreased, resulting in an impaired lipolytic activity. 
Thus, in a condition of insulin insensitivity, the overproduction ofVLDL TG in the 
liver in combination with the altered LPL activity may slow the clearance of plasma 
TG (8-!0,75). 
Although diminished LPL activity may result in part from poorly controlled diabetes 
and insulin deficiency, genetic defects in the LPL gene may also add to 
hypertr1glyceridemia in patients "With type 2 diabetes. About 80 naturally occurring 
mutations in the LPL gene have been described in humans. Most of them are 
missense mutations, but a number of structural mutations has been identified that 
diminish the lipolytic function of LPL. Genetic variants may affect the individual 
response to obesity and diabetes mellitus for the development of lipemia (76). 
Common LPL variants. resulting from amino acid substitutions, are the D9N, the 
N29!S and the S447Stop mutation which have respectively a frequency in the 
Caucasian population of 2-3%, 5% and 5-20% (77-83). In vitro studies showed the 
D9N allele lowers LPL activity with 20% and the N29!S allele with 50%. 
Advancing age might be another potential factor of influence to the LPL activity. 
This is oniy described in one study, that found a significant correlation between 
advanc-ing age and decreasing LPL activity (84). In combination with factors like 
diabetes, obes-ity or genetic variation, changes in LPL activity influence the 
contrl.bution to the atherogen-ic process. 
1.0 Lipid lowerina therapy and the effect on LPL activity 
There is little information about the effect of statin therapy on post-heparin LPL 
activity. Hoogerbrugge et al (64), described a significant decrease in LPL activity 
with atorvastatin 80mg in males and females with Familial Hypercholesterolemia, 
-10% and-14% respectively. In males there was also a significant decrease (-13°/o) 
after atorvastatin 40mg therapy. On the other hand, Kobayashi et al (85) showed 
that atorvastatin l Omg effectively reduced plasma TG, but pre-heparin LPL mass 
was not changed. Also Heller et al (86) demonstrated in patients with mi.-xed 
hyperlipidemia that atorvastatin did not affect LPL activity. They suggested that 
mechanisms other than enhancing lipolysis of TRLs by LPL contributed 
substantially to the TG reduction by atorvastatin. Simvastatin seems to increase 
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LPL activity m patients with combined hyperlipidemia in one study (87). 
Pravastatin did not affect LPL act1v1ty 1n patients ·with moderate 
hypercholesterolemia (88). In male New Zealand white rabbits neither atorvastatin 
nor simvastatin did change LPL activi1y (89). Studies investigating the effect of 
statins on LPL activity in patients with diabetes mellitus are lacking. 
1.10 The role of apolipoprotein Capo)C-111 in the lipid metabolism 
Apolipoprotein (apo)C-Ill is a 8.8 kD glycoprotein, synthesized by the liver and 
intestine (90). It is a constituent of HDL, chylomicrons, VLDL and remnant 
particles. ApoC-III interferes with the clearance of TRLs through inhibition of 
lipolysis by LPL and diminished lipoprotein binding to proteoglycan and lipoprotein 
receptors (91,92). In normolipidemic subjects the majori1y of apoC-III is bound to 
HDL, while in hypertriglyceridemic subjects, the majority is bound to TRL (93). 
Direct evidence for causal involvement of apoG-III in hypertriglyceridemia has been 
obtained in studies with mice overe;., .. ~ressing apoG-III, in ·which TG rises in 
proportion to apoC-III mRNA (94). In patients with 1ype 2 diabetes mellitus, 
hyperlipidemia or renal failure and in healthy individuals, plasma levels of apoC-lll 
correlate with apoC-Ill- and apoB-containing lipoprotein particles (LpB:C-lll), and 
TG levels (95-97). ApoC-!II levels are significantly increased in obese individuals 
with borderline-high TG concentrations compared with controls (98). The increase 
in TRLs in visceral obese individuals with insulin resistance, probably arises from a 
decrease in catabolism of TRLs due to an increase in apoC-Ill. Lowering TG levels 
in these obese individuals seems preferable in order to reduce the amount of 
apoC-III (99). 
Stable isotope studies demonstrate that in hypertriglyceridemic patients there is an 
increase in VLDL apoC-III levels. This increase is due to an increase in apoC-lH 
production rather than a decrease in apoC-III catabolism ( l 00). When the plasma 
concentration of apoC-III increases, apoC-III content in VLDL and HDL increases 
as well (101). Interestingly, the distribution of apoC-Ill among lipoproteins may 
affect the susceptibili1y to the atherogenic process (102). 
Little is known about the mechanism of inhibition of remnant clearance, the 
interference with lipoprotein association with glycosaminoglycans and the inhibition 
of LPL by apoC-IIl. Shachter et al (103, 104) proposed as predominant mechanism 
of hypertriglyceridemia in human apoC-II and apoC-III transgenic mice. a decrease 
in association between VLDL ·with cell-surface glycosaminoglycans, and a 
subsequently decreased lipolysis in-vivo. Another important proatherogenic action of 
apoC-!II may be its interference with the clearance of apoB48lipoproteins (105,106). 
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Several clinical studies have indicated apoC-lll and LpB:C-lll as risk factors for 
cardiovascular disease (107-i!O). The CLAS study (Ill) concluded that HDL 
apoC-l!I was the predominant risk factor predicting the probability of global 
coronary atherosclerosis progression in subjects treated with niacin-colestipol 
therapy. Data from the MARS study (112) suggested that in patients with mild and 
moderate atherosclerotic lesions. apoC-III was the predominant risk factor and that 
individuals with high levels of apoC-III in VLDL would be more likely to have 
progressive atherosclerotic disease. 
Since apoC-III is a marker for the TRL-metabolism and a risk-indicator for 
cardiovascular disease, measurement of apoC-III in patients with type 2 diabetes 
seems important. It "'~!! identity the risk for coronary heart disease and it may be 
he]pful for treatment strategies. 
1.11 Lipid lowerina therapy and the effect on apoC-111 
In rats, it has been reported that HMG-CoA reductase inhibitors reduce plasma TG 
levels through modulation of apoC-II! and LPL (113). Le et al (114) described an 
apoC-!II reduction of 18-30% by atorvastatin 20mg and 80mg after 4 weeks in 27 
patients with primary hypertriglyceridemia. Dallongeville (115) demonstrated an 
efficient reduction of LpB:Clll by atorvastatin 1 Omg in 305 patients with primary 
hypercholesterolemia. In contrast, lovastatin did affect Lipoprotein B (LDL), but 
not apoC-lll nor LpB:C-!II in patients with a coronary bypass graft (97). 
In patients, atorvastatin may affect plasma TG concentration through decreased 
synthesis or secretion of VLDL from the liver by reducing insulin resistance (116) 
and! or through increased clearance of TRLs by lowering plasma apoC-lll content. 
If and by which mechanism atorvastatin lowers the apoC-Ill content is still 
unknovvn. 
From the clinical perspective, the high amount of apoC-III molecules on TRI.:s in 
diabetic dys!ipidemia, resulting in inhibition of lipolysis of VLD L-TG by LPL (117) 
and interference with the hepatic uptake of TRLs by LDL receptors (118), may play 
a pivotal role in the delayed TG catabolism. Therefore, reduction of plasma apoC-
I!l production might be crucial for maintaining a normal plasma lipid profJe. 
Therapeutic intervention aimed at reducing apoC-III production seems to be a 
potentially powerful strategy for the treatment of hypertriglyceridemia. 
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1.12 HL. LPL and apoC-111 in diabetic dyslipidemia as target for therapy 
As described above HL, LPL and apoC-III are, among others, regulators of plasma 
TG and HDL-C levels and of LDL and HDL subclasses composition in diabetic 
dyslipidemia. Current knowledge of these key factors will now be placed within a 
model in order to elucidate targets for therapy. 
In type 2 diabetes, there is due to poor insulinization, increased lipolysis in 
adipocytes. This results in increased FFA release from fat cells, which may cause an 
increase in VLDL secretion from the liver. Besides the enhanced secretion ofVLDL, 
the clearance of VLDL is impaired as well. The VLDL particles are larger, due to a 
greater amount of TG. Most VLDL-TG particles return to the liver without 
complete conversion to LDL. Like the increase of apoB secretion in the liver, apoC-
III secretion is elevated as well. This will also increase VLDL accumulation, by 
preventing the action of LPL and inhibiting lipoprotein uptake. Therefore reduction 
of the amount of apoC-III is a potential tool to restore LPL activity, thereby 
increasing clearance of TRLs and lipoprotein uptake. Atorvastatin may affect 
plasma TG concentration through decreased synthesis or secretion of VLDL TG 
from the liver, but it may also affect TG levels through apoC-III reduction. This last 
possibility will be studied and discussed in this thesis. 
LPL is essential for the conversion of lipoprotein TG into FF A. LPL activity 
decreases plasma TG and TRLs, increases HDL-C and stimulates hepatic clearance 
of remnant particles. Its activity may be altered in diabetes. Therapy aiming to 
increase LPL activity in conditions where LPL activity is impaired, seems a logical 
strategy. Statins often seem to have no influence on LPL activity in dyslipidemic 
patients without diabetes. To date, there is no information about the effect of statins 
on LPL activity in patients with type 2 diabetes and this is a focus of study and 
discussion in this thesis as well. 
Increased HL activity is often seen in type 2 diabetes. The increase in HL activity is 
possibly due to an upregulation of HL activity as a consequence of increased VLD L 
TG production. The long-term insulin resistance might eventually lead to failure of 
TG hydrolysis by HL, since the VLDL-TG supply exceeds the HL-hydrolysing 
capacity. In this situation high HL activity may be a marker of a pro-atherogenic 
lipid profile and might lead to the formation of an excess of atherogenic small, dense 
LDL and the formation of smaller and denser HDL-C. Reduction of HL activity 
may be necessary in patients vvith type 2 diabetes in order to restore a less 
atherogenic lipid profile. There are no data describing the effect of statins on HL 
activity currently available. Therefore the effect of atorvastatin on HL activity in 
patients with diabetic dyslipidemia will be described in this thesis. 
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1.13 Aim of the thesis 
Diabetic dyslipidemia is an established risk factor for CHD and further elucidation 
of the lipoprotein metabolism and the effect of statin therapy seems necessary in 
order to better prevent atherosclerotic disease. Studying the role of lipolytic 
enzymes and apolipoproteins in diabetic dyslipidemia, may lead to more information 
of mechanisms involved and may reveal possible targets for therapeutic intervention. 
Results from the Diabetes Atorvastatin Lipid Intervention (DALI) study may 
deliver some of this information. 
1.14 Description of chapters 
The DALI study included patients with rype 2 diabetes and diabetic dyslipidemia, 
expressed as hypertriglyceridemia in the range between 1.5 and 6.0 mmol!L. In 
Chapter 2, the effect of standard and aggressive lipid lowering therapy with 
atorvastatin 1 Omg and 80mg respectively, in these patients, will be described. The 
possibility of effective and safe treatment of diabetic dyslipidemia with single drug 
therapy might lead to an improvement of patients compliance and drug tolerability. In 
Chapter 3, 4 and 5, the role of HL, LPL and apoC-III in the lipid metabolism in type 2 
diabetes as well as the influence of atorvastatin therapy on these regulators, is evaluated. 
HL activity, LPL activity and the amount of apoC-III were studied before and after 
atorvastatin therapy in the entire study group and in subgroups, like males, females and 
c:ar:riers of gene mutations. With this information, possible mechanisms of action of 
atorvastatin therapy in diabetic dyslipidemia were revealed and will be discussed. 
In Chapter 6 the possible difference in etiology of diabetic dyslipidemia in men and 
women is discussed. Therefore the presence of sex differences in lipase acti-vities before 
and after atorvastatin treatment is studied in order to e."\:plain possible gender differences 
in lipoprotein profiles. In Chapter 7 the effect of atorvastatin on LDL subfractions is 
presented. Besides the improvement of absolute levels of lipids and lipoproteins with 
statin therapy, the reduction of small dense LDL in patients with type 2 diabetes seems 
rewarding for reducing CHD risk, since the difference in risk for CHD between patients 
with and without type 2 diabetes is partly due to qualitative differences in lipoproteins. 
Diabetic dyslipidemia may contribute to cognitive functioning. According to the fact that 
treatment aimed at improvement of lipid profiles may change cognitive functioning, the 
effect of atorvastatin on cognitive functioning in patients vvith diabetic dyslipidemia, is 
evaluated in Chapter 8. Finally, in Chapter 9 the information from previous chapters is 
discussed. 
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Ab<1tract 
Objective 
!n patients with type 2 diabetes mellitus intensive glucose regulation, while effective for 
microangiopathy, has not shown unambiguous preventive effects on the occurrence of 
cardiovascular disease. Diabetic patients show a characteristic dyslipidemia (high triglycerides, 
low HDL-cholesterol). Aggressive lowering of triglycerides might be an effective method to 
reduce the cardiovascular risk in these patients. 
Research design and methods 
A double-blind placebo-controlled randomized study to assess the effect of 30 weeks 
atorvastatin 1omg and Somg on plasma triglyceride levels in 217 patients with type 2 diabetes 
mellitus and fasting triglycerides between 1.5 and 6.o mmoljl. 
Results 
Atorvastatin 1omg and 8omg resulted in significant reductions of plasma triglyceride of 25o/o 
and 35o/o, respectively (both p<o.oo1). The difference between 1omg and Somg was not 
statistically s·1gnificant (p>o.s). Atorvastaf1n 10mg provided s·1gnif1cant reducf1ons from 
baseline in total cholesterol (-30o/o (p<0.001), LDL cholesterol (-40%, p<o.oo1) and apoB (-
31%, p<o.o01), and significantly increased HDL cholesterol from baseline by 6% (p<o.oos). 
Atorvastatin Somg had a similar effect on HDL cholesterol (+s.2o/o, p<o.oos), but decreased 
total cholesterol (-40o/o,p<o.o01), LDLcholesterol (-S2o/o, p<o.oo1) and apoB (-40%, p<0.001) 
significantly (p<o.oos) more than atorvastatin 1omg. The side effects of atorvastatin 1omg and 
Somg were similar and did not differ from the patients receiving placebo. 
Conclusions 
Atorvastatin 1omg and Somg provide similar, significant reductions from baseline in 
triglycerides in patients with type 2 diabetes mellitus. A higher dose of atorvastatin improves 
cholesterol-related parameters. Both dosages were well tolerated in this patient population. 
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Introduction 
Patients with type 2 diabetes mellitus (DM2) have a two to four fold increased risk 
for cardiovascular morbidity and mortality. (l-5) Intensive glucose regulation in 
DlV12, while effective for microangiopathy, has not shown unambiguous preventive 
effects on the occurrence of coronary heart disease, stroke and peripheral artery 
disease. (6) Besides hypertension, dyslipidemia has emerged as a prevalent and 
modifiable atherogenic risk factor in patients with DM2. LDL-cholesterol lowering 
strategies, with the use of HMG-CoA reductase inhibitors, have shown at least equal 
benefits for the diabetic subgroups in large secondary prevention trials. (7-9) In 
primary prevention trials the diabetic subgroups were too small to show significant 
results. (10;!1) However, these were all post hoc analyses and diabetic patients 
included in these studies did not have the typical diabetic lipid profile, i.e. elevated 
triglycerides, decreased HDL-cholestero!, normal or slightly elevated LDL-
cholesterol. (12) In diabetic patients increased plasma triglyceride levels are 
associated with an increased risk for cardiovascular morbidity and mortality. (13-17) 
As a consequence, optimal lipid lowering in DM2 should focus on lowering of LDL-
cholesterol and plasma triglycerides. (14; 15) HMG-CoA reductase inhibitors have 
been proven to effectively reduce total cholesterol and triglycerides in non-diabetic 
patients (18;19) Only one small randomized study on the effect of different doses of 
simvastatin on diabetic dyslipidemia has been published. (20) Because higher doses 
of statins are effective in more aggressive cholesterol lowering, (19) we hypothesized 
that higher doses of statins also result in additional improvement of the diabetic lipid 
profile. 
We performed a double-blind, placebo-controlled, randomized study to assess the 
effect of atorvastatin 1 Omg (A1 0) and 80mg (A80) on the reduction of triglyceride 
levels in patients with DM2 and diabetic dyslipidemia. In addition, we studied the 
effects on other aspects of diabetic dyslipidemia. 
Subjects and methods 
PatientJ 
The Diabetes Atorvastatin Lipid Intervention (DALI) study is a randomized 
double-blind, placebo-controlled, multi-center study, conducted in the Netherlands. 
Patients were recruited from outpatient clinics of the University Medical Centers of 
Leiden, Rotterdam and Utrecht and surrounding community hospitals. The medical 
ethical committees of the three participating institutions approved the study, and 
written informed consent was obtained from all patients. The participants, aged 
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45-75 years, were male or female type 2 diabetic patients with a duration of diabetes 
of at least 1 year and HbA1c 10% or lower. The main inclusion criteria were fasting 
total cholesterol level between 4.0 and 8.0 mmol!L and fasting triglycerides level 
between 1.5 and 6.0 mmol!L. 
Patients were not included in the present study if they had a history of myocardial 
infarction, PTCA, CABG, proven manifest coronary artery disease, severe or 
unstable angina pectoris (> grade II of the Canadian Cardiovascular Society), 
clinically manifest heart failure (> grade II NYHA) and severe cardiac arrhytmias. 
Premenopausal women, patients with acute liver disease or hepatic dysfunction, 
impaired renal function (plasma creatinine > 150 mmol/l), a history of partial ileal 
bypass surgery, any surgical procedure or any systemic inflammatory disease within 
the last three months before randomization, malignancies, vasculitis, rheumatic 
arthritis, idiopathic lung fibrosis, ulcerative colitis or Crohn's disease were excluded. 
Patients who consumed more than 4 alcoholic drinks per day or who used systemic 
steroids, androgens, cyclosporin, other immunosuppressive drugs, erythromycin or 
mibefradil were also excluded. When applicable, lipid-lowering drugs were 
withdrawn at least 8 weeks before the start of the run-in phase. 
Sta/)y duign 
Patients who met the in~ and exclusion criteria started with a placebo run-in period. 
If the lipid levels were still within the inclusion range after two weeks, patients were 
randomized to treatment vvith atorvastatin 1 Omg, 80mg, or placebo, administered 
once daily in the morning. Patients randomized to A80 started with 40mg for four 
weeks after which the dose was increased to 80mg. The total treatment period was 
30 weeks. Follow-up visits were scheduled at weeks 4, 10, 20 and 30, at which 
adverse events were recorded, study medication was counted, blood pressure was 
measured and fasting blood samples were drawn for safety parameters and lipid 
profile. There were no changes in concurrent treatment, including hypoglycemic 
medication during the study. 
Clinical <~afety and lahoratory analy<~u 
At baseline a medical history was taken and physical examination was performed. 
During the follow-up visits, patients were interviewed regarding possible adverse 
events. 
Routine hematology and blood chemistry were determined after an overnight fast 
(12 hours) at screening, at randomization and at the end of the study. All laboratory 
measurements, except for the safety parameters, were performed at the Lipid 
Reference Laboratory Rotterdam, the Netherlands. Standard plasma lipid variables 
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(total cholesterol, HDL-cholesterol (HDL-c), triglycerides (TG), free fatly acids 
(FFA), and ApoB) "Were measured at each visit. Total cholesterol and triglycerides 
"Were measured by enzymatic colorimetric methods (CHOD-PAP and GPO-PAP, 
Boehringer Mannheim, Mannheim, Germany) on a Hitachi 911 analyzer 
(Boehringer Mannheim, Mannheim, Germany). HDL-cholesterol "Was measured by 
a direct enzymatic HDL-cholesterol method, based on PEG-modified enzymes 
method (Boehringer Mannheim, Mannheim, Germany) on a Hitachi 911 analyzer. 
LDL-cholesterol "Was estimated by the Friede"Wald formula. (21) ApoB "Was 
determined on a Hitachi 917 analyzer, using immunoturbidimetric methods (Tina-
quant apo B, Cat.Nr.l551779) from Boehringer (Boehringer Mannheim, 
Mannheim, Germany). Fasting free fatty acids were determined using an enzymatic 
colorimetric method (Wako, NEFA C, Cat. Nr. 994-75409 D). The size of the LDL 
particles "Was measured at baseline and at the end of the study by polycrylamide 
gradient gel electrophoresis. (22). Standardization "Was achieved by inclusion of 
LDL samples "With kno"Wn size donated by dr. R.M. Krauss. Based on their size LDL 
particles were divided into tvvo classes: pattern A reflects the presence of 
predominantly large buoyant LDL (>25.5 nm) and pattern B of predominantly small 
dense LDL particles (< 25.5 nm). IF both patterns "Were equally present, patients 
"Were classified as pattern AB. (23 ). Lipoprotein lipase (LPL) activity "Was 
determined in plasma at baseline and at the end of the study after intravenous 
injection of heparin (50 IU!kg body-"Weight) using an immuno-chemical technique. 
In a sample of 35 healthy subjects (mean age 55.5 years) the LPL activity measured 
"With this technique "Was 147.4 ± 36.1 U/L (range 89-231 U!L). 
Safety laboratory tests, creatine kinase (CK), alanine transferase (ALT) and 
aspartate transferase (AST), "Were performed at all follo"W up visits at local 
laboratories. An increase of the ALT or AST levels to >3 times the upper limit of 
normal, or an increase of CK > 10 times the upper limit of normal, verified by repeat 
testing after one week, were considered clinically important and reported as an 
adverse event. 
Statutic.J 
All data were analyzed by intention-to-treat. Because patients were randomized, 
baseline values were not statistically tested betvveen treatment groups. In subjects 
"Who did not complete the final visit the "last observation carried for"Ward" principle 
"Was applied. Mean differences bet"Ween the study groups "Were analyzed using 
analysis of covariance (ANCOVA), adjusted for baseline levels and study location. 
Intervention effects "Were also further adjusted for additional potential confounders, 
using ANCOVA. If logarithmic transformation "Was applied to parameters "With 
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skewed distributions, the same results were obtained. Sample size of the study was 
based to prove a minimal reduction of OA mmol!L in triglyceride levels (compared to 
placebo), or a difference of OA mmol!L between the two treatment groups (SD 0.8, 
a= 0.05, power 85%). Analyses were performed by SPSS for 'Windows (release 9.0). 
Results 
Ba.~eline CbaracterutiCJ 
After a screening visit, 251 patients fulfilled the in- and exclusion criteria and entered 
the two-week placebo run-in period. At baseline 26 patients had normalized 
triglyceride levels ( d.5 mmol!L) and 8 patients refused to continue. Finally, 217 
patients were randomized. The baseline characteristics of the study population are 
given in Table L In all three groups compliance with trial medication during the study 
was over 95%. Twen1y patients (9.2%) did not complete the study because of adverse 
events (n=7), personal reasons (n=lO), protocol violation (n=l) or loss to follow-up 
(n=2). Personal reasons were defined as not related to the study medication and were 
mostly due to inabili1y to spend time for participating in the study. 
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Table 1. 
Baseline characteristics of the patients in the Diabetes Atorvastatin Lipid Intervention study (DALI) 
Placebo Atorvastatin 1omg Atorvastatin 8omg 
Number 72 73 72 
Male gender(%) 46 6o 53 
Age (years) s8.s ± rs 59-7 ± 7.6 60.1 ± 7-7 
Caucasian ethnicity (%) 84 86 82 
Diabetes duration (years) 8.2 ±5-9 11.1 ± 7-6 12.2 ± 8.3 
Diabetes treatment (number) 
Diet 2 3 0 
Tablets 31 34 30 
Insulin 21 19 21 
Combination tabletsjinsulin 18 17 21 
Neuropathy(%) 39 32 41 
Retinopathy(%) 22 28 37 
Body-Mass Index (kgjm2) 32.2 ± 6.0 30.0 ± 3.8 30-4 ± 4-5 
Waist to Hip ratio 0.99 ± 0.1 1.00 ± 0.08 1.01 ± 0.1 
Treated hypertension(%) so 49 61 
Blood pressure (mmHg) 144 ± 19/85 ± 9 146 ± 17/86 ± 10 145 ± 17/8s ± 9 
Present smoking(%) 22 21 17 
Fasting glucose (mmoljL) 10.5 ± 3.6 10.5 ± 3.0 10.6 ± 2.9 
HbA1C (%) 8.3 ± 1.1 8.3 ± 1.2 8-4 ± 1.1 
Continuous data are expressed as mean ± sd 
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LipiJ<J anfJ lipoprotein.f 
Lipid and lipoprotein plasma values at baseline and after 30 weeks are shown in 
Table 2. In patients treated with AI 0 triglyceride levels were significantly lowered 
by 25% from 2.54 to 1.84 mmol!L (P<O.OOI). Treatment with A80 resulted in a 
significant reduction by 35% from 2.85 to 1.78 mmol!L (P<O.OO!). The difference 
in plasma triglycerides lowering between the two intervention groups was not 
statistically significant (Figure I). 
Figure I. Triglyceride levels in the DALI study. Values are mean ~ SE 
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The effects on triglycerides were also analyzed in two strata of baseline plasma 
triglyceride levels to investigate whether the baseline levels of plasma triglycerides 
did influence the lipid lowering effect of atorvastatin. The first group included all 
patients with baseline plasma triglyceride levels >2.3 mmol!L (n=l20), whereas the 
second group included 97 patients with baseline plasma triglyceride levels ,;2.3 
mmol!L. In both groups the same results were obtained. In patients v.rith high 
baseline triglyceride levels, Al 0 and A80 resulted in a triglyceride reduction of 
29.6% and 23.4%, respectively (compared to placebo both p<O.OOl, AlO versus 
A80 p>0.5). The corresponding figures in patients with low baseline triglyceride 
levels were 23.4% and 27.9%, respectively (compared to placebo both p<O.OOl, AlO 
versus A80 p>0.4). Further adjustment for diabetes duration and BM! did not 
change the results. 
LDL-cholesterol was dose-dependently improved to 2.2 mmol!L in AlO (-40.8%, 
p<O.OOl), and to 1.7 mmol!L in A80 (-52.3%, p<O.OOl). The difference between AlO 
and A80 was statistically significant (p<O.OOl). Like LDL-cholesterol, atorvastatin 
lowered apoB dose dependently (Table 2). AlO and A80 increased HDL-
cholesterol significantly by 5-6%. Consequently, the total cholesterol! HDL ratio 
improved, significantly more in patients treated with A80 (p<0.005) (Table 2). 
At baseline relatively few patients had small, dense LDL particles. Pattern A, AB 
and B was present in 60.5%, 15.3% and 24.2%, respectively, which did not differ 
between the three intervention groups. There was no overall effect of atorvastatin on 
the LDL particle size. As a result, the number of patients with dense LDL particles 
(pattern B) did not differ at the end of the study between the intervention groups: 
21.3%, 21.4% and 22.2% in the placebo, AlO and A80 groups, respectively. 
Atorvastatin had no effect on postheparin LPL activi1y. Further adjustment for 
diabetes duration and BMI did not change the results. 
The effects of treatment were compared to target values defined by the American 
Diabetes Association (ADA). (24) In both atorvastatin treatment groups more than 
75% reached the triglyceride treatment goals (79.5% in AlO and 76.4% in A80, NS). 
LDL-cholesterol treatment goals were reached in 71.2% of the patients treated with 
AlO and 84.7% of the patients treated with A80 compared to ll.l% in the placebo 
group. This difference was statistically significant between AlO and A80. HDL-
cholesterol treatment goals were reached in 35.6% of the AlO group and 44.4% of 
the patients treated with A80 (NS). 
~ 
:.:. 
Table 2. Lipids and lipoprotein at baseline and end of the DALI study. " 0 
0 
Placebo Atorvastatin 10mg Atorvastatin 8omg ct 0 
" Triglycerides (mmoljl) Baseline 2.62 ± 0.11 2.85 ± 0.13 rl 2.54 ± 0.10 0 ~ 
30 weeks 2.88 ± 0.22 1.84 ± 0.10' 1-78 ± o.W w 
"' Change(%) 10.0 (-1-7 to 21.7) -25.4 (-31.9 to -18.9)' -34.6 (-42-7 to -26.5)' "' ;;:
" Total cholesterol (mmoljl) Baseline 6.0 ± 0.1 5·9 ± 0.1 6.0 ± 0.1 " ;:· 
30 weeks 6.0 ± 0.1 4.1 ± o.f 3.6 ± o.l' i 0 < 
0 
Change(%) 0.5 (-2.o to 2.0) -29.8 (-32.4 to -27.2)' -39.2 (-4J.J to -35.1)' ii ;: 
" LDL-cholesterol (mmoljL) Baseline ).8 ± 0.1 ).7 ± 0.1 3-7 ± 0.1 " rl 30 weeks 3.6 ± 0.1 2.2 ± o.f 1-7 ± o.f i w 0 0. 
Change(%) -2-7 (-ro to 1.7) -40.8 (-43.6 to -37.9)' -52.3 (-58.9 to -45.7)' i w 
" HDL-cholesterol (mmoi/L) Baseline 1.05 ± 0.02 1.05 ± 0.0) 1.03 ± O.OJ 
" 30 weeks 1,04 ± O.Q) 1.10 ± 0.04 1.09 ± 0.04 
" 0 
~ Change(%) -0.9 (-J.? to 1.9) 6.o (J.6 to 8.6)" 5.2 (1.8 to 8.6)'' ~ 0 TCJHDL ratio Baseline 5·9 ± 0.2 5·9 ± 0.1 6.1 ± 0.2 " 0 30 weeks 6.0 ± 0.1 ).9 ± 0.2'' 3.5 ± of "' o-"< Change(%) +2.6 (-1.5 to 6.8) -33-7 (-36.3 to -31.1)' -42.0 (-46.3 to -37.8)' ii w rl 
Free Fatty Acids (mmolfl) Baseline 0.67 ± 0.0) 0.64 ± 0.0) 0.69 ± 0.03 0 < 
30 weeks 0.57 ± O.OJ" o.61 ± o.of'' w 0.72 ± 0.04 :'l 
w 
Change(%) 18.6 (2-7 to 34-4) -5.4 (-14.4 to J.6)"' -).2 (-13-7 to nt>+ C'. 0 
Apo B (mgjwoml) Baseline 1.27 ± 0.02 1.22 ± 0.02 1.24 ± O.OJ 0 0 
30 weeks 1.25 ± 0,02 0.84 ± 0.02' 0.74 ± 0.03' ~~ 
"' 
w 
Change(%) -1.5 (-4.3 to 1.2) -30.7 (-33.0 to -28.4)' -40.2 (-44.2 to -36.1)' i o-0 C'. 
LDL particle size (nm) Baseline 26.0 ± 0.1 26.1 ± 0.1 25.9 ± 0.1 " 
"-
30 weeks 26.0 ± 0.1 26.1 ± 0.1 26.0 ± 0.1 "< ~ 
Change(%) 0.3 (-o.J to 0.9) -0.03 (-o.s to o.s) 0.5 (-o.o4 to to) " c: 
ro 
Lipoprotein lipase (mUjml) Baseline 140·4 ± 5.8 142.6 ± 5·3 1)8-7 ± 5·3 3 ~· 
30 weeks 137·7 ± 6.2 1)6.1 ± 5·4 1)3.6 ± 6.2 
Change(%) 2.3 (-7.6 to 12.1) -1.5 (-8.4 to 5.5) -2.o (-9-6 to 5.6) 
Values are meJn ± SE, or percentage change with the 95% confidence interval. Test for difference versus placebo, adjusted for baseline value and study location: t p < o.oo1; o p < o.oos; m 
p < o.os Test for difference versus atorvastatin wmg, adjusted for baseline value and study location: i p < o.o01; ii p < o.oos; iii p < o.os 
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Safety aM metabolic control parameteN 
Adverse events are summarized in Table 3. There was no difference in the number 
of patients reporting adverse events between the three treatment groups. Twelve 
serious adverse events were reported. One patient receiving placebo (non-fatal 
myocardial infarction), l patient treated with AlO (benign neoplasm of skin) and 1 
patient treated with A80 (depressive episode) reported a serious adverse event that 
was considered 'possibly related' to the study drug. The other serious adverse 
events, not considered related to the study drug, included self-limiting 
gastroenteritis (n=l) and trauma (n=2) in patients receiving placebo; self-limiting 
gastroentenns (n=l), diabetes dysregulation (n=l) and malignant 
bronchuscarcinoma (n=l) in patients using AlO; admission for hip replacement 
surgery (n=l), depressive episode (n=l) and benign neoplasm of the skin (n=l) in 
patients using A80. 
Atorvastatin 80mg was associated vvith a slight increase in HbAlc concentration 
from 8.4% to 8.6% after 30 weeks (p=0.06). In both placebo and AlO groups a small 
decrease in HbAlc was observed after 30 weeks. After 30 weeks, HbAlc in the A80 
group differed significantly from either placebo and AlO (both p<0.05). Fasting 
glucose and blood pressure remained stable during the study in all treannent groups. 
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Table 3. Adverse Events and Safety parameters in the DALI study 
Placebo Atorvastatin 1omg Atorvastatin 8omg 
Adverse events Gastrointestinal disorder 8 (1};. 11 9 (1)i 
Mood disturbances 3 (1) :i: 3 
Headache 3 3 3 
Heart diseases 3 (1) + 0 2 
Respiratory tract disorder 6 (1) :i 4 4 
Joint disorderjmyopathy 9 10 7 
Urinary tract disorder 10 13 9 
Malaise 6 (1) :r. 11 (1) \ 
Other 6 19 15 
AST (U/L) Baseline 24± 9 28 ± 12 26 ± 9 
30 weeks 25 ±7 26 ± 8 28 ± 10 
ALT (U/L) Baseline 28 ± 11 36 ± 21 33 ± 19 
30 weeks 28 ± 11 33 ± 14 37 ± 15 
Cl< (U/L) Baseline 117 ± 89 121 ± 73 118 ± 64 
30 weeks 112 ± 66 126 ± 96 133 ± 96'" 
HbA1C (%) Baseline 8.3±1.1 8.3 ± 1.2 8.4 ± 1.1 
30 weeks 8.1 ± 1.1"" 8.0 ± 1.2 8.6 ±1.3 ~ ## 
Fasting glucose Baseline 10.5 ± 3.6 10.5 ± 3-0 10.6 ± 2.9 
(mmoljl) 30 weeks 10.2 ± 2.5 10.3 ± 2.5 11.0 ± 3-2 
Blood pressure Baseline 144 ± 19/85 ± 9 146 ± 17/86 ± 10 145 ± 17/85 ± 9 
(mmHg) 30 weeks 144 ± 21/86 ± 11 140 ± 20/84 ± 11 143 ± 16/84 ± 10 
Continuous data are expressed as mean ±standard deviation. 
Test for difference versus baseline:+ p < o.os 
Test for difference versus placebo:~ p < o.os 
Test for difference versus atorvastatin 10mg: :::-:1: p< o.oos 
t withdrawn from the study due to adverse event 
2:The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. 
Discussion 
Atorvastatin lOmg and 80mg treatment resulted in significant reductions of plasma 
triglyceride and LDL cholesterol, and an increase of HDL cholesterol levels. in 
patients with type 2 diabetes mellitus. A80 had a significant larger effect on 
cholesterol related variables than AlO. The side effects of AlO as well as A80 did 
not differ from placebo. 
The lower limit of plasma triglyceride levels for inclusion was 1.5 mmoiJL. Levels 
above 1.5 mmol!L are associated v.rith an increased risk for cardiovascular disease in 
diabetic subjects in the Paris Prospective Study and the Bezafibrate Infarction 
Prevention Registry. (14,25) Moreover, 98% of the participants had dyslipidemia 
according to the ADA guidelines. (24) The results of the analyses stratified by 
baseline plasma triglyceride levels indicate that the effects of treatment are 
independent of baseline plasma triglyceride levels, as is also seen for plasma LD L-
cholesterol reduction by statins. Our results show that in DM2 patients high dose 
atorvastatin (80mg) does not have a significant additional effect on triglyceride 
lowering compared to a standard dose of lOmg. The triglyceride-lowering efficacy 
of atorvastatin in our study is in agreement v.rith previous small studies v.rith 80mg 
atorvastatin in non-diabetic patients with primary dyslipidaemia (18, 19,26) Among 
the limited number of studies with high doses of other HMG-CoA reductase 
inhibitors (mainly simvastatin) in diabetic patients, only one double-blind study was 
published, showing a 15% reduction in triglycerides after using simvastatin 40mg for 
24 weeks in 42 patients with DM2. (20) 
The mechanism by which atorvastatin lowers plasma triglycerides is not known. 
Diabetic hypertriglyceridemia is often ascribed to overproduction of VLDL 
triglycerides as well as impairment of triglyceride cleating due to decreased LPL 
activity. (12,27) In the present study LPL was in the normal range, and not affected 
by atorvastatin treatment. Therefore, it is likely that the hepatic triglyceride 
secretion is affected. Plasma FF A is the main precursors for hepatic triglyceride 
synthesis and secretion. Since atorvastatin lowered plasma FFA, it may be that 
hepatic triglyceride synthesis and secretion are attenuated. 
The decrease in plasma triglycerides and rise in HDL was not accompanied by an 
increase in LDL size. It should be noted that LDL size was relatively large. 
Moreover, based on epidemiological studies it was found that presence of small 
dense LDL coincides with plasma TG levels above 1.6 mmoiJL. In order to obtain 
a reversal of LDL size towards more buoyant particles an even lower plasma TG 
level might be necessary. Micronised fenofibrate has shown to improve LDL-size in 
patients with DM2 who suffered higher fasting triglycerides and total cholesterol 
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levels and a predominance (52%) of small, dense LOL at baseline compared to our 
study. (28). 
In the current study, total cholesterol, LOL-cholesterol and apoB levels were 
significantly reduced in a dose dependent manner. This reduction is of the same 
magnitude as found 1n studies with atorvastatin 1n non-diabetic 
hypercholesterolemic and hypertriglyceridemic patients. (18,19) Compared to 
studies with simvastatin (40mg) in patients with O.M.2, we found a larger reduction 
in total cholesterol (39o/o versus 30o/o) and LOL-cholesterol (52o/o versus 24-42%). 
(20,29) 
The significant increase from baseline in HDL-cholesterol by atorvastatin was 
consistent with that reported in previous studies. Even small increases in HDL-
cholesterol may be clinically relevant since they contribute to the reduction of the 
total cholesterolJHDL ratio. This ratio was one of the best predictors of future 
cardiovascular events in the Framingham study. (30) Since treatment with A80 
resulted in a significant lower cholesterol!HDL cholesterol ratio than AlO, the high 
dose may have an additional protective effect on future cardiovascular events. 
The number of serious adverse events and side effects were the same in the three 
intervention groups. The present study is the first study showing the safety of A80 
for a longer treatment period in patients with Dl\.12 who concomitantly were using 
a wide variety of other medications. Possible limitations of the study are differences 
at baseline between the placebo and atorvastatin groups. These include duration of 
diabetes, which is not likely to influence the results since there is no relation betvveen 
the duration of diabetes and the metabolism of triglycerides, and body mass index. 
Because visceral adipocytes are the main source for FF A supplied to the liver as 
substrates for triglycerides, the waist to hip ratio and FF A levels are more important 
than BMI (.31) Moreover, adjustment for diabetes duration or BMI did not change 
the results. 
Atorvastatin 80mg induced a small increase in HbAlc values, while HbA1c in 
patients using Al 0 and placebo slightly decreased. Other studies have shown 
inconsistent results of lipid lowering therapy on glycemic control in diabetic 
patients, and several clinical studies reported an increase of HbA1c with either 
fluvastatin or simvastatin. (20,32-34) 
2:The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. 
Conclusions 
In conclusion, atorvastatin 1 Omg and 80mg are both effective in the treatment of 
diabetic dyslipidemia (elevated triglyceride, normal to elevated LDL cholesterol, 
low HDL cholesterol) in patients with 1ype 2 diabetes mellitus. Both doses were well 
tolerated in this patient population. 
Appendix 
DALI-study group (In alphabetical order): Erasmus Medical Center Rotterdam, 
Department ofinternal Medicine (LLL Berk-Planken, N. Hoogerbrugge, H. Jansen); 
Erasmus University Rotterdam, Departments of Biochemistry and Clinical 
Chemistry (H. Jansen); Gaubius Laboratory TNO-PG, Leiden (H.M.G. Princen); 
Leiden University Medical Center (M. V. Huisman, M.A. van de Ree); University 
Medical Center Utrecht, Julius Center for General Practice and Patient Oriented 
Research (R.P. Stalk, F.V. van Venrooij); University Medical Center Utrecht, 
Division ofinternalMedicine (J.D. Banga, G.M. Dallinga-Thie, F.V. van Venrooij). 
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Ab.1tract 
Objective 
Hepatic lipase (HL) is involved ·m the metabol"lsm of several lipoproteins and may contribute to 
the atherogenic lipid profile in type 2 diabetes. Little is known about the effect of cholesterol 
synthesis inhibitors on H L activity in relation to gender and the hepatic lipase gene, the UPC 
promoter variant in type 2 diabetes. Therefore, we studied the effect of atorvastatin 1omg 
(A10) and 8omg (A8o) on HL activity in 198 patients with type 2 diabetes. 
Research design and methods 
Patients, aged 45-75 years, without manifest coronary artery disease and a total cholesterol of 
4.0-8.0 mmoljl and fasting triglycerides (TG) of1.5-6.o mmoljl were included in a double-blind, 
randomized, placebo-controlled trial for 30 weeks (DALI study). 
Results 
HL activity at baseline was significantly higher in our population compared with an age-
matched control group without type 2 diabetes (406 ± 150 vs 357 ± 118 U/L). H L activity in 
males vs females (443 ± 158 vs 358 ± 127 U(L), in carriers of the LIPC C(C allele vs carriers of the 
T(T allele (444 ± 142 vs 227 ± 96 U(L) and in Caucasians vs blacks (415 ± 150 vs 260 ± 127 U/L), 
all differed significantly (p<o.oo1). Atorvastatin decreased HL dose-dependently (A1o -11%, 
ASo -22o/o, both p<0.001). Neither gender or the L!PC C> T variation influenced the effect of 
atorvastatin on HL activity. 
Conclusions 
Gender, UPC promoter variant and ethnicity significantly contribute to the baseline variance in 
HL activity. Atorvastatin treatment in diabetic dyslipidemia results in a significant dose-
dependent decrease in HL activity, regardless of gender or the LIPC promoter variant. 
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Introduction 
Hepatic lipase (HL) is involved in the metabolism of several lipoproteins (1) and is 
a key player in the HDL metabolism (2,3). Hydrolysis of phospholipids and 
triglycerides by HL, leads to the conversion oflarge, buoyant HDL2 to small, dense 
HDL3 and may induce cholesterol (ester) flu." to the liver (4,5). In this way HL is 
involved in the reverse cholesterol transport and is a major determinant of plasma 
HDL concentration (6,7). HL also plays a role in the formation of small dense LDL 
and contributes to the e>.-pression of the LDL subclass phenotype (8,9). Finally, HL is 
proposed to be involved in post prandial lipid clearing (1 0). Thus, HL activi1y seems to 
be central in the metabolism of lipoproteins strongly associated with CAD risk in type 
2 diabetes mellitus. Zambon and coworkers identified HL as a focal point for the 
development and treatment of coronary artery disease (11). 
Genetic variation, gender and abdominal fat mass affect HL activi1y in humans (12-15). 
In the human hepatic lipase gene (denoted as LIPC), variants are found that affect 
the lipase activi1y (16-18). Besides rather rare variants leading to complete HL 
deficiency (19,20), common base substitutions in the proximal LIPC promoter affect 
HL activi1y up to 2 fold (15, 21, 22). Four base substitutions, -250 G-to-A, -514 C. 
to-T, -710 T-to-C, and -763 A-to-G, were found to be completely linked (23). 
Together, they constitute two alleles, indicated as the LIPC C and T allele, after the 
C. to-T variant at -514 bp, which is also indicated as C.480T. The C and T alleles are 
associated with high and low HL activi1y, respectively. The frequency of both alleles 
varies highly among different ethnic populations (21,24,25). The C allele is the most 
common allele in Caucasians, whereas the T allele is the major allele in black 
Americans. Asians contain an intermediate frequency. Beside genetic variance, HL 
lipase activi1y is also hormonally affected. In particular sex hormones influence LIPC 
e:x."Pression and are believed to be responsible for gender differences in HL activity 
being lower in women than in men (13, 25, 26). An increase in HL activi1y is 
associated with an increase in abdominal fat mass, BMI and fasting insulin and 
fasting plasma triglycerides (27). These correlations are reflected in a high HL 
activi1y in type 2 diabetes. 
A change in HL activi1y may also be induced by hypolipidemic drugs. In males, but 
not in females, we found a decrease in HL activi1y during atorvastatin treatment of 
familial hypercholesterolemia (28). Zambon reported a drop in HL activi1y in 
participants of the FATS study during treatment with lovastatin-colestipol and 
niacin-colestipol (29). Interestingly, in both groups the effect of treatment on HL 
activi1y was strongly dependent on the presence of the LIPC T allele. HL activi1y 
was lowered less in carriers of the T allele compared to non-carriers (30). So, gender 
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and the genotype of the LIPC promoter may determine the efficacy of the statin 
treatment. Earlier studies (31-34), showed a beneficial effect of 3-hydro>-y-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the incidence of 
cardiovascular events in type 2 diabetes. Also although atorvastatin, a powerful 
statin, effectively reduces total cholesterol and triglyceride concentrations, no data 
describing its effect on HL activity in type 2 diabetes are currently available. 
Therefore, we conducted a double-blind, placebo-controlled randomized 30-weeks 
study to evaluate the effect of atorvastatin 1 Omg versus 80mg on HL activity in 
subjects with type 2 diabetes mellitus. Gender and the LIPC C> T variation as 
possible modificators of the atorvastatin treatment effect, were considered in this 
study. 
Patients and methods 
Study populatwn 
This study is part of the Diabetes Atorvastatin Lipid Intervention (DALI) study. 
DALI is a randomized double-blind, placebo-controlled, multi-center study 
conducted in the Netherlands. The subjects and methods are described in detail 
earlier (35). 
In short, 217 patients, aged 45 to 75 years, with type 2 diabetes mellitus participating 
in the DALI study were randomized to placebo, atorvastatin 10mg (A10) or 
atorvastatin 80mg (A80) during 30 weeks, to evaluate the effect on lipid metabolism, 
endothelial function, coagulation and inflammatory parameters. The main inclusion 
criteria were plasma triglycerides between 1.5 and 6.0 mmol!l, total cholesterol 
between 4.0 and 8.0 mmol!l and no history of coronary heart disease. Post heparin 
lipase activity blood samples of 198 DALI-patients were available and evaluated in 
the present study. 
Analytical methoiJd 
Blood samples were drawn after 12 h of fasting at baseline and after 30 weeks, the 
end of the study. Standard lipid variables (Total cholesterol (TC), HDL-cholesterol 
(HDL-c) and triglycerides (TG)), free fatty acids (FFA), plasma glucose, HbA1c 
and HL activity were measured. Cholesterol and TG were determined by enzymatic 
colorimetric methods on a Hitachi 911 automatic analyzer (Boehringer Mannheim, 
Mannheim, Germany). Plasma HDL cholesterol was measured by a direct 
enzymatic HDL-cholesterol method, after precipitation of very-low density 
lipoprotein and LDL by addition of manganese chloride. LDL-cholesterol was 
estimated by the Friedewald formula (36). Fasting plasma glucose was determined 
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on a Hitachi 917 analyzer using an UV-hexokinase method (Cat. Nr.18766899) from 
Boehringer Mannheim, Mannheim, Germany. HbA1c was determined by HPLC, 
using the BIO-RAD Variant TM method (Cat.Nr.270-0003.Bio-rad). 
Podtbepa.rin pla.Jma HL activity 
HL activity was measured using an immunochemical method as described 
previously (37) in plasma collected 20 min after contralateral intravenous 
administration of heparin (50 IU/kg body-weight). Leo Pharmaceutical Products, 
Weesp, The Netherlands. HL controls consisted of 93 male and female volunteers, 
aged 45 to 75 years, without rype 2 diabetes mellitus and hypertriglyceridemia. 
DNAAnalydw 
Genoryping of the LIPC gene for the C> T variance was carried out by determination 
of the G>A base substitution at -250 bp (38). Primers for the polymerase chain 
reaction amplification were 5-GAT ACT TTG TTA GGG AAG ACT Gcc-3' and 5-
GGA TCA CCT CTC AAT GGG TC -3'. Amplification was carried out in a 25 pL 
reaction mi..,-ture with an initial denaturation at 95°C for 5 minutes, followed by 31 
cycles of amplification at 95°C for 30 seconds, annealing at 55°C for 30 seconds, and 
e;,.-tension at 72°C for 60 seconds, with a final extension at 72°C using Goldstar Taq 
polymerase (Eurogentec). Fifteen pL of the polymerase chain reaction mix was 
digested with the restriction enzyme Dral during 2 hrs at 3JOC, followed by 
electrophoresis on a 2% agarose gel. The non digested PCR product had a length of 
560 bp. After digestion the -250G variant yielded two products of 449 and 111 bp. 
Digestion of the -250A variant yielded a major product of 335 bp and minor 
products ofll4 and 111 bp. It was shown previously thatthe -250G variant is 100% 
linked to the C variant at --514 and the -710T and -763A variants upstream in the 
LIPC promoter (18). These variants collectively form the LIPC C allele. The variant 
sequence containing -250 A, -514 T, -710 C, and -763 G, will be indicated as LIPC T 
allele. 
Statutical analy•u 
Analyses were performed by SPSS for Windows (release 9.0). Mean differences 
between the study groups were analyzed using analysis of covariance (ANCOVA), 
adjusted for baseline levels of each treatment group and study location. Intervention 
effects were also further adjusted for additional potential confounders, using 
ANCOVA. The student T-test was used to test significance between baseline and 30 
weeks follow-up. Continuous variables are presented as mean values with the 
standard deviation (SD). P values < 0.05 were considered statistically significant. 
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Results 
P aHen£ cbaracterutic.f 
The baseline characteristics of the 198 patients are shown in Table L 
There were no significant differences in the patient characteristics betvveen the three 
groups, except for the duration of diabetes, which was shorter in the placebo 
compared to the A80 group (p<0.05). Fasting glucose and HbAlc at baseline were 
relatively high, but equal in all groups. Fasting glucose did not change during the 
study. The A80 group had a slight increase in HbAlc levels (8.4 ± 1.1 %to 8.6 ± 1.3 
%, p<0.05), whereas in patients using A10 and placebo, the HbAlc levels decreased 
slightly (both 8.3 ± 1.2% to 8.1 ± 1.2 %, p<0.05). 
AtorvtLII:acin 4./ect on lipid" atUJ lipoprotein.;. 
At baseline plasma lipids and lipoproteins were similar in all three groups (Table l). 
As described before (35), administration of A1 0 and A80 resulted in significant 
reductions (25 and 35%, respectively) of plasma triglyceride levels (both p<O.OOl), 
in significant, dose-dependent, reductions (30% and 40% respectively, both 
p<O.OOl) of total cholesterol and LDL (41% and 52% respectively, both p<O.OOl). 
HDL cholesterol levels significantly increased, dose-independently, during 
atorvastatin treatment by 5 to 6% (p<0.01). 
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Table 1. Baseline characteristics 
Placebo (n=65) Atorvastatin 1omg (n=67) Atorvastatin8omg (n=66) 
Male Gender(%) 48 62 54 
Age (years) 58.5 ± 7-3 59-4 ± 7.6 60.5 ± 7.8 
Diabetes duration (years) 9-5 ± 6.1 12.2 ± 7-7 13-2 ± 8.5"' 
Diabetes treatment(%) 
Diet 3-1 1.5 0 
Tablets 40.6 50.0 43-9 
Insulin 31.3 27-3 27-3 
Combination 25.0 21.2 28.8 
Body-Mass Index (kgjm) 31-9 ± 6.1 30.1 ± 3.8 30.6 ± 4-5 
Waist to Hip ratio 0.99 ± 0.1 1.00 ± 0.1 1.00 ± 0.1 
Hypertension (%) 48 49 62 
Current smoking(%) 58 66 70 
Fasting glucose (mmoljl) 10-5 ± 3-6 10-4 ± 3.0 10.6 ± 3.0 
HbAK (%) 8.3 ± 1.2 8.3 ± 1.2 8-4 ± 1.1 
Total cholesterol (mmoljl) 6.1 ± 0.9 5-9 ± 0.8 6.0 ± 1.0 
LDL cholesterol (mmoljl) 3-7 ± 0-9 3.6 ± 0.8 3-7 ± 0.9 
HDL cholesterol (mmoljl) 1.05 ± 0.2 1.06 ± 0.3 1.04 ± 0.2 
Triglycerides (mmoljl) 2.64 ± 0.9 2.50 ± 0.9 2.82 ± 1.1 
Continuous data are expressed as mean values± standard deviation 
.,p <o.os between atorvastatin 8omg and placebo group 
HL a.ctivd:y m type 2 Jiahel:M mellitt.U. 
Baseline HL in the DALI population was significantly higher than in an age-
matched, non-diabetic controls without hypertriglyceridemia, 406 ± 150 U/L 
(n~l98) versus 357 ± 118 U/L (n=93), p<O.OOl. This was due to a significant 
increase in HL activity in the male patients compared with the male controls, 443 ± 
158 vs 397±.125 U/L (p<0.001). Female DALI patients had a comparable HL 
activity compared with female control patients (358 ± 127 vs 328 ± 105 U/L). 
Gender, LIPC genotype, ethnicity and the BMI were all significant and independent 
predictors of HL activity, demonstrated by stepwise linear regression. The LIPC 
genotype contributed 13%, gender 8%, ethnicity 4% and BMI 3% to the variance in 
HL activity (adjusted R2 of the model= 0.28, p<O.OOOl). 
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AwrvaA:a.tin effect on podtheparin tipade aetivity. 
Mean HL activity at baseline was comparable between the three study groups. In 
the placebo group there "Was no significant reduction in HL activity at the end of the 
study. HL activity decreased in the A10 group by ll o/o, p<0.001 and in the A80 
group by 22%, p<0.001 (Table 2). The additional reduction in HL activity by A80 
compared to A10 was highly significant (p<0.005). 
Table 2. Hepatic lipase activity (U/L) after 30 weeks treatment. 
Patients Placebo Atorvastatin 1omg 
All Baseline 406 ± 156 402 ± 152 
n=198 30 weeks 382 ± 146 361 ± 149''! 
Males Baseline 449 ±138 429 ± 154 
n=107 30 weeks 425 ± 128 390 ± 150'''! 
Females Baseline 358 ± 131 360 ± 155 
n=91 30 weeks 343 ± 125 318 ± 138''! 
Continuous data are expressed as mean values ±standard deviation 
1 p< o,001, significantly different from baseline in each treatment group, 
#p<o,oo2, significantly different, adjusted for baseline, from placebo after 30 weeks treatment 
~p< o,os, significantly different, adjusted for baseline, from placebo after 30 weeks treatment 
11 p<o.oos, significantly different, adjusted for baseline, from A10 after 30 weeks treatment 
Atorvastatin 8omg 
410 ± 138 
313 ± 11T'#A 
451 ± 143 
343 ± 98''#A 
356 ± 109 
278 ± 120''#A 
AwrvaJtatin effect on podtheparin lipade activity in male.i a.mJ jenuzled. 
Since HL activity in the DALI participants was significantly higher in males 
compared to females, 443 ± 158 U/L (n=107) versus 358 ± 127 UIL (n=91), p<O.OOl, 
we analyzed males and females separately. The effect on HL activity by atorvastatin 
was not influenced by gender differences. Treatment vvith atorvastatin l 0 or 80 mg 
reduced HL activity similarly ll o/o and 22% in both males and females (Table 2). 
AwrvaJtatin effect on hepatiC tipade activity in the LIPC pronwter variant. 
The C> T variance in the LIPC promoter is a strong, significant predictor of the HL 
activity, therefore we analyzed carriers and non-carriers of the T allele separately. 
In the DALI study population 55.0% of the patients were homozygote for the LIPC 
C allele, 37.4% were heterozygote for the T allele and 7.6% homozygote for the T 
allele, leading to a frequency of the T allele of 0.262. 
At baseline the presence of the T variant significantly affected HL activity (Table 3). 
In heterozygote carriers of the T allele, HL activity was l9o/o lower and in 
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homozygote carriers of the T allele 49% lower than C allele homozygotes, p<O.OOOI. 
The T-allele lowered the baseline HL activity in males and females. Male 
heterozygote and homozygote T allele carriers had respectively a 20% and 57% 
lower HL lipase activity than C homozygotes. In females this was respectively 16% 
and 37% (Table 3). In males and females the &equency of the T allele was 
comparable, 0.252 versus 0.278. 
Table 3- The effect of the L/PC C> T variance on HL activity (U/L) at baseline. 
Total 
CC genotype 444 ± 142 
n=109 
CT genotype 358 ± 135·> 
n=74 
n genotype 227 ± 96·> 
n=15 
., p<o.oo1, compared to non-carriers. 
t p<o.oo1, compared to males. 
## p=0.03, compared to males 
Males 
489 ± 131 
n=61 
390 ± 158"'" 
n=38 
212 ± 56., 
n=S 
Females 
385 ± 137# 
n=48 
324 ± 95'"## 
n=36 
244 ± 131''" 
n=7 
Homozygote carriers of the C allele and heterozygote carriers of T allele showed 
similar percentage reductions in HL activity after atorvastatin treatment (Table 4). 
In both groups, A10 resulted in a 10-12% decrease and A80 in a 21-22% reduction 
in HL activity (p<0.001 compared to placebo effect and dose-dependent, p<0.005). 
Four of the fifteen TIT homozygotes were assigned to the A1 0 treatment group, 
three to the A80 group and eight patients received placebo. Post atorvastatin 
treatment HL activities were only available in five patients. A1 0 treatment lowered 
HL activity in two cases (249 U/L to 216 U/L (-15%) and 349 to 259 U/L (-25%), 
respectively). In one case, A10 did not reduce HL activity (319 U/L to 349 U/L 
(+9%). In both subjects assigned to A80, HL activity was lowered (248 U/L to 218 
U/l (-12%) and 266 Ull to 200 U/L (-25%). A10 lowered HL activity to a similar 
degree in male and female C/C and CIT carriers (10-13%). A80 resulted in a further 
reduction of 16% in the female C/C homozygotes and to 31% in the female CIT 
heterozygotes. In males the additional decrease was respectively 27% and 19%, not 
significantly different from the female values. 
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Table 4. LIPC C> T variance and HL activity (U/L) after 30 weeks treatment. 
Genotype Placebo Atorvastatin 10mg 
CC genotype Baseline 437 ± 124 448 ± 140 
n=109 30 weeks 441 ± 139 402 ± 156<·~ 
CT genotype Baseline 352 ± 144 357 ± 121 
n=74 30 weeks 349 ±137 319 ± 128<·~ 
n genotype Baseline 224±7 306 ± 104 
n=15 30 weeks 236 ±137 273 ± 34 
~ p< o.oo1, significantly different from baseline in each treatment group. 
#p<0.001, significantly different, adjusted for baseline, from placebo after 30 weeks treatment. 
&p<o.os, significantly different, adjusted for baseline, from placebo after 30 weeks treatment 
Ethnic {}if.lerence.f, LIPC polynwrphilm a.n1J HL activity. 
Atorvastatin 8omg 
447 ± 129 
348 ± 98<·# 
366 ± 157 
280 ± 128'''# 
257 ± 76 
209 ± 45 
It has been reported that the prevalence of LIPC C and T alleles, thereby affecting 
HL activi1y, strongly varies among subjects with different ethnic offspring. So, we 
studied the influence of ethnic heterogenei1y in our study population. Mean HL 
activity at baseline was significantly lower among Asians (n=lO), Mediterranean 
(n=9) and black (n=ll) patients compared to Caucasians (n=168), respectively 350 
~ 95 U/L, 269 ~ 124 U/L, 260 ~ 127 U/L vs 415 ~ 150 U/L (p<0.01). The T allele 
frequency was very high in the black (0.590) and the Asian patients (0.400). 
Caucasians and Mediterranean patients had a T allele frequency of 0.235 and 0.222, 
respectively. At baseline HL activi1y was strongly influenced by the LIPC gene 
variance in all ethnic groups. HL activi1y was significantly higher in CC 
homozygotes than in CT heterozygotes or TT homozygotes. To study a possible 
effect of the ethnic background, Caucasians were separately analyzed for the effect 
of atorvastatin in relation with the LIPC geno1ype. Atorvastatin had similar effect in 
caucasians as in the whole study population (data not shown). The other groups 
were not analyzed separately, because of the small numbers. 
Discussion 
This prospective, randomized study demonstrated a decrease in HL activi1y, dose-
dependently by atorvastatin in 1ype 2 diabetes mellitus patients. HL activi1y 
decreased 11% and 22% after treatment with atorvastatin 10 and 80mg, respectively 
(p<0.001). In 1ype 2 diabetes mellitus HL is considered an important factor in the 
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development of the atherogenic lipid profile. Our study results are the first 
published effects in type 2 diabetes mellitus of low versus high dose statin 
influencing the HL activity. Gender and the LIPC C> T polymorphism both influence 
HL activity. Males have a higher HL activity than females. The higher HL activity 
in males is due to a number of endogenous factors, like central adiposity and sex 
steroid hormones (14,15,26,39, 40). Recently, Brunzell et al (41) also demonstrated 
that intra-abdominal fat is a major component of the gender difference in HL 
activity. Also in our diabetic study population males exhibited a higher HL actvity 
than females. While the male patients tended to have a higher HL activity compared 
to controls vvithout diabetes, in the female patients HL activity vvas similar to control 
values. Baseline HL activity correlated significantly with WHR (R= 0.20, p=0.004). 
Males had a higher WHR compared to females (p<O.OOl) and the increased HL 
activity in the males may be partially explained by this increased WHR. Atorvastatin 
treatment abolished the correlation between HL activity and WHR. In preliminary 
results we found that fatty acids may stimulate LIPC expression in HepG2 cells and 
that this effect is abolished by atorvastatin (27). Our present results are in line with 
these observations and suggest that increased HL activity in our male patients may 
be due to stimulation of HL e:\.-pression by increased supply of fatty acids derived 
from a higher abdominal fat mass as reflected in the high WHR. By interfering with 
the stimulation of HL by FF A, atorvastatin may then lower HL activity with the 
consequent loss of the association berureen HL activity and \VHR. Besides gender, 
genetic variation of the LIPC promoter strongly affected HL activity at baseline and 
contributed 13% to the variance in HL activity. In the whole study population, LIPC 
T !T homozygotes had a 50% lower HL activity than the C/C homozygotes. 
Atorvastatin lowered HL activity in all subjects independent of gender and 
genotype. Zambon and coworkers (30), found an attenuating effect of the T-allele 
on HL lowering by hypolipidemic drug treatment in hyperlipidemic patients. In the 
present study already the low dose of statin decreased HL activity in all genotypes 
similarly. It is possible that atorvastatin has a higher intrinsic capacity to lower HL 
than other hypolipidemic drugs. Alternatively, HL activity in type 2 diabetes may be 
affected in a different way than in patients •vithout diabetes. HL activity also varies 
among different ethnic groups. Our results showed that the allele frequency for the 
LIPC T allele in black patients was much higher than in Caucasian patients 
consistent with earlier studies (21). This higher prevalence of the T allele in black 
patients completely accounted for the lowered HL activity at baseline in these 
patients compared to the Caucasian patients (260 U/L vs 415 UIL). However, Nie 
et al (24) described that 97% of African Americans have at least one HL allele that 
is associated with low HL activity. The effect of ethnic background on the frequency 
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of the T allele underscores the importance of this factor, when LIPC allele frequency 
between groups, with or without diabetes, is compared. The T allele frequency in 
our Caucasian subjects was 0.235. Jansen et a! (16) reported a frequency of 0.189 
in a healthy, non-diabetic, Caucasian population. Wlthout correction for ethnicity, T 
allele frequency in the patients with type 2 diabetes, appeared to be higher than in 
Caucasians without diabetes, 0.262 versus 0.189. 
The clinical significance of our findings needs further investigation. HL seems to be 
involved in the metabolism of almost all lipoprotein classes. It may, among others, 
modulate LDL and HDL metabolism and postprandial lipid clearing. How and to 
what extend HL lowering by atorvastatin in type 2 diabetes affects these processes, 
and thereby CAD risk is presently unknown. 
Cone I usions 
Gender, LIPC promoter variant and ethnicity greatly contribute to the baseline 
variance in HL activity in type 2 diabetes mellitus. This should be taken into account 
in studies evaluating the effect of lipid lowering therapy on HL expression. 
Atorvastatin treatment results in a dose-dependent decrease in HL activity, 
regardless of gender or the LIPC promoter variant. 
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4: Genetic variation in the lipoprotein lipase gene in type~ diabetes 
and the effect of atorvastatin on lipid profiles 
Ahdtract 
Objective 
Lipoprotein lipase (LPL) gene variants may influence LPL activity and alter H DL-cholesterol 
(HDLc) and triglyceride (TG) concentrations, thereby affecting atherosclerotic risk. Genetic 
variants may modulate the efficacy of drugs. 
Research design and methods 
We investigated the effect of 3 most common variants in the LPL gene (D9N, N291S and 
S447Stop) on plasma lipids and atorvastatin treatment effects in 217 patients with type 2 
diabetes. 
Results 
At baseline, patients (n=217, aged 45-75 years) had a total cholesterol of 4.0-s.o mmoljL and 
fasting triglycerides (TG) of 1.5-6.0 mmoljl. They were treated for 6 month with atorvastatin 
(10 or So mgjdaily) for 30 weeks in a double-blind, randomized, placebo-controlled trial (DALI 
study). Allele frequencies of the LPL gene variants D9N, N291S and S447Stop were 0.026, 0.028 
and 0.097, respectively. Carriers of the D9N variant had a lowered LPL activity (-9.3%), HDLc 
(-16%) and ApoA-1 (-9.4%), and increased plasma TG ( +21%). The N291S variant did not affect 
LPL activity nor lipid levels. The S447Stop variant showed an allele-dose dependent increase in 
LPL, apoA-1, HDL cholesterol and decrease in plasma TG. Atorvastatin did not substantially 
affect LPL activity in patients without the LPL D9N, N291S or S447Stop mutation (non-
carriers). In patients carrying the LPL S447Stop mutation, LPL activity after atorvastatin 
treatment was significantly higher than in the non-carriers (145 ± 55 Units/L to 120 ± 49 
Units/L, p<o.os). The favorable lipid profile in carriers of the S447Stop mutation persisted 
under atorvastatin treatment. 
Conclusions 
LPL gene mutations influence lipids, lipoproteins and LPL activity in type 2 diabetes. The 
S447Stop mutation modulates the response of LPL activity to atorvastatin. 
Introduction 
4: Genetic variation in the lipoprotein lipase gene in type 2 diabetes 
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Lipoprotein lipase (LPL) is the major enzyme responsible for the clearance of 
plasma triglycerides (TG) (!).On the luminal endothelial surface, LPL catalysis the 
hydrolysis of TG in circulating chylomicrons and very low densi1y lipoprotein 
(VLDL) particles after stimulation by apolipoprotein CII. In this process the 
surplus of surface material, phospholipid and unesterified cholesterol, transfers to 
high densi1y lipoproteins (HDL). Consequently, HDL levels reflect LPL activi1y 
(2). Besides this enzymatic function, LPL has a non-enzymatic 11bridging 11 function 
mediating cellular binding and uptake of lipoproteins (3-6). Due to its effects on 
plasma lipoproteins and lipoprotein metabolism, LPL may affect atherosclerotic 
disease risk. LPL activi1y may lower atherogenic risk by decreasing plasma TG and 
TG-rich lipoprotein (TRLs) levels, increasing HDLc levels and stimulating hepatic 
clearance of remnant particles (7). Low LPL may therefore constitute a pro-
atherogenic condition. Indeed, in a large cohort of patients with angiographically 
proven coronary artery disease (REGRESS population), LPL activi1y was lower 
than in healthy controls (8). The lowered post-heparin LPL activi1y was associated 
with increased plasma TG levels and lowered HDLc levels. Moreover, LPL activi1y 
was inversely correlated with the severi1y of angina pectoris (9). 
Insulin is a powerful stimulatory regulator of LPL in adipose tissue (10) and 
decreased LPL has been implicated in the pathogenesis of dyslipidemia in conditions 
associated v.rith insulin resistance (ll-13). During insulin resistance overproduction 
of very low-densi1y lipoproteins (VLDL) in the liver may be compensated for by 
insulin-mediated stimulation of LPL activity vv:ith subsequent maintenance of 
normal plasma TG levels (14,15). If this system fails, like for instance in 1ype 2 
diabetes mellitus, hypertriglyceridemia might ensue. Couillard et al (16) showed that 
the duration and the extent of hypertriglyceridemia in 43 men with visceral obesi1y 
were dependent on LPL activi1y. 
Variants in the LPL gene may affect the catalytic activi1y of LPL. Three LPL 
variants with frequencies in Caucasians of 2-3% (D9N), 5% (N291S) and 5-20% 
(S447Stop mutation), may have an effect at a population level (8, 17-19). 
In non-diabetic patients, the risk of coronary disease is increased in carriers of D9N 
and N291 S mutations (20,21). The D9N variant is associated with higher TG, lower 
HDL and a trend towards a lowered LPL activi1y. The changes in lipids could 
account for the increased risk in cardiovascular disease among carriers of the LPL 
D9N mutation (17,22,23). The LPL N291S allele appears to increase the 
susceptibili1y to lipid abnormalities and cardiovascular disease in combination with 
other genetic and environmental factors, like low densi1y lipoprotein (LDL) 
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receptor mutations, familial combined hyperlipidemia, apolipoprotein E2, diabetes 
and obesity (24). In contrast, in carriers of the LPL S447Stop mutation lower 
plasma TG is associated with higher LPL activity (25-27). 
Little information is available on the effects of LPL gene variants on diabetic lipid 
metabolism. Zhang et al (28) studied 18 patients with type 2 diabetes and severe 
diabetic dyslipidemia for mutations in the LPL gene. Eight of these patients 
contained 7 different genetic variants at the lipoprotein lipase gene locus and four of 
these patients probably had a functional mutant. Zhang and coworkers concluded 
that genetic variants at the lipoprotein lipase locus are common in subjects ~th type 
2 diabetes mellitus, obesity and hyperlipidemia and that mutations in the LPL gene 
may affect the individual susceptibility for the development of hyperlipidemia. LPL 
gene variants not only determine baseline levels of LPL activity, but also affect the 
response to various drugs in non-diabetic patients (23,25,29). In the DALI study 
(30) patients with type 2 diabetes were treated with atorvastatin, a HMG CoA 
reductase inhibitor. Atorvastatin did not affect mean LPL activity (30), but this does 
not exclude an effect of the LPL gene variants on the response to atorvastatin. We 
now report on the effect of atorvastatin on post-heparin LPL activity, lipids and 
lipoproteins in non-carriers and carriers of LPL gene mutations (D9N, N291S and 
S447Stop). 
Patients and methods 
StWJy popalatwn 
This study is part of the Diabetes Atorvastatin Lipid Intervention (DALI) study. 
DAL! is a randomized double-blind, placebo-controlled, multi-center trial 
conducted in the Netherlands. The subjects and methods are described in detail 
earlier (30). 
In summary, 217 patients, aged 45 to 75 years, with type 2 diabetes mellitus were 
randomized to placebo, atorvastatin 10mg (A10) or atorvastatin 80mg (A80) for 30 
weeks, to evaluate the effect on lipid metabolism, endothelial function, coa,oulation 
and inflammatory parameters. The main inclusion criteria were plasma TG betvveen 
1.5 and 6.0 mmol!l, total cholesterol between 4.0 and 8.0 mmol!l and no history of 
corona:ry heart disease. Patients were recruited at centers in Leiden, Rotterdam and 
Utrecht in the Netherlands. The study protocol was approved by the Ethical 
Committees of the participating centers and all procedures followed were in 
accordance with institutional guidelines. Written informed consent was obtained 
from all subjects. 
Analytical metho()., 
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Blood samples were drawn after 12 h of fasting at baseline and after 30 weeks, at the 
end of the treatment period. Standard lipid variables (Total cholesterol (TC), LDLc, 
HDLc, TG, apolipoprotein A-I (ApoA-1), apolipoprotein B-100 (Apo B-100)), 
plasma glucose and HbA1c were measured. Cholesterol and TG were determined by 
enzymatic colorimetric methods on a Hitachi 911 automatic analyzer (Boehringer 
Mannheim, Mannheim, Germany). Plasma HDLc was measured by a direct 
enzymatic HDLc method, after precipitation of VLDL and LDLc by addition of 
manganese chloride. LDLc was estimated by the Friedewald formula (31). ApoA-1 
and ApoB-100 were determined on a Hitachi 917 analyzer, using 
immunoturbidimetric methods (Tina-quant apoA, Cat.Nr.1551680, apo B, 
Cat.Nr.1551779; Boehringer Mannheim). Fasting plasma glucose was determined 
on a Hitachi 917 analyzer using an UV-hexokinase method (Cat. Nr.18766899) from 
Boehringer Mannheim, Mannheim, Germany. HbA1c was determined by HPLC, 
using the BIO-RAD Variant TM method (Cat.Nr.270-0003.Bio-rad). 
Po.1theparin pla.ima liptUe activity 
LPL activit;y was measured using an immunochemical method as described 
previously (32) in plasma collected 20 min after contralateral intravenous 
administration of 50 IU!kg body-weight heparin (Leo Pharmaceutical Products, 
Weesp, The Netherlands). LPL controls consisted of 185 male and female 
volunteers, aged 45 to 75 years, vvithout type 2 diabetes mellitus and 
hypertriglyceridemia. Of 217 DALI patients, 198 blood samples for evaluation of 
post heparin LPL activi1y were available. Eleven samples were excluded from the 
analysis because very low activities of LPL and HL in post heparin plasma indicated 
insufficient heparin delivery. Of eight patients no blood sample for post heparin 
lipase activi1y was available. 
DNA Analy.1u 
For DNA analysis of the LPL gene, 212 bloodsamples were available. DNA from all 
patients was subjected to mutation analysis by polymerase chain reaction (PCR) 
and densi1y gradient gel electrophoresis (DGGE). To identify carriers for the D9N 
mutation, PCR analysis was performed with primers: 5'-CTC ATA TCC AAT TTT 
TCC TT -3'; 5'-ATA AAT ATA AAA TAT AAA TAG GGG TCA GGG CAA ATT 
TAC TTT CAA TG -3' (33). Amplification yielded a non-digested PCR product 
with a length of 114 bp. After digestion with Taql, the D9N mutant allele yielded 
two products of 74 and 40 bp. To identifY carriers for the N291S mutation, PCR 
analysis was performed with primers:5'- GCC GAG ATA CAA TCT TGG TG -3': 
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5' -CTG CTT CTT TTG GCT CTG ACT GTA -3' (34). Amplification yielded a 
non-digested PCR product >.Vith a length of 238 bp. After digestion with RSAl, the 
N291S mutant allele yielded two products of215 and 23 bp. To identify carriers for 
the S447 Stop mutation, PCR analysis was performed >.Vith primers: 5'-CAT CCA TTT 
TCT TCC ACA GGG -3'; 5'-GCC CAG AAT GCT CAC CAG ACT -3' (33). 
Amplification yielded a non-digested PCR product >.Vith a length of 120 bp. After 
digestion >.Vith Hinfl, the S447 Stop mutant allele yielded two products of98 and 22 bp. 
Statutical analy<~u 
Statistical analyses were performed using SPSS for Windows (release 9.0). JVlean 
differences between the study groups were analyzed using analysis of covariance 
(ANCOVA), adjusted for baseline levels. Continuous variables are presented as 
mean values >.Vith the standard deviation (SD). P values < 0.05 were considered 
statistically significant. 
Results 
PaHent characteruticd 
The baseline characteristics of the DALI patients have been described before (30). 
According to the inclusion criteria, 217 patients were randomized. There were no 
significant differences in the patient characteristics between the placebo, 
atorvastatin l Omg (AI 0) and atorvastatin 80mg (A80) groups, except for the 
duration of diabetes, which was shorter in the placebo group compared to A80, 
respectively 8.2 ± 5.9 vs 12.2 ± 8.3 years (p<0.05). Mean body-mass index (BMI), 
glucose, HbAlc, lipid, lipoprotein plasma values and LPL activi1y at baseline are 
shown in Table 1. 
Mean baseline LPL activi1y in the whole DALI population was not significantly 
different from age-matched, non-diabetic controls >.Vithout hypertriglyceridemia, 
139 ± 40 UIL (n=l98) vs 150 ± 54 U/L (n=l85), p=0.09. There was no correlation 
between LPL activi1y, age, smoking habits, alcohol use, hypertension, BMI and the 
Waist Hip Ratio (WHR). LPL activi1y was correlated significantly >.Vith total 
cholesterol, HDLc and apoA (respectively r=0.24, p=0.001, r=0.22, p=0.002 and 
r=0.26, p<O.OOl), but not >.Vith plasma TG or apoB (r=-0.12, p=0.08 and r=0.10, 
p=0.14). 
Table 1 Baseline characteristics 
Male sex(%) 
Age (years) 
BMI (kgjm2) 
Fasting glucose (mmoljL) 
HbA1c (%) 
Triglycerides (mmoljL) 
Total cholesterol (mmoljL) 
LDL-c (mmoljL) 
HDL-c (mmoljL) 
Apo A-1 (g/L) 
Apo B-100 (mgj1oo mL) 
LPL activity (U/L) 
Data are means± sd. 
BMI=Body mass index, LPL= Lipoprotein lipase 
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DALI patients 
(n=217) 
53 
59-5 
30.9 ± 4-5 
10.6 ± 3-2 
8.3 ± 1.1 
2.62 ± 1.0 
5-99 ± 0.9 
3-71 ± 0.3 
1.04 ± 0.2 
1-40 ± 0.2 
1.24 ± 0.2 
139 ± 40 
LPL a.ctivify and lipid profdu in ca.rrierd and !Wncarrierd of LPL gene nudaMIU-
The D9N mutation was detected in ll out of212 patients, giving an allele frequency 
of 0.026. The N291S mutation was present in 12 patients (0.028) and the S447Stop 
mutation in 38 patients (0.097). Among the 38 carriers of the LPL:S447Stop 
mutation, 35 were heterozygote and 3 homozygote. There was no significant 
difference in age or WHR, blood pressure, alcohol use and smoking habits (data not 
shown) or BMI (Table 2) between carriers and non-carriers of LPL mutations. 
There was a gender associated difference in the frequency of carriers of the N29l S, 
most N29l S carriers being males (Table 2). None of the patients carried more than 
one LPL variant. 
The effect of the D9N and the N291S mutation on LPL activity and plasma lipids is 
shown in Table 2. Compared to patients without a D9N, N291S or S447Stop 
mutation (non-carriers), heterozygote carriers of the D9N allele showed a 
significantly lower LPL activity, a higher plasma TG concentration and a lower 
HDLc and apoA-1 concentration. The N291S allele had no effect on LPL activity, 
TG nor on HDLc concentrations. 
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Table 2 Patients characteristics according to presence of LPL D9N and LPL N291S mutations. 
Noncarriers LPL:D9N carriers 
Total (151) Heterozygotes (11) 
Male(Female 81/70 7/4 
BMI (kg(m2) 30.2 (0.4) 31.6 (1.S) 
TC (mmoi(L) 6.01 (0-9) 5.87 (o.6) 
TG (mmolfL) 2.67 (1.0) 3.22 (1.0)# 
HDLc (mmoi(L) 1.03 (0.2) 0.87 (0.1)$ 
ApoA (g/L) 1.39 (0.1) 1.26 (0.2)# 
LPL activity (U/L) 130 (41) 121 (44)# 
Noncarriers are patients without a D9N, N291S, S447Stop mutation in the LPL gene. 
Data are expressed as mean (sd). 
#p<o.os, ~p=o.o1 compared to non-carriers. 
LPL:N291S carriers 
Heterozygotes (12) 
11/1 
28.1 (1.1) 
6.12 (0.9) 
2.64 (1.1) 
0.98 (0.1) 
1.36 (0.1) 
136 (39) 
In patients carrying a S447Stop allele there was a tendency for higher BMI, LPL 
activity, HDLc, ApoA-1 and lower TC and TG v.~th increasing allele frequency 
(Table 3). Patients who were homozygote for the S447Stop mutation had a 
significant lower TG, higher HDLc and apoA concentration (p<0.05) and a higher 
LPL activity than the non-carriers (p<0.01). The LPL activity was higher in the 
homozygote carriers compared to the heterozygote carriers of the S447Stop 
mutation (p<0.05). 
It is well known that the frequency of mutations may vary among different ethnic 
groups (35). To exclude other ethnic influences on LPL activity, the Caucasians 
carrying a LPL mutation (57 of 61 LPL mutation carriers) were analyzed separately 
for the effect of the LPL gene variance on lipids and lipase activities. The results of 
this analysis were similar to those of the whole study population. 
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Table 3 Patients characteristics according to presence of LPL S447Stop mutation. 
Non-carriers LPL:S447stop 
Total (151) Heterozygotes (35) 
Male/Female 81/70 17/18 
BMI (kg/m2) 30.2 (0-4) 31.5 (0-3) 
TC (mmolfL) 6.01 (0-9) 5.92 (o.8) 
TG (mmolfl) 2.67 (1.0) 2.64 (1.0) 
HDLc (mmolfL) 1.03 (0.2) 1.09 (0.1) 
ApoA (g/L) 1.39 (0.1) 1.44 (0.2) 
LPL activity (U/L) 130 (41) 136 ( 61) 
Noncarriers are patients without a D9N, N291S, S447Stop mutation in the LPL gene. 
Data are expressed as mean (sd). 
#p<o.os, ~p<o.o1 compared to non·carriers 
&p<o.os compared to heterozygote carriers 
LipUJ profil.eJ an2 LPL activit:y in carrier.1 of a LPL S447Stop 
muJ:ation treated with alorvadtatin. 
LPL:S4475top 
Homozygotes (3) 
1/2 
32.0 (0.4) 
5-7 (0.6) 
2.11 (1.1)# 
1.30 (0.1)# 
1.60 (0.2)# 
162 (2o)!& 
We compared the effect of atorvastatin versus placebo treatment in non-carriers and 
carriers of LPL mutations on LPL activity and lipid profiles. For reasons of small 
numbers of carriers of the LPL D9N and N291S mutations treated with 
atorvastatin, only the patients that were carriers of the S447Stop mutation were 
analyzed. Patients receiving A1 0 or A80 were analyzed together. The single 
S447Stop homozygote patient that received atorvastatin was analyzed together with 
the heterozygote carriers as separate analysis did not reveal any significant 
differences (data not shown). Placebo treatment had no effect on LPL activity in 
non-carriers nor in carriers (126 ±50 U/L, n~42, at baseline vs 129 ±58 U/L after .30 
weeks and 1.30 ±41 U/L, n~9, at baseline vs 1.3.3 ±4.3 U/L after .30 weeks, 
respectively). Atorvastatin tended to lower LPL in the non~carriers and to increase 
LPL in the carriers of the S447Stop variant (Table 4). Consequently, after 30 weeks 
atorvastatin, LPL activity was significantly higher in the carriers compared to the 
non-carriers (p<0.05). In the carriers and non-carriers of the S447Stop mutation, 
there was a beneficial change in lipid profJe after atorvastatin treatment. The apo A-
I concentration was significantly higher and there was a tendency towards a higher 
HDLc level compared with the levels in the non-carriers receiving atorvastatin. 
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Table 4 Effect of atorvastatin in non-carriers and carriers of the S447Stop mutation 
Effect atorvastatin Non-carriers 
N;109 
LPL activity (U/L) Baseline 130 (47) 
30 weeks 138 (58) 
Total cholesterol (mmoljL) Baseline 5-96 (0.9) 
30 weeks 3.86 (1.0) 
Triglycerides (mmoljL) Baseline 2.68 (1.0) 
30 weeks 1.79 (1.1) 
HDLc (mmoljL) Baseline 1.04 (0.3) 
30 weeks 1.09 (0.3) 
ApoA (g/L) Baseline 1.39 (0.2) 
30 weeks 1.35 (0.2) 
Noncarriers are patients without a D9N, N291S, S447Stop mutation in the LPL gene. 
Patients receiving atorvastatin 1omg or 8omg were analyzed together. 
+p<o.os compared to non-carriers at end of study, adjusted for baseline levels. 
Discussion 
LPL:S447Stop 
N;29 
120 (49) 
145 (55) 
5-79 (o.S) 
3-96 (0.9) 
2.39 (1.0) 
1.74 (1.1) 
1.14 (0.3) 
1.21 (0.3) 
1-48 (0.2) 
1.46 (o.2r 
In a previous study (30), we described the lipid-lowering effects of atorvastatin in a 
population of type 2 diabetes patients. Both plasma cholesterol and TG levels were 
significantly lowered by low (lOmg) as well as high (80mg) treatment doses of 
atorvastatin. The TG-lowering effect of atorvastatin occured without affecting LPL 
activity'. Although it remains controversial (36), previous studies also suggested that 
mechanisms other than enhancing lipolysis of TRLs by LPL contributed 
substantially to the TG-reduction by atorvastatin (37,38). However, in patients 
carrying a LPL gene variant it is still possible that the LPL gene variant affects the 
response to atorvastatin. The information on the presence of LPL gene mutations in 
patients with diabetes mellitus, is confined to some isolated cases (39) and a small 
group (four out of 18 patients) with functional mutations in the LPL gene resulting 
in lower plasma LPL activity (28). Therefore, we studied the occurrence of LPL 
gene mutations and the influence of a common LPL mutation (S447Stop) on the 
ability of atorvastatin to improve lipid profiles in patients with type 2 diabetes and 
mild hypertriglyceridemia. The carrier frequencies of LPL D9N, LPL N29lS and 
LPL S447Stop mutation were 5.2%, 5.7% and 18%, respectively. This frequency of 
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the LPL mutations is in line with frequencies found in a meta-analysis described by 
Wittrup et al (20). Carriers of the LPL D9N mutation had a significant lower LPL 
activity and a more atherogenic lipid profile than patients without a D9N, N291S or 
S447Stop mutation in the LPL gene. This is in accordance with previous studies in 
patients without diabetes (17,22,23). The reduced LPL activity and consequently 
elevated TG levels and reduced HDLc levels probably affect an individual's risk of 
ischemic heart disease (40). Elevated TG levels result in remnant accumulation and 
reduced HDLc in reduced reverse cholesterol transport, both promoting 
atherosclerosis. Prolonged post-prandial lipemia accompanying depressed LPL 
activity, is also linked to increased risk for coronary artery disease. 
Carriers of the LPL N291S mutation had similar LPL activity and lipid profiles as 
non-carriers. Homozygote carriers of the S447Stop mutation had significant higher 
LPL activity and a more favorable lipid profile compared with non-carriers or 
carriers of the LPL D9N and N291 S mutations. As described earlier by Henderson 
and coworkers (8), the S447Stop mutation is associated with an increase in LPL 
activity which manifests with lower plasma TG and higher HDLc levels in carriers 
of this variant. Our results also point to an allele dose dependency regarding LPL 
activity and its effect on lipid profiles of the patients. Compared to homozygote 
carriers, heterozygote carriers of the S447 stop mutation only had slightly higher 
LPL activity, HDLc and apoA-1 levels and lower TC and TG levels. However, in 
carriers of the S447Stop mutation the risk of ischemic heart disease is possibly 
decreased (20), therefore even small, favorable changes in lipid profiles in these 
carriers are probably of importance. 
In this study we report that although atorvastatin does not significantly increase 
LPL activity in carriers of the S447Stop mutation that those carriers do have a 
significant 20% higher LPL activity after 30 weeks atorvastatin compared with the 
non-carriers. This is due to a tendency of atorvastatin to lower LPL activity in non-
carriers and to elevate LPL activity in carriers of the LPL S447Stop mutation. So 
this mutation seems to modulate the effect of atorvastatin on LPL activity positively 
and results in a differential response to treatment. After atorvastatin treatment the 
less atherogenic lipid profile of the LPL S447Stop carriers is still detectable. This is 
important information since the S447Stop mutation is very common in different 
populations, with a carrier frequency of 17-22% (20). Due to a small number of 
carriers of the LPL D9N and N291 S mutation, that were treated with atorvastatin, 
we were not able to study the influence of these LPL mutations on the ability of 
atorvastatin to improve lipid profiles in the diabetes patients. More population-
based research to investigate whether these LPL mutations influence the 
hypolipidemic effect of statins drugs is required. 
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It is important to realize that our LPL data are data gathered in the fasted state. 
Since LPL plays an important role during the postprandial period in the plasma 
lipoprotein homeostasis (41), it is possible that the difference in LPL between the 
non-carriers and the carriers of the LPL S447Stop mutation will have an even 
greater impact in the postprandial state. Recently, Panarotto and coworkers (ll) 
concluded that the regulation of adipose tissue LPL is significantly affected in 
insulin-resistant individuals in the postprandial period and that the impaired effect 
of insulin on LPL postprandially contributed to the atherogenic dyslipidemia 
described in the insulin resistance syndrome. 
The American Diabetes Association (ADA) recommends HMG-CoA reductase 
inhibitors (statins) as first choice lipid regulating pharmacotherapy in patients with 
diabetes and a diabetic dyslipidemia in order to reach clinical targets ( 42). 
Therefore, more information about the contribution of the genetic variation in the 
LPL gene to the lipid profile is warranted, not only for cardiovascular risk 
stratification, but also to elucidate the response to hypolipidemic treatment. 
Conclusions 
LPL gene mutations influence lipids, lipoproteins and LPL achVIty m type 2 
diabetes, which will affect the risk for cardiovascular disease. The S447Stop 
mutation modulates the response to atorvastatin resulting in a further improvement 
of the diabetic dyslipidemia profile. 
References 
4: Genetic variation in the lipoprotein lipase gene in type 2 diabetes 
and the effect of atorvastatin on lipid profiles 
Eckel RH. Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic 
diseases. N Eng! J Med 1989;320:1o6o-1o68. 
2 Eisenberg S, Chajek T, and Deckelbaum R. The plasma origin of low density and high 
density lipoproteins. In: Parnow B, Carlson L, editors. Metabolk risk factors ·m ischaemk 
CV disease. New York: Raven Press, 1981:56. 
3 Mulder M, Lombadri P, Jansen H, van Berkel TJ, Frants RR, and Havekes LM. Low density 
lipoprotein receptor ·mterna!izes low dens.lty and very low density lipoprote·1ns that are 
bound to heparan sulfate proteoglycans via lipoprotein lipase. J Bioi Chem 1993;268:9369-
9375. 
4 De Beers F, Hendriks WL, van Vark LC, Kamerling SWA, van Dijk KO, and Hofker MH. 
Binding of B-VLDL to heparan sulfate proteoglycans requires lipoprotein lipase, whereas 
a poE only modulates binding affinity. Arterioscler Thromb Vase Bioi. 1999;19:633-637. 
5 Saxena U, Klein MG, Vanni TM, and Goldberg !J. Lipoprotein lipase increases low density 
lipoprotein retention by subendothelial cell matrix. J Clin Invest 1992;89:373-380. 
6 Krapp A, Zhang H, Ginzinger D, Lin MS, Lindberg A, Olivecrona G, Hayden MR, and 
Beisiegel U. Structural features in lipoprotein lipase necessary for the mediation of 
lipoprotein uptake into cells. J Lipid Res 1995;36:2362-2373. 
7 Skottova N, Savonen R, Lookene A, Hultin M, and Olivecrona G. Lipoprotein lipase 
enhances removal of chylomicrons and chylomicron remnants by the perfused rat liver. J 
Lipid Res.1995;36:1334-1344. 
8 Henderson HE, Kastelein JJ, Zwinderman AH, Gagne E, Jukema JW, Reymer PW, 
Groenemeyer BE, Lie Kl, Bruschke AV, Hayden MR, and Jansen H. Lipoprotein lipase 
activity is decreased in a large cohort of patients with coronary artery disease and is 
associated with changes in 1"1pids and lipoproteins. J Lipid Res1999;40:735-743. 
9 Kastelein JJ, Jukema JW, Zwinderman AH, Clee S, van Boven AJ, Jansen H, Rabelink TJ, 
Peters RJ, Lie Kl, Liu G, Bruschke AV, and Hayden MR. Lipoprotein lipase activity is 
associated with the severity of angina pectoris. REGRESS Study Group. Circulation 
2000;102:1629-1633· 
10 Farese RV Jr, Yost TJ, and Eckel RH. Tissue-specific regulation of lipoprotein lipase activity 
by insulin/glucose in normal weight humans. Metabolism 1991;40:214-216. 
11 Panarotto D, Remillard P, Bouffard L and Maheux P. Insulin resistance affects the 
regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific 
manner. Eur J Clin Invest 2002,32:84-92. 
12 Nikki1.3 EA, Huttunen JK, and Ehnholm C. Postheparin plasma lipoprotein lipase and 
hepatic lipase in diabetes mellitus. Relationship to plasma triglyceride metabolism. 
Diabetes 1977;26:11-21. 
13 Taskinen M-R, Nikkila EA, Kuusi T, and Harne K. Lipoprotein lipase activity and serum 
lipoproteins in untreated type 2 (insulin-independent) diabetes associated w·1th obesity. 
Diabetologica 1982;22:46-so. 
4: Genetic variation in the lipoprotein lipase gene in type 2 diabetes 
and the effect of atorvastatin on lipid profiles 
14 Chen YD, Coulston AM, Zhou MY, Hollenbeck CB, and Reaven GM. Why do low-fat high-
carbohydrate diets accentuate postprandial lipemia in patients with NIDDM? Diabetes 
Care 1995;18:10-16. 
15 Howard Band Howard WJ. Dyslipidemia in NIDDM. Endocrine Rev 1994;15:26;-:qs. 
16 Couillard C, Bergeron N, Prud'homme D, Bergeron J, Trembly A, Bouchard C, Mauriege P, 
and Despres JP. Postprandial triglyceride response in visceral obesity in men. Diabetes 
1998:47=953-960. 
17 Mailly F, Tugrul Y, Reymer PW, Bruin T, Seed M, Groenemeyer BF, Asplund-Carlsen A, 
Vallance D, Winder AF, Miller GJ, l<astelein JJP, Hamsten A, Olivecrona G, Humphries SE, 
and Talmud PJ. A common variant in the gene for lipoprotein lipase (Asp9-->Asn). 
Functional implications and prevalence in normal and hyperlipidemic subjects. 
Arterioscler Thromb Vase Biol1995:15:468-478. 
18 Assmann G, Cullen P, and Schulte H. Risk factors from epidemiology to genetics in the 
Munster Heart Study (PRO CAM). 66th Congress of the European Atherosclerosis Society. 
Florence: Foundazione Giovanni Lorenzini; 1996, p, 29. 
19 Mattu RK, Needham EW, Morgan R, Rees A, Hackshaw AK, Stocks J, Elwood PC, and 
Galton DJ. DNA variants at the LPL gene locus associate with angiographically defined 
severity of atherosclerosis and serum lipoprotein levels in a Welsh population. Arterioscler 
Thromb 1994;14:1090-1097. 
20 Wittrup HH, Tybjaerg-Hansen A, and Nordestgaard BG. Lipoprotein lipase mutations, 
plasma lipids and lipoproteins, and the risk of ischemic heart disease. A meta-analysis. 
Circulation 1999;99:2901-2907. 
21 l<astelein JJ, Ordovas JM, Wittekoek ME, Pimstone SN, Wilson WF, Gagne SE, Larson MG, 
Schaefer EJ, Boer JM, Gerdes C, and Hayden MR. Two common mutations (D9N, N291S) 
in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and 
lipoproteins in men and women. Clin Genet.1999;s6:297-305. 
2.2 Kastelein JJ, Groenemeijer BE, Hallman DM, Henderson H, Reymer PW, Gagne SE, Jansen 
H, Seidell JC, l<romhout D, Jukema JW, Bruschke AV, Boerwinkle E and Hayden MR. The 
Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an 
increased risk of coronary artery disease. The Regress Study Group. Clin Genet 1998;53:27-
33. 
23 Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JHC, Bruschke AVG, 
Henneman JA, Mol hoek GP, Bruin T, Jansen H, Gagne E, Hayden MR and Kastelein JJ. The 
Asn9 mutation in the lipoprotein lipase gene is associated with increased progression of 
coronary atherosclerosis. Circulation 1996;94:1913-1918. 
24 Hokanson JE. Functional variants in the lipoprotein lipase gene and the risk of 
cardiovascular disease. Curr Opin Lipidol1999;1o:393-399. 
25 Groenemeijer BE, Hallman MD, Reymer PW, Gagne E, !<uivenhoven JA, Bruin T,Jansen H, 
Lie 1<!, Bruschke AV, Boerwinkle E, Hayden MR, and Kastelein JJ. Genetic variant showing 
a positive interaction with beta-blocking agents with beneficial influence on lipoprotein 
lipase activity. H DL cholesterol, and triglyceride levels in coronary artery disease patients: 
4: Genetic variation in the lipoprotein lipase gene in type 2 diabetes 
and the effect of atorvastatin on lipid profiles 
The Ser447-Stop substitution in the lipoprotein lipase gene. Circulation 1997;95:2628-
2635. 
26 Humphries SE, Nicaud V, Margalef J, Tiret L, and Talmud PJ. Lipoprotein lipase gene 
variat"1on is associated with a paternal history of premature coronary artery disease and 
fasting and postprandial plasma triglycerides: the European Atherosclerosis Research 
Study (EARS). Arterioscler Thromb Vase Biol1998;18:s26-534. 
27 Nykjaer A, Nielsen M, Lookene A, Meyer N, Roigaard H, Etzerodt M, Beisiegel U, 
Olivecrona G, and Gliemann J. A carboxyl-terminal fragment of lipoprotein lipase binds to 
the low density lipoprotein receptor-related protein and inhibits lipase-mediated uptake 
of lipoprotein in cells. J Bioi Chem 1994;269:311747-31755. 
28 Zhang Q, Cavallero E, Hoffmann MM, Cavanna J, Kay A, Charles AK, Braschi S, Marz W, 
Perlemuter L, Jacotot B and Galton DJ. Mutations at the lipoprotein lipase gene locus in 
subjects with diabetes mellitus, obesity and lipaemia. Clin Sci 1997;93:335-341. 
29 Brisson D, Ledoux 1<, Bosse Y, St-Pierre J, Julien P, Perron P, Hudson TJ, Vohl, M-C and 
Gaudet D. Effect of apolipoprotein E, peroxisome proliferator-acflvated receptor alpha 
and lipoprotein lipases gene mutations on the ability of fenofibrate to improve lipid 
profiles and reach clinical guideline targets among hypertriglyceridemic patients. 
Pharmacogenef1cs 2002;12:313-320. 
30 The Diabetes Atorvastatin Lipid lntervention(DALI) study group. The effect of aggressive 
versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The DALI study: a 
double-blind random·1zed placebo controlled trial in patients with type 2 diabetes mellitus 
and diabetic dyslipidemia. Diabetes Care 2001; 24:1335-1341. 
31 Friedewald WT, Levy RJ, and Fredrickson DS. Estimation of the concentration of low-
density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. 
Clin Chem 1972;178:499-502. 
32 Jansen H. Hop W, van To! A, Brusschke AV, and Birkenhager JC. Hepatic lipase and 
lipoprotein lipase are not major determinants of the low density lipoprotein subclass 
pattern in human subjects with coronary heart disease. Atherosclerosis 1994;107:45-54. 
33 Hoffer MJ, Bredie SJ, Snieder H. Reymer PW, Demacker PN, Havekes LM, Boomsma Dl, 
Stalenhoef AF, Frants RR, and Kastelein JJ. Gender-related association between the 
--93Tft.GjD9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial 
combined hyperlipidemia. Atherosclerosis 1998;138:91-99. 
34 Zhang H, Reymer PW, Liu MS, Forsythe IJ, Groenemeyer BE, Frohlich J, Brunzell JD, 
l<astelein JJ, Hayden MR, and MaY. Patients with apoE3 deficiency (E2(2, E3(2, and E4(2) 
who man·lfest with hyperlipidem·la have increased frequency of an Asn 291 tSer mutaf1on 
in the human LPL gene. Arterioscler Thromb Vase Biol1995;15:1695-1703. 
35 Goldberg !J and Merkel M. Lipoprotein lipase: physiology, biochemistry, and molecular 
biology. Frontiers in Bioscience 2001;6:388-405. 
36 Hoogerbrugge N and Jansen H. Atorvastatin increase low-density lipoprotein size and 
enhances high-density lipoprotein cholesterol concentration in male, but not in female 
patients with familial hypercholesterolemia. Atherosclerosis 1999;146:167-174. 
4: Genetic variation in the lipoprotein lipase gene in type 2 diabetes 
and the effect of atorvastatin on lipid profiles 
37 Kobayashi J, Maruyama T, Masuda M, and Shinomiya M. Effect of atorvastatin treatment 
on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. 
Clin Chim Acta 2001a14:261-264. 
38 Heller FR, Descamps OS, Hondekijn JC, and Desager JP. Atorvastatin and the plasma 
activities of lipoprotein lipase, hepatic lipase and lecithin:cholestero! acyltransferase in 
patients with mixed hyperlipidemia. Eur J lnt Med. 2000;11:33-38. 
39 Wilson DE, Hata A, and Kwong LK. Mutations in exon 3 of the lipoprotein lipase gene 
segregating in a family with hypertriglyceridemia, pancreatitis and non-insulin-dependent 
diabetes. J Clin Invest 1993;92:203-211. 
40 Kastelein JJ, Jukema JW, Zwinderman AH, Clee S, van Boven AJ, Jansen H, Rabelink TJ, 
Peters R.J, Lie 1<1, Liu G, Bruschke AV, and Hayden MR. Lipoprotein lipase activity is 
associated with severity of angina pectoris, Regress Study Group. Circulation 
2000;102:1629-1633· 
41 Karpe F, Steiner G, Olivecrona T, Carlson LA, and Hamsten A. Metabolism of triglyceride-
rich lipoproteins during alimentary lipemia. J Clin Invest 1993;91:748-758 
42 Haffner SM. Management of dys!ipidemia in adults with diabetes. (Technical Review). 
Diabetes Care 1998; 21:160-178. 
4: Genetic variation in the lipoprotein lipase gene in type 2 diabetes 
and the effect of atorvastatin on lipid profiles 

Atorwutatin JecretUe.J atherogenic LpB:CIII in 
type 2 ()Uzhete.J mellittU, a mecbanifm to 
lower pla.ima triglycerwu 
Ingrid IL Berk-Pianken, 
MD', Geesje M Dallinga-
Thie, MRBC, PhD,, Aart H 
Bootsma, MD, PhD', Hans 
Jansen, MRBC, PhD'·3, on 
behalf of the 
DALI study group. 
1 Department of Internal 
Medicine and 
3 Departments of 
Biochemistry and Clinical 
Chemistry, 
Erasmus MC, University 
Medical Center 
Rotterdam, Rotterdam, 
The Netherlands. 
2 Department of Internal 
Medicine, University 
Medical Center Utrecht, 
Utrecht, The Netherlands. 
Submitted 
---------------
-~-~----~":.:_Lv 
s: Atorvastatin decreases atherogenic LpB:CIJI in type 2 diabetes mellitus, 
a mechanism to lower plasma triglycerides 
Ab<itract 
Objective 
Apolipoprotein (apo)C-111 is a constituent of HDL (HDL apoC -Ill) and apolipoproteinB-100 
(apoB-1oo)-containing lipoproteins (LpB:CIII). It slows the clearance of triglyceride-rich 
lipoproteins (TRLs) by inhibiting lipoprotein lipase (LPL) activity and interfering with 
lipoprotein binding to cell-surface receptors. Elevated levels of LpB:CIII are an independent risk 
factor for cardiovascular disease. 
Research design and methods 
We studied the effect of 30 weeks treatment with 10mg (A1o) and Somg (A8o) atorvastatin on 
apoC-IIIIeve!s in a randomized double-blind placebo-controlled trial with 217 patients with type 
2 diabetes mellitus and fasting triglycerides between 1.5 and 6.o mmoljl. 
Results 
Basel"me levels of total apoC-111, HDL apoC-111 and LpB:CIII were respectively 41.5 (10.0) mg/L, 
17.7 (5-5) mgjL and 23.8 (7-7) mgjL. ApoC-111 strongly correlated with plasma triglyceride, 
r=0.74, p<0.001. ApoC-111 (75%) (75% LpB:CIII and 25% HDL apo Clll) and LPL activity (-14%) 
were major determinants of plasma triglyceride levels. A10 and A8o significantly decreased 
apoC-111 (23%), HDL apo C-111 (16% and 23%) and LpB:CIII (28%). The decrease in apoC-111, 
mainly in LpB:CII! strongly correlated with a decrease in triglycerides (r=o.?8, p<o.oo1). 
Conclusions 
Atorvastatin treatment resulted in a significant dose-dependent reduction in plasma apoC-1!1, 
HDL apoC-111, and LpB:CIIIIevels in patients with type 2 diabetes mellitus. These data indicate 
a potentially important anti-atherogenic effect of statin treatment and explain part of the 
triglyceride lowering effect of atorvastatin. 
Introduction 
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Hypertriglyceridemia, low levels of HDL-cholesterol, and preponderance of small 
dense LDL particles are risk factors for cardiovascular disease (1,2). These factors 
are part of the atherogenic lipoprotein profile often found in patients with type 2 
diabetes mellitus. Hypertriglyceridemia may develop as a consequence of both 
overproduction and delayed clearance of triglyceride-rich lipoprotein particles 
(TRL). Plasma concentrations of triglycerides and apolipoprotein (apo)C-III are 
strongly correlated in healthy controls and hyperlipidemic patients (3). ApoC- Ill is 
an important element in the metabolism of TRL. Our understanding of the function 
of apoC-III present on TRLs has been derived from animal studies as well as studies 
using cell culture systems. In vitro studies have implicated apoC-III as a 
noncompetitive inhibitor oflipoprotein lipase (LPL) activity (4,5). ApoC-III is also 
implicated in the clearance of TRL remnants. It may interfere with lipoprotein 
uptake by hepatic lipoprotein receptors, resulting in accumulation of large TRLs in 
plasma (6,7). The assumption that apoC-Ill is involved in the metabolism of TRLs 
is supported by studies with genetically modified animals. Transgenic animals 
overeA"Pressing the human apoC-III gene developed severe h_ypertriglyceridemia 
(8). It is likely that the increased apoC-III content of TRLs impaired the catabolism 
of these particles resulting in hypertriglyceridemia (9, 1 0). Mice lacking apoC-Ill, on 
the other hand, cleared VLDL particles very efficiently due to increased lipolysis 
and enhanced selective uptake of VLDL cholesteryl esters (11). 
Patients with elevated levels of plasma triglycerides have increased plasma levels of 
apoC-Ill with a four-times larger proportion of apoC-III present in VLDL sized 
lipoprotein particles compared to normolipidemic individuals (12-15). Several 
clinical studies have shown that both total apoC-III and apoC-III present on TRLs 
(LpB:CIII) are risk indicators for cardiovascular disease (16,17). Data from the 
MARS study (18) suggest that apoC-III, particularly in apoB-containing 
lipoproteins, is a major risk factor for the severity of corona:r:Y heart disease in 
patients with mild and moderate atherosclerosis. In the CLAS study, in subjects 
treated with niacin-colestipol, the HDL apoC-II! level was the major predictor of 
global coronary atherosclerosis progression (19). 
Atorvastatin is a powerful HMG-CoA reductase inhibitor proven to reduce 
effectively total cholesterol and triglycerides. The mechanism leading to the decrease 
in plasma triglycerides is unknovvn. Previously, we found that atonrastatin lowers 
plasma triglyceride by 25 and 35% in subjects with type 2 diabetes. No effect was 
observed on LPL activity (20). Since in situ LPL activity may be inhibited by apoC-
III, we studied whether atorvastatin affects apoC-III levels. To this end, we 
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determined the effect of low (1 Omg) and high (80mg) dose atorvastatin on plasma 
apoC-III levels and the distribution of apoC-III on plasma lipoprotein fractions in 
patients with type 2 diabetes mellitus and hyperlipidemia. 
Methods 
Sta/)y population 
This study is part of the Diabetes Atorvastatin Lipid Intervention (DALI) study. 
DALI is a randomized double-blind, placebo-controlled, multi-center study 
conducted in the Netherlands (20). Briefly, 217 patients, aged 45 to 75 years, with 
type 2 diabetes mellitus of at least 1 year and an HbAl c of l Oo/o or lower, 
participating in the DALI study were randomized to placebo, atorvastatin lOmg 
(Al 0) or atorvastatin 80mg (A80) during 30 weeks, to evaluate the effect of 
treatment on lipid metabolism. The diagnosis of type 2 diabetes was defined 
according to the ADA classification (21). Inclusion criteria were fasting plasma 
triglycerides between 1.5 and 6.0 mmol!l, total cholesterol between 4.0 and 8.0 
mmol!l and no history of coronar:Y heart disease. Patients were recruited in Leiden, 
Rotterdam and Utrecht. The study protocol was approved by the Ethical 
Committees of the participating centers and all procedures followed were in 
accordance vvith institutional guidelines. Written informed consent was obtained 
from all subjects. 
Analytical metbo()d 
Blood samples were drawn after a fasting period of 12 h at baseline and after 30 
weeks' treatment at the end of the study. Plasma was prepared by immediate 
centrifugation and samples were stored at -SO o C for further analyses. Cholesterol 
and triglycerides were determined by enzymatic colorimetric methods on a Hitachi 
911 automatic analyzer (Boehringer Mannheim, Mannheim, Germany). Plasma 
HDL cholesterol was measured by a direct enzymatic HDL-cholesterol method, 
after precipitation of apoB-containig lipoproteins vvith manganese chloride. LDL-
cholesterol was estimated by the Friedewald formula (22). Fasting plasma glucose 
was determined on a Hitachi 917 analyzer using an UV-hexokinase method (Cat. 
Nr.18766899) from Boehringer Mannheim, Mannheim, Germany. HbA1c was 
determined by HPLC, using the BIO-RAD Variant TM method (Cat.Nr.270-
0003.Bio-rad). Plasma apoC-III was analyzed by a commercially available 
electroimmuno assay (Sebia hydragel LP CIII, Issey-les-Moulineau:\:, France). 
HDL apoC-III is determined in the supernatant after precipitation of the apoB 
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containing lipoproteins with the use of a specific antibody. LpB:CIII is calculated 
from by subtracting HDL-apoC-III from total apoC-IIL 
Podtbeparin pUunuz LPL activity 
LPL activity was measured using an immunochemical method as described 
previously (23) in plasma collected 20 min after contralateral intravenous 
administration of heparin (50 IU!kg body-weight, Leo Pharmaceutical Products, 
Weesp, The Netherlands). LPL was measured in a control normolipidemic 
population of 103 male and female volunteers, aged 45 to 75 years, without type 2 
diabetes mellitus and hypertriglyceridemia. 
StatutU:a.L an.alydu 
Analyses were performed by SPSS for Windows (release 9.0). Continuous variables 
are presented as mean values with the standard deviation (SD). Pearson's 
correlation coefficients were calculated to study associations between apoC-III and 
other variables at baseline. Mean differences between the study groups were 
analyzed using analysis of covariance (ANCOVA), adjusted for baseline levels and 
study location. P values < 0.05 were considered statistically significant. 
Results 
Patient characterWti.cd 
Baseline characteristics of the patients in the DALI study were described elsewhere 
(20). According to the inclusion criteria, 217 patients were randomized. There were 
no significant differences in baseline characteristics between the placebo, A1 0 and 
A80 group, except for the duration of diabetes, which was shorter in the placebo 
group compared to the atorvastatin 80mg (A80) group, respectively 8.2 ± 5.9 versus 
12.2 ± 8.3 years (p<0.05). Body-Mass Index (BMI), glucose, HbA1c, LPL activity, 
lipid and lipoprotein plasma values at baseline are shown in Table L 
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Table 1 Baseline characteristics 
Male sex(%) 
Age (years) 
Body Mass Index (kgjm2) 
Fasting glucose (mmoljL) 
HbA1c (%) 
LPL (U/L) 
Triglycerides (mmoi/L) 
Total cholesterol (mmolfL) 
LDL-c (mmolfl) 
HDL-c (mmolfL) 
ApoA (g/L) 
ApoB (mgj10omL) 
Data are means ::sd. 
LPL= lipoprotein lipase. 
DALI patients 
(n=217) 
53 
59-5 
30-9 ± 4-5 
10.6 ± 3-2 
8.3 ± 1.1 
129 ± 50 
2.62± 1.0 
5-99 ± 0.9 
3-71 ± 0.3 
1.04 ± 0.2 
1.40 ± 0.2 
1.24 ± 0.2 
Apolipoprotein C-III at ba.~eline. 
Baseline levels of apoC-III were similar in all three treatment groups (Table 2). 
Mean apoC-III was 41.5 ± I 0.0 mg/L. ApoC-III correlated significantly with plasma 
triglyceride (r=0.74. p<O.OOI) • apoB ( r=0.24. p<O.OO!) and TC (r=0.33. p<O.OOI). 
After division apoC-III levels into quartiles, subjects in the highest quartile (apoC-
III >48.0 mg!L). compared to those in the lowest quartile (apoC-III <34 mg!L). 
showed an increase in plasma triglyceride levels from 1.86 to 3.79 mmol/l. ApoC-III 
is a constituent of HDL and triglyceride-rich apoB containing lipoproteins, 
(LpB:CIII). Average HDL apoC-III and LpB:CIII were respectively 17.7 ± 5.5 
mg/L (12.8- 21.8 mg/L) and 23.8 ± 7.7 mg/L (17.1 - 29.5 mg/L). HDL apoC-III 
and LpB:CIII both correlated with plasma triglycerides. However, the correlation 
between plasma triglyceride and LpB:CIII was stronger than the correlation with 
HDL apoC-III (r=0.76. p<O.OOl and r=0.28. p<O.OOl, respectively) (Figure 1). 
ApoC-III did not correlate with LPL activity while LPL activity showed only a 
weak inverse correlation with plasma triglyceride, r=-0.13, p=0.05. ApoC-III and 
LPL activity contributed 75% (75% LpB:CIII and 25% HDL apoC-III) and 
inversely 14% to the variance in plasma triglycerides. 
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Table 2 Apolipoproteins at baseline and after 30 weeks atorvastatin. 
Placebo Atorvastatin 1omg Atorvastatin 8omg 
(n=71) (n=71) (n=71) 
Total apoC-111 Basel'me 41.3 (9.0) 39·8 (9.5) 43.1 (9-9) 
(mgjl) 30 weeks 41.2 (12.0) 31.8 (10.6)' 31.1 (11-3)' 
HDL apoC-111 Baseline 17.6 (5-2) 16.7 (5-3) 18-4 (6.0) 
(mgjl) 30 weeks 17.6 (8.o) 14.1 (5.2)"f 13-2 (s.8)'t 
LpB:CIII Baseline 23.6 (6.8) 23.1 (7-3) 24-7 (8.6) 
(mgjl) 30 weeks 23.6 (7-7) 1].7 (?.8}' 17.9 (8.?)' 
Data are expressed as mean (sd). 
Test for difference among the three groups, adjusted for baseline value:+p< o.oo1, i"p=o.oos 
Test for difference versus A1o, adjusted for baseline:t p=o.os. 
Figure I. Association between HDL apoC-I!I, LpB:C!II and plasma triglycerides. 
r denotes correlation coefficient. 
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Atorwutaiin effect on apolipoprotein.d atUJ podt-beparin LPL activit:y. 
After 30 "Weeks' treatment "With atorvastatin, apoC-III in the AlO and A80 groups 
"Was 23% lo"Wer than in the placebo group (Table 2). AlO and A80 decreased apoC-
lll in both the HDL and the non-HDL (LpB:CIII) fractions to a similar extent (16-
23% and 28%). Since the LpB:C-lll fraction contained the major part of the total 
apoC-lll, atorvastatin decreased the absolute amount of apoC-III in the non-HDL 
fraction more than in the HD L fraction. 
Earlier (20), "We reported that Al 0 and ASO decrease plasma triglycerides in the 
DALI population by 25 and 35%, respectively (both p<O.OOl). The decrease in total 
plasma apoC-III strongly correlated "With the decrease in plasma triglycerides in 
both AlO and A80, respectively r=0.70 and r=0.78, both p<O.OOl. Especially in the 
ASO group, the decrease in LpB:CIII correlated more strongly "With the decrease in 
plasma triglyceride (r=0.80, p<O.OOl) (Figure 2), than the decrease in HDL apoC-
lii (r=0.43, p<O.OOl). This suggested that the apoC-III content of the non-HDL 
fraction "Was a better determinant of plasma triglyceride levels than the HDL apoC-
III level. 
Figure 2. Association bet"Ween the reduction of plasma LpB:CIII and the reduction 
of plasma triglycerides after atorvastatin 80mg. r denotes correlation coefficient. 
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In this study, we showed that in hypertriglyceridemic patients with 1ype 2 diabetes, 
atorvastatin treatment profoundly lowered the apoC-III content of HDL and of 
non-HDL (apoB-100 containing) lipoproteins (LpB:CIII). This may represent an 
important anti-atherogenic effect of statin treatment. In several studies, a high 
content of apoC-Ill in LpB:Clll and! or in HDL was found to be associated with 
increased coronary risk (18,19,24,25). 
The LpB:CIII concentration has been previously been sugested to be a more specific 
measure of coronary heart disease risk than plasma triglycerides (26). 
Hypertriglyceridemia is an independent risk factor for atherosclerosis in type 2 
diabetes (27). The hypertriglyceridemia may be caused by several mechanisms. The 
number ofVLDL particles, secreted by the liver may be enhanced. Alternatively, or 
additionally, the clearance of triglyceride-rich VLDL may be impaired. Kissebah 
and coworkers (28) demonstrated that in subjects with 1ype 2 diabetes, either 
normolipidemic or hypertriglyceridemic, apoB and VLDL-TG secretion is 
enhanced. The rate of clearance is likely, therefore, to determine whether 
hypertriglyceridemia develops or not. Indeed, Wuson et al (29) showed that 
hypertriglyceridemia only developed in 1ype 2 diabetic subjects with genetically 
lowered LPL activity. In our population LPL activity was not affected (20), 
indicating that the hypertriglyceridemia vvas not due to a lowering of this enzyme. 
The in situ activity of LPL may however, be affected by apoC-IIL ApoC-III inhibits 
the lipolysis of VLDL-TG by LPL (4) and interferes with the hepatic uptake of 
TRLs by LD L receptors ( 6). Consequentely, high apoC-Ill leads to accumulation of 
apoB- and apoC-III-containing particles, VLDL and IDL, and thus to 
hypertriglyceridemia. In our patient group, plasma apoC-III, mainly in LpB:C-III, 
accounted for 75% of the variance in plasma triglycerides. LPL had a much smaller 
effect. Batal et al (12), demonstrated that in hypertriglyceridemia the increase in 
VLDL apoB is the result of delayed removal rather than of increased production. 
The delayed removal was ascribed to increased apoC-III synthesis. Studies in rats 
have demonstrated that apoC-III expression is lowered by statins (30). We found, 
total plasma apoC-Ill levels reduced by 23% in respons to atorvastatin therapy. Low 
(Al 0) and high (A80) dose had similar effects. The largest reduction was established 
in the LpB:CIII fraction. The decrease in LpB:CIII strongly correlated ,vith a 
decrease in plasma triglycerides. These results suggest that lowering of plasma 
triglycerides by atorvastatin is at least partly due to increased clearance of TRL 
because of a lowering in plasma (LpB:CI!I) apoC-III content. Similar effects of 
atorvastatin on plasma apoC-III levels were found after 4 weeks' treatment in a 
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population of 27 patients with primary hypertriglyceridemia (31). In a study in 305 
patients with primary hypercholesterolemia (32). atorvastatin 1 Omg and pravastatin 
20mg also reduced LpB:CI!l (26% and 33%, respectively). In contrast, a study in 
patients with a coronary artery bypass graft treated with lovastatin, statin therapy 
did affect Lp:B (LDL), but not plasma apoC.III or LpB:C.III (15). 
Conclusions 
Our results demonstrate that atorvastatin may lower the elevated risk of 
atherosclerotic disease in patients 'With type 2 diabetes through several mechanisms. 
It effectively reduces total cholesterol and triglycerides and elevates HDL 
cholesterol but in addition it lowers atherogenic apoC.l!I in LpB:CIII and HDL. 
Since apoC.III is a risk-indicator for cardiovascular disease and a marker for the 
TRL-metabolism, measurement of apoC.III in patients at risk for atherosclerotic 
disease may be helpful in risk assessment and treatment strategies. 
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Objective 
Quantitative and qualitative differences in lipoprotein profiles in men and women with type 2 
diabetes may partly explain the increased relative risk of coronary heart disease (CHD) in 
women. It is possible that sex differences in hepatic lipase (H L) and lipoprotein lipase (LPL) 
activities contribute to a different etiology of diabetic dyslipidemia. 
Research design and methods 
HL and LPL activity were determined in relation to lipids and lipoproteins before and after 30 
weeks treatment with placebo, atorvastatin 1omg or atorvastatin Somg in a double-blind, 
randomized, placebo-controlled trail (DALI study). 
Results 
Baseline HL activity in Caucasian DALI males was 12% higher than in Caucasian male volunteers 
without diabetes or hypertriglyceridemia (452 ±155 (n=96) vs 397 ±125 (n=?S), 
p<0.001).Baseline LPL activity in Caucasian DAL! women was 10% lower than in Caucasian 
female volunteers (147 ±32 (n=72) vs 162 ±58 (n=107), p=o.oo3). In males, HL activity 
significantly correlated with HDL-C (r=-0.22, p=o.o3), apoA-1 (r=-0.28, p=0.04) and TG 
(r=0.32, p=o.oo2). In females, LPL activity significantly correlated with HDL-C (r=0.35, 
p=o.003) and apoA-1 (r=0.33, p=o.oos). After atorvastatin treatment H L activity was similarly 
reduced in males and females and LPL activity was not affected in both genders. Atorvastatin 
treatment abolished gender differences in plasma lipids and lipoproteins. 
Conclusions 
In patients with type 2 diabetes, there is a gender specific etiology of low HDL-C levels, which 
may contribute to the increased relative risk for CHD in women. 
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Introduction 
Major changes in lipoprotein profiles in type 2 diabetes result in partial or complete 
loss of the "female survival advantage" for cardiovascular death (1,2). Whereas pre-
menopausal women ·without diabetes have a more favourable lipoprotein profile 
than men and a lower risk of coronary heart disease (CHD), women with type 2 
diabetes show the same combination of high triglycerides (TG) and low HDL-C as 
men, but the association v.rith CHD seems to be more prominent in women (2,3). 
This change in CHD risk might be due to differences in levels or properties of 
lipoproteins and/or different dynamics oflipoprotein metabolism. Compared to men, 
the combination of diabetes, low levels of HDL-C, and high levels of VLDL in 
women seems to constitute a higher-risk metabolic profile (2). The predominance of 
atherogenic small dense LDL particles in diabetes may contribute to a greater 
relative risk of CHD in women as well. LD L size is often significantly lower in 
patients with diabetes of both sexes than in patients without diabetes, but there is a 
stronger association between LD L size and diabetes in women than in men, even 
after controlling for TG and HDL-C levels (4). These quantitative and qualitative 
differences in lipoprotein profiles in men and women partly explain the increased 
risk for CHD in women (5). In type 2 diabetes, gender specific differences in 
lipoprotein profiles are possibly related to gender specific changes in etiology of the 
dyslipidemia. Sex steroids may affect key factors in the regulation of plasma 
lipoproteins, like for instance hepatic lipase (HL) and lipoprotein lipase (LPL) 
activities (6,7). HL and LPL are considered to be important factors in the 
development of hypertriglyceridemia, low HDL-C levels and compositional 
abnormalities in lipoprotein fractions (8-!0). HL is a lipolytic enzyme that appears 
to be involved in the metabolism of TG-rich and cholesterol-rich lipoproteins (ll-
!4). HL is a major determinant of plasma HDL-C levels and of LDL-size, and is 
proposed to be involved in the post-prandiallipid clearance (15). In humans, HL is 
affected by several factors, like gender, visceral adiposity and a HL gene promoter 
polymorphism (denoted as LIPC C>T variation) (16-22). HL activity is higher in 
males than in females. This gender-related variation is mostly explained by sex 
steroid hormones and by intraabdominal fat mass (IAF) (!7,23-26). Estrogen levels 
are negatively and IAF positively associated with HL activity. 
LPL is the major enzyme responsible for the clearance of TG from the plasma and 
is a major determinant of HDL-C levels (27). Therefore HDL-C levels may also 
reflect LPL activity (28). LPL activity is also influenced by gender and genetic 
variation (29-32) and has been implicated in the pathogenesis of dyslipidemia in 
conditions associated vvith insulin resistance (8). 
We hypothesised that possible sex differences in lipase activities contribute to 
gender differences in etiology of diabetic dyslipidemia. Therefore we examined in 
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patients with type 2 diabetes the effect of gender on HL and LPL activities in 
relation to differences in lipoprotein profiles. We also studied the effect of 
atorvastatin on lipase activities and how this affected the atherogenic lipoprotein 
profiles in men and women. 
Patients and methods 
St:ady popala.twn 
This study is part of the Diabetes Atorvastatin Lipid Intervention (DALI) study. 
DALI is a randomized double-blind, placebo-controlled, multi-center study 
conducted in the Netherlands. The subjects and methods are described in detail 
earlier (33). 
In short, 217 patients, aged 45 to 75 years, with type 2 diabetes mellitus participating 
in the DALI study were randomized to placebo, atorvastatin 10mg (A10) or 
atorvastatin 80mg (A80) during 30 weeks, to evaluate the effect on lipid metabolism, 
endothelial function, co2.ooulation and inflammatory parameters. The main inclusion 
criteria were plasma TG between 1.5 and 6.0 mmoi!L, total cholesterol between 4.0 
and 8.0 mmoi!L and no history of coronary heart disease. Post heparin lipase activity 
blood samples of 198 DALI-patients were available. Since ethnicity might influence 
lipase activities, only Caucasian patients (n~l68) were evaluated in the present 
study. Patients were recruited in Leiden, Rotterdam and Utrecht. The study 
protocol was approved by the Ethical Committees of the participating centres and 
all procedures followed were in accordance with institutional guidelines. Written 
informed consent was obtained from all subjects. 
Analytical metbod<J 
Blood samples were drawn after 12 h of fasting at baseline and at the end of the 
treatment period. Standard lipid variables, free fatty acids (FFA), plasma glucose, 
HbA1c, LDL size, HDL2 and HDL3 were measured. Total cholesterol (TC) and 
triglycerides (TG) were determined by enzymatic colorimetric methods on a Hitachi 
911 automatic analyzer (Boehringer Mannheim, Mannheim, Germany). Plasma 
HDL cholesterol was measured by a direct enzymatic HDL-cholesterol method, 
after precipitation of very-low density lipoprotein and LDL by addition of 
manganese chloride. LD L cholesterol was estimated by the F riedewald formula 
(34). Apo A-1 and apo B were determined on a Hitachi 917 analyzer, using 
immunoturbidimetric methods (Tina-quant apo A-1 and apo B, Cat. no. 1551680 
and no.1551779; Boehringer Mannheim). Fasting FFA:s were determined using an 
enzymatic colorimetric method (Wako, NEFA C. Cat. no.994-75409 D). Fasting 
plasma glucose was determined on a Hitachi 917 analyzer using an UV~hexokinase 
method (Cat. Nr.18766899) from Boehringer Mannheim, Mannheim, Germany. 
HbA1c was determined by HPLC, using the BIO-RAD Variant TM method 
(Cat.Nr.270-0003.Bio-rad). LDL size was measured as described earlier (32). DNA 
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analysis for geno1yping of the LIPC gene for the C> T variance and of the LPL gene 
to identifY carriers for the D9N, N29lS and S447Stop mutations were measured as 
described before (35,36). 
Podtbeparin pla4mo. liptL1e activity 
HL and LPL activity was measured using an immunochemical method as described 
previously (37) in plasma collected 20 min after contralateral intravenous 
administration of 50 !Uikg body-weight heparin (Leo Pharmaceutical Products, 
Weesp, The Netherlands). HL and LPL controls consisted of healthy Caucasian 
males (n=78) and female volunteers (n=107), aged 45 to 75 years, without 1ype 2 
diabetes mellitus or hypertriglyceridemia. 198 blood samples of DALI patients for 
evaluation of post heparin lipase activities were available. Eleven samples were 
excluded from the analysis because very low activities for HL and LPL in post 
heparin plasma indicated insufficient heparin delivery. Of eight patients no blood 
sample for post heparin lipase activity was available. Of these 198 bloodsamples, 30 
bloodsamples belonged to non-Caucasian patients and were excluded from this 
study. 
StatuticaL analy•u 
Analyses were performed by SPSS for Windows (release 9.0). Continuous variables 
are presented as mean values with the standard deviation. Mean differences 
betvv"een men and women were analyzed using analysis of covariance (ANCOVA), 
adjusted for baseline levels. Pearson correlation coefficients were calculated to study 
associations between post-heparin HL and LPL activities and other variables at 
baseline(SD). Multiple linear regression analysis was used to assess the 
relationships between gender, lipase activities, age, WHR and lipid- and lipoprotein 
variables simultaneously. P values < 0.05 were considered statistically significant. 
Results 
BtL1eline cbaracterutic.f of maw a.n.d femal&J 
The baseline characteristics of 96 male and 72 female participants of the DALI study 
are listed in Table l. There were no significant gender differences in age, diabetes 
duration or treatment, glucose, and HbA1 c. Males had a lower body mass index 
(BMI) than the females, but they had a significant higher waist hip ratio (WHR). 
Although the WHR was higher in males, they had a lower fat mass (24 .2 kg ) , 
compared with the females (34,4 kg), as calculated by the formulas described by 
Flier et a! (38). Males had 26,2 % body fat and weighted 93.1 kg, while females had 
40.5% body fat and weighted 86.1 kg. As described earlier (35,36) the frequency of 
the LIPC-T allele and the LPL S447Stop mutation was similar in men as in women. 
There were significantly more male (n=6) than female (n=2) carriers of the 
LPL:D9N mutation. 
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Table 1 Baseline characteristics. 
Males Females 
(n=96) (n=72) 
Age (years) 58.6 ± 7.6 61.2 ± 7.8 
BMI (kgjm2) 29.8 ± 4·7 32-4 ± 5.0 
Waist-to-hip ratio 1.02 ± 0.1 0.97 ± 0.1 
Diabetes duration (years) 10.7 ± 6.6 12.8 ± 8.2 
Diabetes treatment(%) 
Diet 0,92 1.1 
Tablets 45-4 44-4 
Insulin 31.5 25.6 
Combination 22.2 28.9 
Glucose (mmoljL) 10.2 ± 3.1 10.] ± 34 
HbA1c (%) 8.2 ± 1.2 8.3 ± 1.1 
Data are expressed as mean ±sd 
Ba.~eline lipidd and lipoprotei.Ju in nude., and Jemaled 
Baseline lipids and lipoprotein variables are listed in Table 2. 
p-value 
Ns 
p=0.001 
p<0.001 
Ns 
Ns 
Ns 
Ns 
Ns 
Ns 
Ns 
Females had significantly higher total cholesterol (TC), HDL-C. LDL-C, apoA-1, 
apoB-100 and FFA levels. There were no gender differences between TG and LDL 
size. Adjustment for BMI or WHR did not change the gender differences in lipids 
and lipoproteins. 
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Table 2 Baseline lipids and lipoproteins. 
Males Females p-value 
(n=96) (n=72) 
Total cholesterol (mmoljL) 5.87 ± o.9 6.23 ± 0.8 p=o.oo8 
HDL-C (mmoljL) 0.99 ± 0.2 1.11 ± 0.2 p=0.002 
Triglyceride (mmoljL) 2-73 ± 1.1 2.59 ± 0.9 p=0.34 
LD L-C (mmoljL) 3·64 ± 0.9 3·95 ± 0.8 p=0.02 
Apo A-1 (g/L) 1.34 ± 0.2 1-48 ± 0.2 p<0.001 
Apo B (mgj10omL) 1.21 ± 0.2 1.30 ± 0.2 p=o.oo6 
LDL-size (nm) 25.9 ± 0.8 26.2 ± 0.] p=0.09 
FFA (mmoljl) o.6o ± 0.2 0.76 ± 0.3 p<0.001 
Data are expressed as mean ±sd 
Lipa.Je activitied in maled and fenuzled 
The lipase activities in the DALI population and the healthy individuals are listed in 
Table 3. Male DALI patients had a 12% increase in HL activi1y ( p<O.OOl) 
compared with healthy, male individuals. Female DALI patients and healthy females 
showed comparable HL activities. DALI females had a l 0% lower LPL activi1y than 
healthy, female individuals (p=0.003). DALI males and male volunteers showed 
equal LPL activities. 
Table 3 Gender differences in lipase activities. 
Males 
HL activity (U/L) 
LPL activity (U/L) 
Females 
HL activity (U/L) 
LPL act·lvity (U/L) 
Caucasian DALI patients 
(n=168) 
452 ± 155'' (n=96) 
138 ± 43 (n=96) 
367 ± 125 (n=72) 
147 ± 32 (n=72) 
Healthy Caucasians 
(n=185) 
397 ± 125 (n=78) 
132 ± 42 (n=78) 
328 ± 105 (n=107) 
162 ± 58# (n=107) 
Healthy Caucasians are subjects, matched for age but without DM or hypertriglyceridemia. 
+p<o.o01, compared with HL activity in DALI females, 
:-p<o.oo1, compared with LPL activity healthy Caucasian males. 
p-value 
p<0.001 
Ns 
Ns 
p=0.003 
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Lipade activit:iu correlatioru. 
Caucasian DALI males showed a significant correlation between HL activiiy and 
HDL-C (r=-0.22, p=0.03), apoA-1 (r=-0.28, p=0.04), TG (r=0.32, p=0.002) or FFA 
(r=-0.21. p=0.04). Multiple regression analysis revealed that HDL-C and TG were 
independently determined by HL activi1y, Beta -0.240, p=0.40, r2 = 0.196 and Beta 
0.344, p=0.001, r2 = 0.115, respectively. Caucasian DALI females showed no 
correlation between HL activiiy and HDL-C (r=0.09, p=0.42), apoA-1 (r=0.06, 
p=0.60), TG (r=-0.08, p=0.49) or FFA (r=0.14, p=0.24). In both genders, there were 
no significant correlations between HL activity and age, BMI, WHR, TC, LDL-C 
or LDL-size. 
In females there was a correlation between LPL activity and HDL-C (r=0.35, 
p=0.003) and apo A-1 (r=0.33, p=0.005). Multiple regression analysis revealed that 
HDL-C and apoA-1 were independently determined by LPL activi1y, Beta 2.894, 
p=0.003, r2 = 0.127 and Beta 0.301. p<O.OO!, r2 = 0.200, respectively. Males showed 
correlations between LPL activi1y and TC (r=0.25, p=0.02), LDL-C (r=0.21, 
p=0.05) and apoA-1 (r=0.23, p=0.02). In both genders, there were no significant 
correlations between LPL activity and age, BMI, WHR, TC, LDL-C or LDL-size. 
Contribation of gender fJijferencu in lipade a.ctivil:ied to 
lipoprotein profi.le.i after 50 weefu atorvadtal:in. 
After 30 weeks treatment with atorvastatin 1 Omg (A1 0) or atorvastatin 80mg (A80), 
gender differences in lipids and lipoproteins disappeared. Using analysis of 
covariance (ANCOVA), adjusted for baseline, males and females had a comparable, 
significant, dose-dependent reduction in TC (-30% (A10) to -40% (A80)), LDL-C 
(-41% (A10) to -52% (A80) and apo B (-31% (A10) to -40% (A80)) and a 
significant, not dose-dependent reduction in TG ( -25% (A1 0) to -35% (A80)) and 
increase in HDL-C (+6% (A10 and A80)) (data not shown). Atorvastatin therapy 
did not affect LDL-size in males and females. As reported before (38), there was still 
a significant gender difference in HL activity after treatment. HL activiiy was 
similarly reduced in males and females by ll% (A10) and 22% (A80), p<O.OOl. LPL 
activity showed still no gender difference after atonrastatin treatment. 
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Discussion 
Diabetes is the only condition that equalizes cardiovascular risk betvveen men and 
women (2,39). This implicates that diabetes is relatively more hazardous for women 
than for men. Gender differences in the etiology of diabetic dyslipidemia may 
contribute to this gender-related cardiovascular disease risk. Previously, it was 
demonstrated in patients vvithout diabetes that lipase activities are important 
determinants of lipoprotein profiles (40-42). We investigated in patients with type 2 
diabetes gender differences in HL and LPL activity, since these enzymes play a 
pivotal role in lipid metabolism and diabetic dyslipidemia in particular. Our results 
demonstrated that diabetes seems to affect lipase activities differently in men and 
women. There was no difference in HL activity between healthy male and female 
subjects, but male patients suffering from type 2 diabetes showed a significant higher 
HL activity than female diabetic patients. In contrast, LPL activity differed 
significantly between healthy male and female subjects. Diabetes equalized the 
gender difference in LPL activity. In agreement with the study of Goldschmid and 
coworkers (2), our females, all postmenopausal, showed higher plasma HDL-C, 
apoA-1. TC, LDL-C and apo B levels but equal TG levels compared with the males. 
The gender differences in lipase activities may partly explain the sex dimorphism in 
HDL-C levels in our population. One of the possible mechanisms underlying low 
HDL-C levels can be explained by the influence of HL and LPL on the HDL 
metabolism (Figure 1). In type 2 diabetes increased rates of secretion ofVLDL into 
plasma appears to drive the exchange of TG from TRLs for HD L cholesteryl ester. 
The TG-enriched HDL is a substrate for either HL and LPL (7). When the TG in 
HDL is hydrolyzed, the smaller HDL3 particles affect the binding of apoA-1. Free 
apoA-1 and HD L3 are then more easily catabolized in the kidney. 
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Figure 1. A model of the role of hepatic lipase and lipoprotein lipase m HDL 
metabolism 
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HDL is a substrate for plasma lipases. HL converts large cholesterol ester (CE)-rich HDLl to smaller HDL3 particles that are more 
rapidly cleared from the plasma via the kidney. HL action stimulates cholesterol uptake by the liver. 
Surface unesterified cholesterol (UC) and phosholipids (PL) from triglyceride-rich lipoproteins (TRL5) are transferred to HDL during 
VLDL and chylomicron lipolysis by LPL. 
Since removal of surface lipids from TRLs by LPL activity causes their transfer to 
HD L, relatively low LPL activity might lead to a decreased capacity of unesterified 
cholesterol uptake from peripheral tissues, reflected in a relative low HDL-C level 
in diabetic dyslipidemia. Indeed, in our female patients there was a significant 
correlation between LPL activity, HDL-C and apoA-1 levels. This relatively low 
HDL-C levels in the DALI females may be caused by an attenuated HDL formation 
due to a relatively low LPL activity. This decrease in HDL synthesis might then lead 
to a.~ attenuated reverse cholesterol transport, which might promote atherosclerosis. 
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In the male DALI patients, LPL activity was not affected in the diabetic state. In 
contrast, HL activity was increased and showed an inverse correlation between 
plasma HDL-C and apoA-1 levels. The increased HL activity may lead to 
accelerated HDL apoA-1 clearance, as discussed above. Therefore low HDL levels 
in our DALI men may be due to increased HDL (apoA-1) clearing. At the same 
time, increased HL activity may induce cholesterolester uptake in the liver and 
therefore promote reverse cholesterol transport. As Jin and coworkers stated ( 43), 
there will probably be an optimal level of HL activity and having too much HL 
activity will further reduce HDL-C levels and increase atherosclerotic risk. Based 
on these considerations, one can expect that low HDL-C due to increased HL 
activity probably increases reverse cholesterol transport, while low HDL-C due to 
impaired LPL activit.Y does not increase inverse cholesterol transport. Therefore it 
is feasible that the relatively low levels of HDL-C seen in women with type 2 
diabetes, may constitute a higher-risk metabolic profile and may contribute to a 
greater relative risk of CHD in women compared with diabetic men. 
Since gender differences in lipase activities might partly explain the sex difference 
in lipoprotein profiles and almost every male and female patient with type 2 diabetes 
will sooner or later receive hypolipidernic treatment, we also wondered whether 
improvement of the atherogenic lipid profile after hypolipidemic treatment would 
change the gender differences in lipase activities. Therefore we studied in the DALI 
population vvith regard to gender differences, the influence of lipase activities on the 
lipoprotein proEle after 30 weeks atorvastatin. Atorvastatin treatment abolished the 
gender differences in TC, HDL-C, LDL-C, apo A-1, apo B and FFA, but as 
reported earlier gender difference in HL activity remained (35). Atorvastatin did not 
influence LPL activity, except for patients with a LPL:S447Stop mutation (36). 
These results demonstrated that women with diabetes, that are more at risk for 
ischaemic heart disease, may benefit at least equal to men from hypolipidemic 
treatment. 
Conclusions 
The results of the present study provide support for the notion that gender 
differences in lipase activities partly explain a different etiology of lowered HDL-C 
levels in patients with type 2 diabetes. Further prospective studies evaluating lipase 
activities in men and women with diabetes for developing diabetic dyslipidemia are 
needed to establish the validity of our study results. 
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7: Low-density lipoprotein subfractions are reduced by aggressive lipid lowering 
in patients with type 2 diabetes mellitus 
Abc~ tract 
Objective 
Diabetic dysl'lpidemia is characterized by increased triglycerides (fG), reduced high density 
lipoprotein cholesterol and a predominance of smaller, more dense low density lipoprotein 
particles (LDL3). LDL3 is associated with increased cardiovascular risk. 
Research design and methods 
A randomized double-blind placebo-controlled trial to assess the effect of 30 weeks atorvastatin 
1omg (A1o) and Somg (ASo) on LDL subtraction distribution and concentration in 85 patients 
with type 2 diabetes mellitus. 
Results 
At baseline, 93o/o of the patients showed a LDL subtraction distribution with the major LDL peak 
within the intermediate-dense LDL2 range (d=1.030-1.040 gjml). Atorvastatin significantly 
reduced cholesterol concentrations in all LDL subtractions and plasma apoB (p<o.oo1), 
resulting in a reduced number of particles. Compared to placebo, large, buoyant LDL1 
cholesterol concentration was dose-dependently reduced from 0.93 ±0.3 to o.ss ±0.3 mmoljl in 
A1o (p<O.o01), and to 0.39 ±0.2 mmoljl in A8o (p<o.oo1) (A8o vs. A10; p<o.oos). L"lke LDL1, 
intermediate-dense LDL2 cholesterol concentration was dose-dependently reduced from 1.64 
±0.4 to 1.06 ±0.4 mmoljl in A10 (p<0.001), and to 0.79 ±0.4 mmoljl in A8o (p<o.oo1) (A8o vs. 
A1o; p<o.oos). Both A1o and A8o significantly reduced LDL3 cholesterol concentrations to 0.38 
±0.2 (A10) and 0.39 ±0.2 mmoljl (A8o) (both vs. placebo; p<o.oo1). Despite substantial fasting 
plasma TG reductions of 28-35o/o (p<0.001), both A10 and ASo did not shift the LDL subtraction 
density distribution. 
Cone I usions 
Atorvastatin significantly reduced cholesterol concentration in all LDL subtractions but did not 
induce a shift in LDL subtraction density distribution towards larger and more buoyant LDL 
particles in pat"1ents with type 2 diabetes mellitus. 
Introduction 
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Dyslipidemia is a common feature of the atherogenic risk profile of type 2 diabetes 
mellitus and is characterized hy hypertriglyceridemia and reduced high density 
lipoprotein (HDL) cholesterol, with compositional abnormalities in the lipoprotein 
fractions rather than large quantitative changes in lipids (1,2). Low density 
lipoprotein (LDL) cholesterol concentration is not elevated, while in many patients 
with type 2 diabetes a preponderance of LDL particles with smaller size and 
increased density (LDL3) are observed (3). This small, dense LDL subfraction 
pattern is associated with increased levels of triglyceride (TG) (4) and the presence 
of insulin resistance, central obesity and hypertension (5). Increased cholesteryl 
ester transfer protein (CETP) concentration (6) and hepatic lipase (HL) activity (7) 
appear associated with small, dense LDL. The presence of a major LDL peak in the 
small, dense LDL fraction is associated with an increased risk of coronary artery 
disease (CAD) in the general population (8). As the patient with type 2 diabetes is 
at higher than average cardiovascular risk (9), modification of the LD L density 
pattern may be an additional therapeutic target (10). 
Atorvastatin is a powerful HMG-CoA reductase inhibitor, proven to be safe (11-13) 
and effective in reducing total cholesterol and triglycerides in non-diabetic patients 
with hypercholesterolemia and primary hypertriglyceridemia (14-16). Previous 
studies suggest that atorvastatin modifies the LDL subfraction pattern in subjects 
without diabetes (17). 
The aim of the present study was to examine the effect of the standard dosage 
atorvastatin 10mg (A10) versus the aggressive dosage 80mg (A80) versus placebo 
on LDL subfraction distribution and concentration in type 2 diabetes patients. 
Patients and methods 
SttUJy population 
This study comprised 85 patients with type 2 diabetes enrolled in the Diabetes 
Atorvastatin Lipid Intervention (DALI) study. DALI is a double-blind, 
randomized, placebo controlled, multi-center study, conducted in the Netherlands, 
designed to evaluate the effect of atorvastatin l 0 mg versus 80 mg on lipid 
metabolism, endothelial function, coa,o-ulation and inflammatory factors in men and 
women with type 2 diabetes. The protocol and eligibility criteria have been 
described in detail elsewhere (18) Briefly, men and women, aged 45 to 75 years, with 
HbAlc £ 10% were eligible. The lipid criteria were: total cholesterol (TC) between 
4.0 and 8.0 mmol!l and fasting TG between 1.5 and 6.0 mmol!l. The subjects 
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participating in the present study were the first 85 patients who were randomized in 
the DALI study, and had a baseline, 10 week, and final visit evaluation of their LDL 
subfraction distribution analyzed in addition to the DALI protocol. The DALI study 
had three recruiting centers: Leiden, Rotterdam and Utrecht. The study protocol 
was approved by the Ethical Committees of the participating centers and written 
informed consent was obtained from all subjects. 
Analyti.cal methoiJd 
After an overnight fast for a minimum of 12 hours, blood was drawn and plasma was 
prepared and stored at -80°C for further analysis. Lipids and apolipoproteins were 
quantified as described e"-tensively (18). Plasma cholesterol ester transfer protein 
(CETP) mass was analyzed as described (19). 
LDL dubjraction iJutribuJ:wn by iJendity grtUJknt centrifugatwn 
The LDL subfraction distribution was analyzed by density gradient 
ultracentrifugation using a si..'\:-Step discontinuous salt gradient as described by 
Griffin (20). Fresh plasma (3 ml) was fractionated into twenty distinct LDL 
subfractions after 24h (40.000 rpm at 4°C) centrifugation in a Beckman SW40 
swinging bucket rotor. The LDL &actions were recovered from the tube by upward 
displacement, collected in 500ml aliquots, and identified by absorbance at 280 nm. 
The isolated fractions were frozen immediately at -80°C for subsequent duplicate 
measurement of cholesterol. Cholesterol in all fractions was analyzed enzymatically 
using a Cobas Mira S auto-analyzer (ABX Diagnostics, Montpellier, France). Major 
LDL subfractions were identified according to their density and divided into three 
LDL categories: 1.020-1.029 g/ml (LDLl: &action 6-10), 1.030-1.040 g/ml (LDL2: 
fraction 11-13), or 1.041-1.066 g/ml (LDL3: fraction 14-17) (21). 
Statittkd 
All values are expressed as mean ±standard deviation. Spearman's correlation 
coefficients were calculated to study associations between the LDL subfraction 
distribution and other variables at baseline. Mean differences between the study 
groups were analyzed using analysis of covariance (ANCOVA), adjusted for 
baseline levels and study location. Intervention effects were also further adjusted for 
additional potential confounders, using Al"\fCOVA. All analyses were performed 
using SPSS software, version 9.0 for Windows. 
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Results 
The baseline characteristics of the study population are given in Table 1. 
Table 1. Baseline characterisf1cs. 
Placebo Atorvastatin 10mg Atorvastatin 8omg 
Number 26 29 30 
Male gender (%) 58 69 63 
Age (years) s8.o ±7.5 60-4 ±6.] 59.8 ±7.3 
Blood pressure (mmHg) 146/85 147/86 146/85 
Diabetes duration (years) 10.1 ±].0 12.5 ±7-9 12.2 ±7.5 
HbA1c (%) 8.4 ±1.2 8.3 ±1.2 s.s ±1.3 
Fasting glucose (mmoljl) 10.5 ±3.0 10.1 ±p 10.0 ±2.9 
Body-Mass Index (kgjm) 32-3 ±5.3 29.2 ±3-3 30.2 ±4-9 
Waist to Hip ratio 1.00 ±0.09 1.02 ±0.07 1.02 ±0.1 
Present smoking(%) 15 28 30 
Total cholesterol (mmoljl) 5-9 ±0.8 s.s ±1.o 6.2 ±0.8 
LDL cholesterol (mmoljl) 3.6 ±0.8 3-7 ±0.9 3-9 ±0.8 
HDL cholesterol (mmoljl) 1.04 ±0.2 1.01 ±0.2 0.99 ±0.2 
Triglycerides (mmoljl) 2.83 ±1.2 2-45 ±0.] 2.87 ±1.1 
Free fatty acids (mmoljl) 0.66 ±0.2 0.59 ±0.2 0.66 ±0.2 
ApoA-1 (g/1) 1.41 ±0.2 1.37 ±0.2 1.35 ±0.2 
ApoB (g/1) 1.23 ±0.2 1.20 ±0.2 1.26 ±0.2 
CETP mass (mg/1) 2.60 ±0.6 2.31 ±0.8 2.35 ±o.s 
Continuous data are expressed as mean ±standard deviation. 
At baseline, the majority of the patients (80/85) showed a LDL subfraction 
distribution with the maximal peak within the intermediate-dense LDL2 range. 
Within the LDL2 range, the highest LDL cholesterol concentration was found in 
fraction 11 in 24% (19/80), in fraction 12 in 52% (42/80) and in &action 13 in 24% 
(19/80). In 4 subjects the LDL sub fraction density distribution was within the small, 
dense LDL3 range, whereas in one subject it was vvithin the large LDLl range. The 
LDL subfraction density distribution was positively associated with TG (r =0.493; 
p<0.001), CETP mass (r =0.330; p<0.005), fasting glucose (r =0.219; p<0.05) 
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and inversely associated with HDL cholesterol (r ~ -0.201; p~0.07). No associations 
were found with other lipid variables, lipolytic enzymes, other diabetes parameters 
and lifestyle variables. 
Atorvastatin treatment effectively improved all lipid variables. After 30 weeks, LD L 
cholesterol (SO) was reduced to 2.2 (0.8) mmol!l in A10 (-42%; p<0.001) and 1.6 
(0.8) mmol!l in A80 (-59%; p<0.001, A80 vs. A10; p<0.005). Plasma apoB was 
reduced to 0.82 (0.19) gil in A10 (-32%; p<0001) and 0.71 (0.18) gil in A80 (-
43%;p<0.001, A80 vs. A10; p<0.001). Fasting TG were reduced to 1.63 (0.78) 
mmol!l in A10 (-33%; p<0.001) and 1.97 (1.58) mmol!l in A80 (-28%; p<0.001). 
CETP mass was reduced to 1.76 (0.47) mgll in A10 (-21 %; p<0.001) and 1.58 (0.32) 
mgll in A80 (-31 %; p<O.OOl, A80 vs. A10; p<0.05). The effects of atorvastatin 
treatment on lipid variables have been described e:\.'tensively elsewhere (18). 
Atorvastatin significantly reduced the absolute cholesterol concentrations in all 
LDL subfractions (Table 2). 
Table 2. Concentration of cholesterol (mmoljl) in LDL subfractions at baseline and after 30 weeks 
atorvastatin treatment. 
Baseline Placebo 
Large, buoyant LDL1 (mmoljl) 
Intermediate-dense LDL2 (mmolfl) 1.65 ±o.s (51%) 
Small, dense LDL3 (mmoljl) 0.60 ±0.3 (19%) 
After 30 weeks of treatment 
Large, buoyant LDL1 (mmoljl) 0.92 ±0.3 (29%) 
Intermediate-dense LDL2 (mmoljl) 1.61 ±o.s (51%) 
Small, dense LDL3 (mmoljl) o.6s ±o.2 (20%) 
Continuous data are expressed as mean ±standard deviation. 
The number between brackets indicates the percentage cholesterol content. 
Atorvastatin 1omg Atorvastatin 8omg 
0-93 ±0.3 (3o%) 0-98 ±0.4 (31%) 
1.64 ±0.4 (53%) 
0-52 ±0.2 (17%) 
1.59 ±0.6 (51%) 
o.s8 ±0.2 (18%) 
o.s8 ±0.3 ., (29%) 0.39 ±0.2 ,. i (25%) 
1.06 ±0.4 ·· (53%) 0-79 ±0-4 .,. i (so%) 
0.38 ±0.2 ,. (19%) 0.39 ±0.2 <· (25%) 
Test for difference among the 3 study groups, adjusted for baseline value and study location: f p<o.oo1 
Test for difference versus atorvastatin 10 mg, adjusted for baseline value and study location:~ p<o.oos 
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The substantial plasma apoB reduction after atorvastatin therapy indicates that the 
total number of LDL particles is reduced. Compared with placebo, large, buoyant 
LDLl cholesterol concentration was dose-dependently reduced to 0.58 ±0.3 mmol!l 
in AlO (p<O.OOl), and to 0.39 ±0.2 mmol!l in A80 (p<O.OOl) (A80 vs. AlO; p<0.005). 
Atorvastatin also reduced intermediate-dense LDL2 cholesterol concentration dose-
dependently. Both AlO and A80 significantly reduced small, dense LDL3 to a 
similar concentration (0.38 ±0.2 (AlO) vs. 0.39 ±0.2 mmol!l (A80), both vs placebo; 
p<O.OOl). The relative proportion of cholesterol present in LDLl, LDL2 and LDL3 
did not change after 30 weeks of treatment. Figure 1 shows the treatment efficacy of 
atorvastatin to reduce LDLl, LDL2 and LDL3. 
Figure 1. Percentage reduction in cholesterol concentration in each LDL subclass 
after 30 weeks of treatment in the DALI study. 
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Atorvastatin did not shift the LDL subfraction density distribution (Figure 2). In 
the majority of the patients (n=79; 93%) the LDL peak remained within the LDL2 
density. In only 6 subjects (7%) the LDL peak shifted towards another LDL 
subclass. In the upper part of figure 3 these 6 subjects are depicted by the 6 symbols 
on the arrows. A closer look at the individual LDL fractions (l-20) revealed that. 
within the LDL2 density range, 21% (A!O), 13% (A80) and 35% (placebo) of the 
patients showed a shift to the right (towards fraction !3; a more dense LDL profile) 
after 30 weeks of treatment. On the other hand, 38% (AI 0), 13% (A80) and 19% 
(placebo) showed a shift to the left (towards fraction !!; a more buoyant LDL 
profile) (lower part of figure 3). In the majority of the patients (4!% (A!O), 70% 
(A80) and 42% (placebo)) the major LDL peak remained unchanged during the 
study (not shown in figure 3). These results after 30 weeks of treatment are similar 
to the results after 10 weeks treatment (data not shown). 
Figure 2. Cholesterol concentration in LDL subfractions after 30 weeks of treatment 
in the DALI study. 
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Compared with placebo, the peak cholesterol concentration was dose-dependently 
reduced to 0.40 ~0.17 mmolll (p<0.001) by A10 and to 0.30 ~0.16 mmolll by A80 
(p<0.001, ASO vs. A10; p<0.05) (Figure 2). 
Because the LDL subfraction distribution was associated with fasting TG and 
CETP mass at baseline we performed additional analyses to investigate whether the 
baseline levels of TG and CETP mass did influence the effect of atorvastatin. The 
first group included all patients with baseline plasma TG levels >2.5 (median) 
mmol!l (n=43), whereas the second group included 42 patients with baseline plasma 
TG levels <2.5 mmolll. In both groups similar effects were observed. When the 
results were analyzed in strata of CETP mass, again similar results were obtained. 
Further adjustment for BMI did not affect the results either. 
Figure 3. Changes in density distribution of LDL after 30 weeks of treatment in the 
DALI study. 
density (glml)1.020 
Cl1' A10 
011 
1' 1' 1' placebo 
lDlz LD~ 
1' placebolli> 1' placebo~ 
fraction 6-11 fraction 11-14 fraction 14-17 
1.030 1.040 
\,..______, ,-----") y 
fraction 11 fraction 12 fraction 13 
1.030 1.033 1.036 1.040 
21% (A10), 13"/o (ABO), 35% (PI more dense 
more buoyant 38% (A1 0), 13% {ASO), 19% (P) 
1.064 
In only six subjects, who are depicted by the 6 symbols (,) on the arrows in the upper part ofthe figure, the LDL peak shifted 
(e.g. LDL1, LDL2 or LDLJ). The majority (n~79) remained in the LDL2 subfraction density range. In these patients the percentage 
of shifts within the LDL2 density range are shown in the lower part of the figure. 
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Discussion 
Atorvastatin therapy resulted in a dose-dependent reduction of cholesterol 
concentrations in large, buoyant LDL1 and intermediate-dense LDL2. Cholesterol 
in small, dense LDL3 was significantly reduced to a similar e>..-tent by both the 
standard dosage atorvastatin l 0 mg and the aggressive dosage 80 mg. Despite 
substantial reductions in fasting plasma TG of 28-35% towards levels of 1.63-1.97 
mmol!l, both A1 0 and A80 did not shift the LDL subfraction density distribution 
towards a more buoyant LDL pattern. In 93% of the subjects the LDL peak 
remained in the LDL2 subfraction density range after 30 weeks of treatment. 
An increased level of plasma LDL cholesterol is a major risk factor for CHD (22). 
There is considerable heterogeneity in the size, density and composition of LDL 
particles. Classification according to size by gel electrophoresis (pattern A, B) does 
not take into account the concentration of cholesterol in LDL subfractions. Recent 
data from the CARE study suggest that the concentration of cholesterol in the LDL 
subfractions may be more relevant than LDL size concerning CHD risk (23). We 
measured LDL subfraction by a density gradient ultracentrifugation method (20) 
that provides both a distribution and a quantitative measurement of cholesterol in 
individual LDL subfractions. Using this method, we found that 94% of the patients 
had an LDL subfraction distribution with the peak in the intermediate-dense LDL2 
density range at baseline. These results are in accordance vvith our observation that 
the majority of the total DALI population (n=217) had large, buoyant LDL particles 
(pattern A or AB) when LDL size was measured by gel electrophoresis (18). These 
observations are remarkable because our population expressed a typical diabetic 
dyslipidemia with mean fasting TG of 2.71 mmol!l (Table 1). Fasting TG levels 
above 1.7 mmol/1 are associated with an increased prevalence of small, dense LDL 
(24). Furthermore, patients with type 2 diabetes frequently have an abnormal 
composition of LD L particles and a predominance of small, dense LD L (3). Indeed, 
compared to data in non-diabetic controls, which mainly show an LDL1 density 
pattern, the patients in the DALI study have a more dense LDL2 density 
distribution. 
We observed significant associations betv..reen the LDL subfraction density 
distribution and TG, CETP mass and fasting glucose levels. The association between 
the presence of small, dense LDL and TG or fasting glucose levels is well known 
(4,25,26). The observed association between CETP mass and LDL subfraction 
distribution is interesting. Recently, Guerin et al. reported a significant contribution 
of CETP to the formation of small, dense LDL particles by a preferential CE 
transfer from HDL particles to small, dense LDL particles, as well as through an 
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indirect mechanism involving an enhanced CE transfer from HDL to VLDLl, the 
specific precursor of small, dense LDL in plasma (6). We observed a significant 
decrease in CETP mass after atorvastatin treatment, that may have contributed to 
the reduction in LDL3. Atorvastatin reduced the cholesterol content in all three 
LDL subtractions. Statins may enhance removal of LDL1 and LDL2 by LDL 
receptor upregulation and may reduce the formation of LDL3 from large, 
triglyceride-rich VLDL1, by stimulating clearance of remnants in VLDL2 and 
intermediate densi1y lipoprotein (IDL) densi1y ranges (27). In addition, VLDL 
concentration is reduced by inhibition of VLDL synthesis in the liver. 
Small, dense LDL particles are atherogenic because they bind to the arterial wall 
with greater affini1y than native LDL (28). Furthermore, they are more susceptible 
to glycation and oxidation (29). In non-diabetic populations the presence of small, 
dense LDL is associated with increased CHD risk (8,30-32). One may debate 
whether the presence of small, dense LD Lis an independent risk factor for CHD in 
patients with 1ype 2 diabetes (10,33,34) because their presence is related to elevated 
plasma TG level that is a characteristic feature of diabetic dyslipidemia. In our study 
we found a strong association between plasma TG levels and LDL subfraction 
densi1y distribution as well. 
In a recent study in non-diabetic patients 'With an atherogenic lipid profile, a 
reduction in the concentration of small LDL particles after atorvastatin was 
observed (35). McKenney et a!. suggested that small, dense LDL particles are 
reduced to a larger extent v.rith a higher dose of atorvastatin than with a lower dose 
(35). However, in our study both atorvastatin 10 and 80 mg significantly reduced 
small, dense LDL cholesterol concentration similarly by 24%. On the other hand, 
this study shows that cholesterol concentrations in LDL1 and LDL2 are dose-
dependently reduced by atorvastatin, which suggests that a higher dose of 
atorvastatin is more effective in reducing LDL-mediated risk for atherosclerosis. 
Two reports suggested that atorvastatin not only reduces overall concentrations of 
TG and LDL cholesterol but induces a shift in LDL subtraction distribution as well 
(36,37). These were open-labeled, uncontrolled studies in small numbers of non-
diabetic patients. Data from double-blind, randomized, placebo-controlled studies in 
type 2 diabetes are lacking. As far as we know, there is one valid-designed study 
addressing this issue. Frost et al. compared the effect of atorvastatin 10 mg versus 
fenofibrate on LDL subtraction pattern and composition in patients with type 2 
diabetes and observed results, regarding atorvastatin 10 mg, comparable to our data 
(21). They hypothesized that a higher dosage of atorvastatin might further decrease 
plasma TG concentration resulting in a shift in LDL subtraction distribution 
towards more buoyant, larger LDL (21). We observed a substantial reduction of 
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plasma TG levels induced by statin therapy that was similar for both dosages (18), 
without a shift of LDL subfraction distribution towards a large, buoyant LDL 
pattern. In addition, the proportion of cholesterol in LDLl, LDL2 and LDL3 did 
not change after 30 weeks of treatment, which underlines the absence of a shift. In 
the same study of Frost et aL fenofibrate induced a shift in LDL subfraction 
distribution from small, dense LDL (-31%) to intermediate-dense LDL (+36%) 
(21). The effects of fibrates are different from statins because they decrease TG 
concentration by activation of peroxisome proliferator-activated receptors a. 
Fibrates reduce the proportion of LDL3 by increasing LDL2 concentration and 
therefore induce a shift in LDL subfraction distribution without reducing total LDL 
concentration (38,39). The mechanism by which fib rates reduce concentrations of 
small, dense LDL particles is thought to be due to a specific reduction in hepatic TG 
levels relative to apoB, thereby promoting the secretion of smaller very low density 
lipoprotein (VLDL2) precursor particles and decreased neutral lipid exchange (40). 
Furthermore, fibrates may stimulate lipoprotein lipase activity, thereby increasing 
VLDL clearance (40). This suggests that only combination therapy of a statin and a 
fibrate will lead to the desired effect of total LDL cholesterol reduction together 
with a shift in LDL subfraction distribution towards less atherogenic, larger and 
more buoyant LDL particles in patients with type 2 diabetes. Indeed, recently 
Niemeijer-Kanters et a!. showed that a strategy of intensive lipid-lowering by 
combination therapy leads to LDL cholesterol lowering and a shift towards more 
large, buoyant particles in patients with type 2 diabetes (19). 
We studied the role of TG and CETP mass on the effect of atorvastatin on LDL 
subfraction distribution. Triglycerides may influence LDL particles through a cycle 
oflipid exchange via the action of CETP (41). LDL becomes enriched in TG and a 
population of small, dense LDL is formed by the action of hepatic lipase (7). 
However, we did not find evidence for a modulating effect of these parameters on 
the effect of atorvastatin on LDL subfraction density distribution. This could be due 
to the fact that the majority of the subjects in this study expressed an LDL2 
subfraction profile. This does not exclude that the observed reduction in CETP mass 
after atorvastatin therapy may add favorably to the reduction in LDL3 cholesterol 
and to the reduction of the total number of LDL particles present. 
Cone I usions 
T Low-density lipoprotein subtractions are reduced by aggressive lipid lowering 
in patients with type 2 diabetes mellitus 
Compared with placebo, atorvastatin 10 and 80 mg dose-dependently reduced the 
cholesterol content in LDLl and LDL2. The cholesterol concentration in small, 
dense LDL3 was significantly reduced to a similar extent. However, both dosages of 
atorvastatin did not induce a shift towards a larger, more buoyant LDL pattern 
although the total number of LDL particles present was substantially reduced. 
These observations suggest that probably combination therapy of statins and 
fibrates is needed to achieve the desired effect of LDL!, LDL2 and LDL3 
cholesterol reduction together with a shift in LDL subfraction density distribution 
towards less atherogenic, larger and more buoyant LDL particles in patients with 
type 2 diabetes. 
7: Low-density lipoprotein subtractions are reduced by aggressive lipid lowering 
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Letter to the editor 
Cognitive functioning u reduced in patientd with type 2 diabetu mellitw (DLIJ) 04 compared to 
age-matched patientd without D/71 (I). &pecialfy verbal memory and comple.-r: information 
procuding are affected in patientd with Dl/1, which will have an impact on daily functioning 
(2). The deverity of cognitive Jydjunction in patienu with Dl/1 pruumahly ruulto from an 
interaction between ridk factortJ for macro- and microva.Jcu!ar didea.Je (5). Previow .1tUdied 
Jttgg&Jt a potJitive a.JtJOciation between indic&J of cognitive impairment and elevation of p!adma 
triglyceride level (4,5). The effect of lowering derum triglyceride level.! by gemfibrozil on 
cognitive functioning htM been invutigated in elderly hypertriglyceridemic patienu, II out of 44 
patienu had Dl!f. Lowering triglyceride level.! appeared beneficial to cerebral perfwion and 
cognitive performance after four to dlx month, (6). Therefore we dtudied in the Diabetu 
Atorwutatin Lipid Intervention (DALI) &tady (7) the effect of atorwutatin on diabetic 
dy,!ipidemia and cognitive functioning. Thirty patientd with Dl/1, aged 45 to 75 yeard with 
faAing triglyceridu between I.5 and 6.0 mmol!L and total cho!edterol level.! between 4,0 and 
8.0 mmof!L, without idchemic heart and cerebrova.Jcular didea.Je were inc/u})ed. PatienttJ received 
placebo (n=8), IOmg atorvtMtatin (n=7) or 80rng atorvadtatin (n=ll) during 50 weekd. Two 
patienl:<i withdrew before the end of the otudy for peNOnal readoM and two patienu becawe of 
protocol violation. Fadting lipidd and neuropdychological tutd were addUded at badeline and 
after 50 weekd. The neuro{Mychological tut-battery Wad compoded in line with the finding' of 
preview dtudie.J with comparable groupd (I). Orientation and auditory-verbal memory were 
t&Jted, acJ weLL tLJ attention, ptiychomotor tipeed and executive functioning. Furthermore, we 
utimateJ premorbid intelligence with the Dutch veroion of the National Adult Reading Tut 
(NLV). Badeline characterutie.J, lipidd and neuropdychological tufd ruuitd did not differ 
between the intervention groupd. The mean HbAic wad 8.1 ± I.O% and the diabetu duration 
wtM 8.2 ± 5.2 year d. Atorvadtatin I Orng and 80rng rupectively reduced piadma triglyceride by 
12% and 52% and total cho!edterol by 27% and 42%. The badeline auditory-verbal tut 
ruultd were lowered in 7I% of the dtudy population, ad compared to a population without D/11. 
The badeline ruuitd on the other neuropdychological tufd did not differ from a non-diabetic 
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population. The verbaL memory tut (CVLT) improved 24% (a mean of 7 e.:-ctra wordd) after 
50 weelw of treatment with atorva4tatin 80mg.ln the atorva4tatin JOmg group the CVLT 
improved only 8% (a mean of 2 &'Ctra word&) and in the p!aabogroup no effect wad obderved. 
Verba! memory improvement correlated with an increade in HDLc (r=0.67, p<0.05), a 
reduction in LDLc (r=-0.54, p<0.05), and a reduction in TG (r=-0.54, p=0.07) after 
adjwtment for age, bade!ine HDLc, LDLc, TG and verba! memory. Atorvadtatin dW not affect 
p<~ychonwtor dpeeO, attention and e..ucutive functioning. 
To dummarize, in tbiJ <!mal! cohort of hyperlipidemic patient<! with type 2 di£Lbetu m.e!!itw 
treated with atorvadtatin, verbal memory improvement Wad a.JdociateO with improvement of the 
Ji£Lbetic dyd!ipidemia profile. Low and bigb dode atorvadtatin bad no dignificant effect on 
cognitive functioning. 
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Introduction 
Clinical studies have shovvn that cognitive functioning is reduced in type 2 diabetic 
patients, particularly in patients older than 60 years of age, compared with an age-
matched nondiabetic group (l-4). Especially verbal memory and complex 
information processing are affected in type 2 diabetes mellitus patients which will 
have an impact on daily functioning.(5-7). With the increase of the prevalence of 
type 2 diabetes, the prevention and treatment of possible cognitive dysfunction 
attracts more attention. The severity of cognitive dysfunction in patients vvith type 2 
diabetes mellitus presumably results from an interaction between risk factors for 
macrovascular and microvascular disease, like elevated serum triglyceride (TG) 
levels and hypertension (8,9), the duration of the diabetes and the presence of 
peripheral neuropathy (l, l 0), and metabolic changes like fasting plasma glucose and 
HbAlc (1!,12). A critical review of published studies (3) on cognitive impairment 
in patients v.rith type 2 diabetes mellitus strongly suggests a correlation betvveen 
indices of cognitive impairment and elevation of plasma TG (8,13,14). To our 
knowledge, only one study with 44 elderly hypertriglyceridemic patients, among 
them 11 patients with type 2 diabetes, investigated the effect of lowering serum TG 
levels on cognitive functioning. In this study lowering TG levels, as part of the 
diabetic dyslipidemia, by gemfibrozil appeared beneficial to cerebral perfusion and 
cognitive performance after four to si..x months (15). 
The Diabetes Atorvastatin Lipid Intervention (DALI) study (16) is a double-blind, 
placebo-controlled, randomized study which investigates the effect of atorvastatin 
10mg (AlO) and 80mg (A80) on plasma TG levels in 217 patients with diabetes 
mellitus type 2 without coronary heart disease. In this study, as part of the DALI 
study, we investigated the dose effect of atorvastatin on diabetic dyslipidemia and 
cognitive functioning. 
Patients and methods 
Patient.; 
The DALI study is a 30 week, double blind, randomized, placebo-controlled 
multicenter clinical trial, designed to assess the effect of aggressive lipid lowering by 
atorvastatin 80mg versus low dose atorvastatin 1 Omg versus placebo on TG level in 
type 2 diabetes mellitus patients without a history of manifest ischaemic heart 
disease. The design, methodology and baseline characteristics of this study are 
earlier described (16). The main inclusion criteria were total cholesterol between 4.0 
and 8.0 mmol/1 and a fasting TG between 1.5 and 6.0 mmol/1. Of the 80 patients 
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recruited for the DALI study in the study center Rotterdam, 30 patients fulfilled the 
in- and exclusion criteria and were willing to participate in the present study. 
We excluded patients with a history of stroke, dementia, cerebral tumor, use of 
centrally acting drugs, severe psychiatric symptoms and hypothyroidism. 
Furthermore, known alcohol or drug abuse and insufficient command of the Dutch 
language lead to exclusion. All patients gave written informed consent and the study 
was approved and performed according to the rules of the hospital medical ethics 
committee. 
Stu£Jy De.~ign 
At baseline we performed a full medical history and physical examination. Routine 
hematology, blood chemistry, fasting lipid profiles and diabetes parameters -were 
determined at baseline and at the end of the study. Neuropsychological tests were 
assessed at baseline and after 30 weeks treattnent. Before neuropsychological 
testing, the bloodpressure was taken and the plasma glucose was measured. The 
plasma glucose had to be above 4.5 mmolJI. 
N earopJycbologica.L l:&tl<l 
Neuropsychological tests were performed by a trained physician or a 
neuropsychologist. The test battery consists of si.-x neuropsychological tests, 
composed in line with the findings of previous studies in comparabel groups 
(1,6,9,11,13,17). These tests were always administrated in the same order: the 
orientation items of the Mini-Mental State Examination (M.tYl.SE) (18), the Dutch 
version of the California Verbal Learning Test (CVLT) (19), the Trail Making Test 
part A and B (TMT) (20), two subtests of the Wechsler Adult Intelligence Scale 
(WAIS) (21): the Digit Symbol Substitution Test (DSST) and the digit span 
forward (DSF) and digit span back-ward (DSB) and the Verbal and Category 
Fluency test (VCF) (22). 
The NLV (23), the Dutch version of the National Adult Reading Test (NART) was 
administered at the end of the neuropsychological assesment at baseline. The 
orientation items consists of orientation to time and place, each 5 items. The score 
was calculated as the total number of correct responses. The CVLT is an auditory 
verbal memory test, which consists of five presentations with recall of a 16--word list, 
followed by one presentation of a different 16--word list. Then, the free and cued 
recall of the initial list are measured. After a 20 minutes delay, the long-term free and 
cued recall condition are administrated. Finally, recognition is tested by requiring 
the patient to identifY correctly the words that were originally presented. 
The total CVLT score was obtained by summing the total number of words correctly 
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recalled in the first five trials The TMT is used as a measure for psychomotor speed, 
attention and executive functioning and given in two-parts. The subject must first 
draw lines to connect consecutively numbered circles (part A), and then connect the 
same number of consecutively numbered and lettered circles by alternating between 
the two sequences (part B). The score is eA.-pressed in seconds needed to finish the 
test. The DSST is a test in which subjects are allowed 90 seconds to replace each 
symbol in a series with a digit, with which it has been paired. This test indexes the 
psychomotor speed and focus of attention. The independent measure was the 
number of symbols correctly transcribed. The DSF and DSB are both tests for 
measuring span of immediate verbal recall and auditory attention. A string of three 
to nine single-number digits were presented orally and inunediately asked to recall 
the string aloud in the same order (DSF) or the reversed order (DSB). The 
dependent measure in each case was the longest string of digits correctly recalled 
without error. The VCF test was used mainly as a measure of executive functioning. 
The participants were asked to recall during one minute as many words as possible 
in the category given by the examiner (animals and professions) or starting with a 
specific letter (letter B). The score of the category fluency (animals and professions) 
and the letter fluency, was the sum of the number of words generated. The NLV 
comprises 50 phonetically irregular words which have to be read out loud. The NLV 
provides an estimate of premorbid intelligence. The NLV-score is based on the 
amount of right pronounced words. 
StaJ:iitU:a.l method<! 
Statistical analyses were carried out by SPSS for Windows release 9.0. Mean 
differences between the study groups were analysed using analysis of covariance 
(ANCOVA), adjusted for baseline levels. Intervention effects were also further 
adjusted for additional potential confounders, using ANCOVA. The association 
between lipids and cognitive function was assessed by multiple linear regression 
analysis, adjusted for baseline lipid levels and other potential confounding factors. 
Results 
Ba.;eline Chara.cteriiticd 
Thirty patients with type 2 diabetes mellitus and mild dyslipidemia, who met the in-
and exclusion criteria were randomized. Two patients withdrew before the end of 
the study for personal reasons and two patients because of protocol violation. The 
baseline characteristics of remaining 26 patients are described in Table I. There 
were no significant differences between the three groups prior to the treatment. 
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Table 1. Baseline characteristics 
Placebo Atorvastatin 1omg Atorvastatin So mg 
Number of patients 8 7 11 
Male gender (%) 3 (37-5) 4 (57.1) 6 (54-5) 
Age (yrs) 59.1 ± 7.6 63.3 ± 9.8 59.8 ± 8.6 
Duration diabetes (yrs) 10.4 ± 5.2 9.6 ± 7.6 8.] ± 4-9 
Current smoking(%) 75.0 85.7 63.6 
Neuropathy (%) 50.0 28.6 36.4 
Hypertension(%) 62.5 71.4 72-7 
Fasting glucose (mmoljl) 10.5 ± 2.8 9-9 ± 3-3 9-0 ± 24 
HbA1C (%) 8.2 ± 1.3 S.2 ± 0.9 7-9 ± o.S 
Values are mean± standard deviation 
Effecl:d on 4eru.m lipUJ4 
The baseline and on-treatment values of total cholesterol. HDL cholesterol (HDL-
C), plasma TG, LDL cholesterol (LDL-C), Apo A1 and Apo B-100 are summarized 
in Table 2. The results were similar as those earlier described in the DALI study (16). 
Table 2. Lipids and lipoproteins at baseline and percentage change after 30 weeks treatment.. 
Placebo Atorvastatin Atorvastatin 
10 mg So mg 
Total cholesterol Baseline 6.14 ± 0.9 6.02 ± 14 6.02 ± 0.] 
(mmoljl) %Change (lOR) -3-4 (0.1) -26.6 (0.3)'" -41.9 co.2r·~ 
HDL-C Baseline 1.12 ± 0.2 0.92 ± 0.2 o.S1 ± 0.2 
(mmoljl) % Change (IQR) -0.07 (0.1) +0.2 (0.07) +3-4(0.2) 
Triglycerides Baseline 2.51 ± 0.72 2.51 ± 0.66 3-26 ± 1.18 
(mmoljl) % Change (IQR) +8.3 (o.6) -18-9 (o.S) -39-4 (o.6)'" 
LDL-C Baseline 3-94 ± 0.7 4.02 ± 14 3-50 ± 0.6 
(mmoljl) % Change (IQR) -5.3 (o.2) -35.5 (o.8)'" -55.7 C o.2y-·~ 
Values are median,, standard deviation or median percentage change with interquartile range (IQR). 
Test for difference versus placebo:~p<o.os,'""' p<o.oos, ·~,...'p<o.Oo1. 
Test for difference versus atorvastatin 10 mg:? p< o.os 
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Effect.; on cognitive functioning 
Cognitive tests results at baseline and after 30 weeks treatment are shown in Table 
3. Intelligence, as estimated with the NLV at baseline, was not significantly different 
between the three groups, but patients receiving AI 0 had the lowest NLV score. 
Orientation in place and time was completely normal in all patients. The baseline 
auditory-verba! memory (CVLT) test results were lowered in 71% of the study 
population, as compared to an age-matched population without diabetes mellitus. 
The baseline results on the other neuropsychological tests did not differ from a non-
diabetic, age-matched population. The CVLT showed a trend to improve with the 
atorvastatin dose. The CVLT test results improved 24% (a mean of 7 extra words) 
after 30 weeks treatment with A80. In the AI 0 group the CVLT improved only 8% 
(a mean of two extra words) and in the placebo group no effect was observed. All 
three treatment groups scored better in immediate and delayed memory testing as 
well as in correctly recalled words. There was no change in performance at baseline 
and after 30 weeks treatment between the groups in the other tests of psychomotor 
speed, attention, and executive functioning. 
An inverse association between verbal memory and LDL-C reduction (Beta-0.34, 
p=0.03) and a positive association with HDL-C improvement (Beta +0.67,p=0.02) 
was observed, after adjustment for age, respectively baseline LDL-C and HDL-C 
and verbal memory at baseline. Increase in verbal memory correlated also, but not 
statistically significantly with reduction in total cholesterol and TG (Beta -0.27, 
p=0.08 and Beta -0.34, p=0.07), after adjustment for age, baseline total cholesterol, 
TG and verbal memory). Changes in TG, HDL-C and LDL-C are stronger 
correlated with verbal memory improvement then total cholesteroL These data 
suggests that changes in the profile of diabetic dyslipidemia was associated with 
verbal memory changes. Further adjustments for plasma glucose, HbAlc, 
polyneuropathy, smoking, duration of the diabetes, hypertension, BMI or 
intelligence, did not alter these associations. 
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Table 3. Cognitive function test at baseline and percentage change after 30 weeks treatment. 
Cognitive function test Placebo Atorvastatin Atorvastatin 
10 m So m 
NLV (score) Baseline 104-5 ± 22.7 84.0 ± 19.1 92.0 ± 22.2 
California Verbal Baseline 40-5 ± 6.4 34-0 ± 13.6 41.0 ± 10-5 
Learning Test (score) % Change (IQR) +1-7 ± 0.4 +n ± o.3 +23-5 ± 0.01 
Trail making test A Baseline 43-5 ± 17.0 45.0 ± 22.2 50.0 ± 15.9 
(sec) % Change (IQR) -12.9 ± 0.4 ·11.] ± 0.5 ·9.1 ± 0.3 
Trail making test B Baseline 75-5 ± 43-7 95.0 ± 49.6 100.0 ± 28.2 
(sec) %Change (IQR) -1.8 ± 0-4 +17-9 ± 0.3 +2.5 ± 0.3 
Digit symbol substitution Baseline 42.0 ± 9.8 40.0 ± 17.4 49-0 ± 10.2 
test (score) % Change (IQR) 2.5 ± 0.4 -2.4 ± 0.3 ·4-4 ± 0.3 
Digit span forward Baseline 5.0 ± 0.5 6.0 ± 1.1 5.0 ± 1.2 
(score) %Change (IQR) +0.0 ± 0.2 +0.0 ± 0.3 +0.0 ± 0.4 
Digit span backward Baseline 3-5 ± 1.0 3-0 ± 1.3 5.0 ± 1.0 
(score) %change (IQR) +0.0 ± 0.5 +0.0 ± 0.0 +0.0 ± 0.2 
VCF animal Baseline 21.0 ± 8.5 22.0 ± 3-5 23.0 ± 4.6 
(score) % Change (IQR) +0.0 ± 0.2 +5.8 ± o.5 +0.0 ± 0.3 
VCF profession Baseline 19-0 ± 8.0 15.0 ± 5-5 19.0 ± 3-8 
(score) %Change (IQR) ·25.5 ± 0.3 +21.0 ± 0.2 ·17.3 ± 0.2 
VCF letter B Baseline 17.0 ± 8.7 8.0 ± 6.8 13.0 ± 8.3 
(score) % Change (IQR) ·4-5 ± 0-4 +33-3 ± 0.6 ·16.7 ± 0.2 
Values are median ±standard deviation or median percentage change with interquartile range (IQR). 
N LV (Dutch version of the National Adult reading Test), VCF (Verbal and Category Fluency test). 
For the CVLT, DSF, DSB and VCF tests higher scores indicate better performance. 
For the TMT and DSST tests lower scores indicate better performance 
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Discussion 
Our study in patients with type 2 diabetes mellitus indicates that improvement of 
verbal memory is associated with normalization of the lipid profile by atorvastatin. 
To our knowledge this is the first study that shows that both treatment of 
hypertriglyceridemia (and associated low HDL-C levels) as well as treatment of 
elevated LDL-C levels may enhance cognitive function on patients with type 2 
diabetes mellitus. Although a relatively small group of patients was studied and 
interpretation and extrapolation of data to larger group of patients should be done 
vvith care, the results of our study are promising for carrying out larger studies. The 
patients in this study were relatively young, betvveen 55 and 65 years of age, 
compared to other cognitive function studies. It is known that older adults have an 
increased risk of diabetes-associated memory dysfunction (24). As a result our 
patients had no or only slightly impaired cognitive function and although no further 
improvement can be eA-pected in this group, they did show positive changes in verbal 
memory. A previous investigation used gemfibrozil instead of a statin to study the 
effect on cognitive functioning in patients with type 2 diabetes mellitus. Gemfibrozil 
has its main effect in lowering triglycerides and increasing HD L-C levels while 
statins have proven also to reduce LDL-C, next to its reduction of TG and increase 
of HDL-C. HDL-C levels are inversely related to plasma TG levels. In this study 
HDL-C correlated stronger with verbal memory improvement than TG levels. 
From literature it is known that hypertriglyceridemia in patients with type 2 diabetes 
mellitus is associated with a decline in verbal memory, in reaction time and 
backward digit span (25). The specific pathophysiology of cognitive disturbances 
associated with elevated TG levels is unknown. Probably, the induction of 
atherosclerosis by dyslipidemia, reducing cerebral blood flow and the acute effect of 
hypertriglyceridemia on the cognitive function (26), contribute to cognitive 
dysfunction. Lowering serum TG levels decreases blood viscosity, resulting in 
increased blood flow and a better hemorheology (27). 
There are speculations about the psychological and behavioral effects of changes in 
serum lipid levels in humans. Two studies (28,29) found some correlation between 
cholesterol levels and cognitive function. A higher cholesterol level was associated 
with a better cognitive function. To the eA.-tent that cholesterol lowering is a 
necessary treatment for the prevention of atherosclerotic disease in t;ype 2 diabetic 
patients, it is important to look for changes in cognitive function and quality of life. 
A few studies evaluated the effect of pharmalogical cholesterol lowering on cognitive 
function and psychological well being. In order to investigate the effect of statins on 
the CNS, Cutler et a! (30) described the effect of simvastatin and pravastatin on 
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cognitive function in patients with hypercholesterolemia. There was no change in 
the cognitive function during a 4 weeks period of active treatment. Another recent 
study showed no difference in psychological distress and cognitive function after 
reducing LDL-C by lovastatin during a 6-month treatment period (31). To our 
knowledge there is no further information about the effect of atorvastatin on 
cognitive performance. Our study showed no reduction of cognitive functioning 
after cholesterol reduction by low and high dose atorvastatin but suggested an 
improvement in verbal memory after reduction of total and LDL cholesterol. 
Statins reduce ischaemic stroke by the anti-thrombotic and anti-atherosclerotic 
effects and are neuroprotective. Vaughan eta! (32) reviewed the effect of statins on 
the cerebral circulation and brain parenchyma during ischaemic stroke and 
reperfusion. Statins upregulate endothelial nitric oxide synthetase and inhibit 
inducible nitric oxide synthetase, both neuroprotective effects. They also influence 
the inflammatory c;ytokine responses and reduce ischemic oxidative stress in the 
brain through antioxidant properties. An other recent study (33) showed the 
lowered risk of developing dementia by statins, independent of hyperlipidemia. It is 
clear that additional studies on the neuroprotective effects of statins are necessary. 
Conclusions 
In this small cohort of hyperlipidemic patients with type 2 diabetes mellitus treated 
with atorvastatin, verbal memory improvement was associated with improvement of 
the diabetic dyslipidemia profile. Low and high dose atorvastatin showed no decline 
in cognitive functioning. The results encourage further investigation of the effect of 
adequate lipid lowering on cognitive functioning during a longer period and in a 
larger type 2 diabetic population. 
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Discussion 
The main results of the studies described in this thesis can be outlined as follows: 
l Administration of atorvastatin at doses of either l 0 or 80 mg is effective in 
lowering plasma cholesterol and rriglycerides in patients with type 2 diabetes 
mellitus. Both doses are well tolerated in our patient population. 
2 Gender, LIPC promoter variant and ethnicity signi£cantly contribute to the 
baseline variance in HL activ-ity. Atorvastatin treatment in diabetic dyslipidemia 
results in a significant dose-dependent decrease in HL activ-ity, regardless of 
gender or the LIPC promoter variant. 
3 LPL gene mutations influence lipids, lipoproteins and LPL activity in type 2 
diabetes mellitus, which may affect the risk for cardiovascular disease. The 
S447Stop mutation modulates the response to atorvastatin which may result in 
a further improvement of the diabetic dyslipidemia profile. 
4 Atorvastatin treatment results in a significant dose-dependent reduction in 
plasma apoC..III, HDL apoC..III, and LpB:CIIllevels in patients with type 2 
diabetes mellitus. These data indicate a potentially important anti-atherogenic 
effect of statin treatment and e>.l'lain part of the triglyceride lowering effect of 
atorvastatin. 
5 In patients with type 2 diabetes, there is a gender specific etiology of low HD L-
C levels. Gender differences in lipase activities may partly e:>.l'lain this sex 
difference in etiology. Especially in women this may conrribute to the increase 
in relative risk of CHD. 
6 Atorvastatin significantly reduces cholesterol concentration in all LDL 
subfractions but does not induce a shift in LDL subfraction density distribution 
towards larger and more buoyant LDL particles in patients with type 2 diabetes 
mellitus. 
7 Apart from effects on lipids and CHD, improvement of the diabetic 
dyslipidemia profile with atorvastatin associates with verbal memory 
improvement. 
TriglycerUJe lowering in the DALI population, efficacy an2 mechani.mu 
Diabetic dyslipidemia is characterized by increased plasma TG and decreased 
HDL-C levels together with compositional changes in VLDL, LDL and HDL 
particles. Improvement of clinical outcome in type 2 diabetes may be expected when 
the atherogenic lipid profile is changed into a less atherogenic lipid profile. 
Statins are efficacious for LDL-lowering and disease prevention in diabetic patients. 
High dose statins also reduce elevated levels of plasma TG. In the DALI study we 
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used a standard dose of l Omg atorvastatin and an aggressive dose of 80mg 
atorvastatin, in order to endeavour normalisation of lipoprotein profiles in patients 
with rype 2 diabetes. In Chapter 2 we reported a reduction of 25% in plasma TG 
after 30 weeks treatment with low dose atorvastatin and a reduction of 35% with 
high dose atorvastatin. Although there is no statistical significance betvveen both 
dosages of atorvastatin, the 10% further reduction in plasma TG levels with high 
dose atorvastatin might indicate a possible dose-response reaction. Identification in 
our study of subjects that benefited most of the high dose atorvastatin therapy is not 
possible. It would be very interesting to identify those patients, since further 
reductions of plasma TG levels may lead to a further reduction in cardiovascular 
risk. Moreover, a study by co-investigators of the DALI study, favours the titration 
to a higher dose of atorvastatin (I). They studied the effect of high versus low dose 
atorvastatin on postprandial hyperlipidemia, since dyslipidemic patients with rype 2 
diabetes usually have both increased fasting and postprandial TG levels. Increased 
postprandial TG levels are associated vvith increased intima media thickness in type 
2 diabetes mellitus (2). Both dosages of atorvastatin resulted in a reduced 
postprandial TG and TRL response -with a significant greater improvement of the 
higher dose. Also the dose-dependent effect of atorvastatin on cholesterol-related 
parameters (Chapter 2) and the dose-dependent reduction of the cholesterol-
content in the LDL subfractions (Chapter 7), may favour high dose statin therapy 
in order to reach ADA treatment goals. 
\Vhat is the mechanism involved in plasma TG reduction by atorvastatin in our 
population? In Chapter 2 and 4, we described the influence of atorvastatin on LPL 
activity, since LPL is the major enzyme responsible for clearance of plasma TG. The 
results demonstrating the effect of atorvastatin on LPL activity, pointed out that the 
reduction of plasma TG by atorvastatin is not due to enhanced LPL expression. 
In Chapter 4 we studied the effect of atorvastatin on post-heparin LPL activity in 
relation to lipids and lipoproteins in non-carriers and carriers of LPL gene 
mutations. The post-heparin LPL activity seemed to be in the normal range, 
suggesting that the hypertriglyceridemia is mainly caused by an increased secretion 
of TG into the blood. We don't know why LPL activity is "normal" in our 
population, but it is possible that this relatively " normal" LPL activity represents a 
situation in which there is already an insufficient compensation of insulin-mediated 
stimulation of LPL activity for the enhanced TG secretion. In rype 2 diabetes a 
relatively increase in LPL activity is probably necessary, since substrate deliverance 
(VLDL-TG) is often increased and plasma TG levels may rise if lipolysis by LPL is 
impaired. It is therefore likely in patients with rype 2 diabetes that especially in the 
postprandial state LPL activity may be affected and may contribute significantly to 
the atherogenic lipid proflle. 
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This may be even more the case in carriers of the LPL D9N allele, since this allele 
appears to be associated with a trend towards a decrease in LPL activity. In contrast, 
the LPL S447Stop mutation seems to be associated with an allele-dose dependent 
increase in LPL activity and it is therefore likely that the difference in LPL activity 
betvveen carriers and non-carriers of the S447Stop mutation will have an even 
greater impact in the postprandial state. 
Atorvastatin did not affect LPL activity in non-carriers of LPL mutations. The LPL 
S447Stop mutation seemed to modulate the effect of atorvastatin on LPL activity. 
Carriers of the S447Stop mutation had a significant 20o/o higher LPL activity after 
30 weeks atonrastatin compared with non-carriers. Since the S447Stop mutation is 
very common in different populations, more population-based research seems to be 
necessary for studying the effect of statin therapy on lipid profiles and CHD risk. 
In addition to LPL activity, it is likely that the hypertriglyceridemia is due to an 
increased apoC-lll content of TRLs, impairing the catabolism of these particles. 
ApoC-lll is a risk indicator for atherosclerotic disease and in Chapter 5 we 
suggested that atonrastatin may reduce plasma TG through a modulation in apoC-
!Il e)o.-pression. Atorvastatin treatment profoundly lowered the apoC-ll! content of 
HDL and of non-HDL (apoB-100 containing) lipoproteins (LpB:Clll). This 
reduction of apoC-l!I probably partly restored altered LPL activity and increased 
lipoprotein uptake. 
One could argue that the reduction of apoC-!Il is due to the TG reduction and not 
the other way around. ApoC-III partitions to VLDL, the more VLDL in the 
circulation, either from increased secretion or decreased fractional removal, the 
more apoC-l!I in LpB (VLDL). 
Therefore lowering TG will very likely lower apoC-!Illevels. But, Schoonjans et al 
(3) demonstrated in rats that statins decreased mRNA as well as plasma levels of 
apoC-!Il. 
Although this information favours our results, more studies unravelling mechanisms 
involved in apoC-II!lowering are necessary. 
Implication of HL activity lowering by dtal:Uu 
Besides LPL activity and apoC-III levels, HL activity is also a major factor in the 
maintenance of normal lipid profJes. Atorvastatin decreased HL activity in type 2 
diabetes dose-dependently regardless of gender or the LIPC promoter variant, as 
described in Chapter 3. In most studies, elevated HL activity in patients with 
diabetes is strongly associated with reduced HDL cholesterol and increased small, 
dense LDL. Zambon and Brunzell identified HL as focal point for the development 
and treatment of CHD. They proposed a new pathway of regresswn of 
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atherosclerosis through HL-mediated improvement in LDL buoyancy (4). In our 
DALI population increased HL activity is associated with decreased HDL and 
increased plasma TG, but not with an excess of small dense LDL particles. 
Atorvastatin therapy reduced HL activity significantly without abolishing the 
association between HL and TG or HDL-C. Changes in HL activity showed no 
correlation vvith changes in LDL-size. 
Remarkably, most of the DALI patients had already large, buoyant LDL particles 
before treatment, as described in Chapter 2. One should expect that patients, that 
are often obese, inactive and hypertriglyceridemic, have increased levels of small 
dense LDL. Our patients had no overt ischemic heart disease and this may eA.-plain 
the low levels of small dense LDL particles, since most patients with CHD will have 
an excess of small dense LDL particles. 
Since HL lowering by atorvastatin did not affect LDL size in our DALI population, 
the question remains whether HL lowering is beneficial for treatment of diabetic 
dyslipidemia. J aosen et al pointed out in an excellent review ( 5) that HL lowering 
may have pro- as well as anti-atherogenic consequences dependent on the 
conditions, which makes its difficult to predict whether HL is a suitable target for 
intervention to lower CHD risk. As stated before, high HL activity is most likely 
associated with low HDL-C, increased reverse cholesterol transport and clearing of 
remnaot particles, but also with an excess of small dense LDL particles. HL 
lowering will probably reverse these processes. If HL lowering by statin therapy 
does not affect LDL size, the clinical significaoce of our findings is hard to assess. 
However, this does not exclude the clinical significance of our findings and follovving 
mechanism can be proposed to demonstrate whether HL lowering by statins may be 
beneficial in patients with type 2 diabetes. 
HL activity increases with the degree of insulin resistance in type 2 diabetes ( 6). The 
impact of HL on lipoprotein metabolism will vary depending on the amount of 
potential substrate. Longterm insulin resistance is associated vvith an excess of 
VLDL-TG production. This probably stimulates HL eA.-pression in order to increase 
hydrolysis ofHDL-TG and maintain intracellular lipid levels in the liver. Eventually, 
the TG deliverance exceeds the HL capacity which may subsequently lead to the 
atherogenic lipid profile seen in diabetic dyslipidemia. Lowering HL activity during 
this hypertriglyceridemic state may decrease the atherogenic risk through the 
improvement of the lipid profile. Atorvastatin decreases hepatic production of 
VLDL and stimulates LDL receptor activity. This might possibly prevent 
impairment of the reverse cholesterol transport during HL activity lowering and 
direct the lipid metabolism in type 2 diabetes into a less atherogenic direction. 
However, atorvastatin reduced the CETP mass in the DALI population as well (7). 
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Reductions of HL and CETP are both associated with increased HDL. Of course 
raising HDL is one of the main targets to reduce atherosclerosis, since the 
antiatherogenic properties of HDL include promotion of cellular cholesterol efflux 
and reverse cholesterol transport, as well as antioxidant, anti-inflammatory- and 
ar1ticoagulant properties. High HDL-C levels may represent enhanced reverse 
cholesterol transport, but what will happen if both pathways of facilitating the 
process of reverse cholesterol transport are influenced by statin therapy? Since HL 
stimulates HDL cholesterol ester uptake by hepatocytes and CETP facilitates 
reverse cholesterol transport by transferring cholesterol from HDL to LDL, HDL 
particles are probably not able to loose their cholesterol ester-content, which leaves 
an atherogenic situation. At this moment, already randomized phase II dose-reponse 
studies are performed to study the effect of novel CETP inhibitors in humans (8). 
Four weeks treatment with a CETP inhibitor in healthy patients with mild 
hyperlipidemia led to 37% decrease in CETP activity and to 34% increase in HDL-
C. Although these results are promising, further studies are needed to investigate 
whether the observed increase in HDL cholesterol translates into a concomitant 
reduction in CHD and whether concomitant CETP mass reduction affects the 
response of other hypolipidemic treatment. 
Gen4er Jifference.J in etiology of diabetic dydlipUJemia.; implicatwn.1 for therapy? 
Elizabeth Barrett-Connor vvrote an review article describing the se.."'( differences in 
CHD (9). Women with type 2 diabetes loose their "female survival advantage" for 
cardiovascular death. This loss seemed partially due to major changes in lipoprotein 
profiles. Besides gender differences in the quantity and quality of lipoproteins, we 
postulated in Chapter 6, that gender differences in lipase activities participated in 
the gender speci£c etiology of HDL-C levels. As mentioned above, HDL probably 
has many antiatherogenic properties and is therefore recognised as a potential target 
for therapeutic intervention of atherosclerotic vascular diseases. The relatively low 
HDL-C levels in the DALI women are probably caused by an attenuated HDL 
formation due to a relatively low LPL activity. In contrast, low HDL-C levels in the 
DALI males are caused by accelerated HDL or apoA-1 clearance due to increased 
HL activity. Increased HL activity may induce cholesterol ester uptake in the liver 
and therefore promote reverse cholesterol transport, it is therefore possible that low 
HDL-C levels in women with diabetes may constitute a higher-risk metabolic profile 
than in men with diabetes. Since HL and LPL may play a major role in determining 
the HDL-C levels as well as influencing the function of HDL particles, they may 
have important effects on atherosclerosis and are viable targets for (new) drug 
therapy. 
g: Discussion 
These interesting results point out that a differentiation in treatment strategy 
towards men an women might be necessary, but more studies on sex differences in 
etiology of diabetic dyslipidemia are necessary. 
Quality of life 
In Chapter 2 we concluded that low (lOmg) and high (80mg) dose atorvastatin are 
effective and safe in the treatment of diabetic dyslipidemia and that there are no 
differences in side effects between placebo, atorvastatin l Omg and atorvastatin 
80mg. Since lipid-lowering drugs are used within a framework of systematic 
approach for effective treatment of patients with 1ype 2 diabetes mellitus, one single 
drug that lowers plasma TG and cholesterol levels will certainly increase patient 
compliance and probably improves quality of life. 
Finally in Chapter 8, we found an association between improvement of verbal 
memory and improvement of diabetic dyslipidemia by atorvastatin. Our study was 
based on the intriguing hypothesis that cognitive functioning is reduced in patients 
with diabetic dyslipidemia. As described in the article, the study was not without 
limitations. One could argue about the small number of patients involved or the 
chance on finding associations betvveen lipid improvement and the large battery of 
cognitive function tests in this study. Of course, the small number of patients 
restricted us from making any conclusions of note, but the interesting results are 
promising for carrying out further studies. To the eA-tent that lipid improvement 
reduces the risk for atherosclerotic disease and may lead to changes in cognitive 
functioning, our study may serve as a stimulus to look more closely at the hypothesis 
that statins affect cognitive functioning in hyperlipidemic patients with 1ype 2 
diabetes. In order to obtain this information, a larger study with a demographically-
similar nondiabetic, non-hyperlipidemic control group to compare the baseline 
neuropsychological test results and a longer duration of therapy is necessary. 
Clinical, epidemiologic, and pathologic observations suggest that vascular risk 
factors are associated vvith impaired cognition. For example, recently the VLDL 
receptor polymorphism, that constitute a genetic susceptibility factor for dementia, 
is suggested to be a vascular risk factor in the occurrence of dementia (1 0). 
Since 1ype 2 diabetes is such a complex metabolic disorder, the etiology of any 
associated cerebral dysfunction is likely to be multifactorial. Therefore more studies 
of the nature of cognitive impairment in 1ype 2 diabetes must be carefully designed. 
9: Discussion 
Cone I usions 
Standard and aggressive lipid lowering with atorvastatin is effective, safe and well 
tolerated in patients with type 2 diabetes and diabetic dyslipidemia. 
Lowering of hepatic lipase activity by statins may have pro- as well as anti-
atherogenic consequences. 
Reduction of plasma triglycerides by atorvastatin is not due to enhanced LPL 
expression, but is possibly due through modulation of apoC-III expression. 
Since gender and genetic variance may influence key factors in the pathogenesis of 
lipoprotein abnormalities in type 2 diabetes and genetic factors may interact with the 
efficacy of statin therapy, differentiation in treatment strategy seems usefuL 
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Summary 
10: Summary 
Diabetic dyslipidemia is an established risk factor for coronary heart disease (CHD) 
and further elucidation of the lipoprotein metabolism and the effect of statin therapy 
seems necessary in order to prevent atherosclerotic disease. As discussed in 
Chapter l, studying the role of lipolytic enzymes and apolipoproteins in diabetic 
dyslipidemia, may lead to more information of mechanisms involved and may reveal 
possible targets for therapeutic intervention. Results of the Diabetes Atorvastatin 
Lipid Intervention (DALI) study revealed some of this information, The DALI 
study is a double blind, placebo controlled, randomized multi-center study, 
conducted in Leiden, Rotterdam and Utrecht, The Netherlands, between 1998 and 
2000. The participants in this study are male and female patients, aged 45-75 years, 
with type 2 diabetes, The main inclusion criteria are fasting total cholesterol (TC) 
levels between 4.0 and 8.0 mmolJL and fasting triglyceride (TG) levels between L5 
and 6.0 mmol/L. Patients were randomized to receive with placebo, atorvastatin 
!Omg or atorvastatin 80mg for a period of 30 weeks. The HMG-CoA reductase 
inhibitor atorvastatin was chosen for its hypothesized eA"tra effect on TG reduction. 
In Chapter 2 the effect of low and high dose atorvastatin on fasting plasma TG 
levels, the primary endpoint of the study, is described. Both dosages provided 
significant reductions in fasting TG levels. Atorvastatin l Omg reduced plasma TG 
with 25% and atorvastatin 80mg with 35%, not statistically significantly different. 
Baseline TG levels did not have any effect on the outcome. Total cholesterol and 
LDL-C levels are both dose-dependently reduced. More patients reached the ADA 
treatment goals with atorvastatin 80mg. Both dosages seemed safe and well 
tolerated. 
In Chapter 3 the role of hepatic lipase (HL), the influence of gender, L!PC promoter 
variant and ethnicity on HL activity, as well as the influence of atorvastatin on HL 
activity in diabetic dyslipidemia is described. Gender, LIPC promoter variant and 
ethnicity significantly contributed to the baseline variance in HL activity. 
Atorvastatin treatment resulted in a dose~dependent significant reduction of HL 
activity, regardless of gender or the LIPC promoter variant. 
In Chapter 4 the influence of lipoprotein lipase (LPL) gene mutations on LPL 
activity, lipids and lipoproteins is described. Carriers of the D9N LPL mutation had 
a significantly lower LPL activity and a more atherogenic lipid profile than patients 
without a mutation in the LPL gene. Carriers of the LPL N291S mutation had 
similar LPL activity and lipid profiles as non-carriers. The S447Stop variant showed 
an allele-dose dependent increase in LPL activity, apoA-1, HDL-C and decrease in 
plasma TG. Since genetic variants may modulate the efficacy of drugs, the effect of 
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atorvastatin treatment on plasma lipids in carriers of a LPL gene variant 1s 
evaluated. Only the S447Stop mutation modulated the response of LPL activi1y to 
atorvastatin. LPL activity after atorvastatin treatment was significantly higher in 
patients carrying the LPL S447Stop mutation than in non-carriers. 
In Chapter 5 the effect of atorvastatin on apolipoprotein (apo)C-III is studied. 
ApoC-III is a risk indicator for atherosclerotic disease. Increased apoC-III content 
of triglyceride-rich lipoproteins (TRLs) may impair the catabolism of these TRLs, 
resulting in hypertriglyceridemia. Atorvastatin therapy profoundly lowered the 
apoC-III content of HDL and of non-HDL (apoB-100 containing) lipoproteins. 
These results suggest a possible mechanism of TG reduction by atorvastatin. The 
TG reduction by atorvastatin is possibly due mediated through a modulation in 
apoC-III e .. -pression. Our data may indicate a potentially important anti-atherogenic 
effect of statin treatment. 
In Chapter 6 the gender specific etiology of low HDL-C levels in patients with 1ype 
2 diabetes is discussed. Female patients with diabetes had relatively low LPL 
activi1y and male patients with diabetes had increased HL activi1y compared with 
non-diabetic patients. The relatively low HDL-C levels in females are possibly 
caused by an attenuated HDL formation due to low LPL activi1y. Low HDL-C 
levels in males are possibly caused by increased HDL (apoA-1) clearance due to 
increased HL activi1y. Although atorvastatin therapy did not affect LPL activity and 
reduced HL activity equally in males and females. Lipids and lipoproteins in males 
and females are influenced similar. 
In Chapter 7 the effect of atorvastatin therapy on LDL subfractions is discussed. In 
patients with 1ype 2 diabetes LDL-C levels are often not elevated, but there is a 
preponderance of LDL particles with smaller size and increased densi1y that are 
associated vhth increased cardiovascular risk. Atorvastatin significantly reduced 
cholesterol concentration in all LDL subfractions but did not induce a shift in LDL 
subfraction density distribution towards larger and more buoyant particles. 
In Chapter 8 the effect of improvement of the lipid profile by atorvastatin on 
cognitive functioning is studied. Improvement of verbal memory correlated with 
improvement of the diabetic dyslipidemia by atorvastatin. These results may serve 
as a stimulus to conduct further studies in this area, since improvement of cognitive 
functioning in patients with 1ype 2 diabetes will certainly improve the quali1y of life. 
Finally in Chapter 9 the implications of the DALI study results for treatment of 
diabetic dyslipidemia are discussed. 
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Diabetische dyslipidemie is een bewezen risicofactor voor hart~ en vaatziekten. Voor 
de preventie van atherosclerose is verdere opheldering van het lipiden metabolisme 
en het effect van statine behandeling daarop noodzakelijk. Zoals besproken is in 
Hoofdstuk l, zal het bestuderen van de rol van lipolytische enzymen en 
apolipoprote1nen in diabetische dyslipidemie leiden tot beter inzicht in het 
mechanisme. Dit kan weer leiden tot herkenning van mogelijke nieuwe 
therapeutische aangrijpingspunten. De resultaten van de Diabetes Atorvastatin 
Lipid Intervention (DALI) studie leverden aanvullende informatie op over het 
mechanisme en de therapeutische opties ten aanzien van diabetische dyslipidemie. 
De DALI studie IS een dubbel-geblindeerde, placebo-gecontroleerde, 
gerandomiseerde studie, welke in Leiden, Rotterdam en Utrecht is uitgevoerd van 
1998 tot 2000. De deelnemers zijn mannen en vrouwen met type 2 diabetes, met een 
leeftijd tussen de 45 en 75 jaar. Het belangrijkste inclusiecriteria is een totaal 
cholesterol gehalte tussen 4.0 en 8.0 mmol!L en een nuchtere triglyceride gehalte 
tussen de 1.5 en 6.0 mmol!L. Patienten zijn gerandomiseerd voor placebo, 
atorvastatine 1 Omg of atorvastatine 80mg en behandeld gedurende 30 weken. De 
HMG CoA reductase remmer atorvastatine is gebruikt in de studie vanwege het 
veronderstelde eA.-tra therapeutisch effect op de triglyceriden. 
In Hoofdstuk 2 is het effect van een lage en hoge closeting atorvastatine op de 
nuchtere plasma triglyceriden, het primaire eindpunt van de studie, beschreven. 
Beide doseringen zorgden voor een significante verlaging van de plasma 
triglyceriden. Atorvastatine 1 Omg reduceerde plasma triglyceriden met 25% en 
atorvastatine 80mg met 35%. Er is geen significant verschil tussen beide doseringen. 
De plasma triglyceriden spiegel bij aanvang van de studie beYnvloedde het resultaat 
niet. Zowel het totale cholesterol als het LDL-cholesterol is dosisafhankelijk 
verlaagd met atorvastatine. Met name bij de patienten die behandeld zijn met 
atorvastatine 80mg zijn de streefwaarden, volgens de ADA criteria, gehaald. Beide 
doseringen zijn veilig en goed verdragen. 
In Hoofdstuk 3 is de rol van hepatisch lipase (HL) in diabetische dyslipidemie en 
het effect van atorvastatine behandeling beschreven. Geslachtsverschillen, de LIPC 
promotor variant en verschillen in etniciteit, belnvloeden de HL activiteit bij 
aanvang van de studie. Atorvastatine therapie resulteerde in een dosisafhankelijke 
reductie van de HL activiteit, onafhankelijk van geslacht of dragerschap van een 
promotor variant. 
In Hoofdstuk 4 is de invloed van lipoproteine lipase (LPL) genmutaties op LPL 
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act:rvrtert, lipiden en lipoprote'inen beschreven. Dragers van de D9N LPL mutatie 
hebben een significant lagere LPL activiteit en een meer atherogeen lipiden profiel 
in vergelijking met patienten die geen drager waren van een LPL genmutatie. 
Dragers van de N291S mutatie hebben een vergelijkbare LPL activiteit en lipiden 
profiel als patienten zonder genmutaties. De patienten met de S447Stop mutatie 
toonden een allel-dosis aflrankelijke toename in LPL activiteit, apoA-1, HDL-C en 
daling in plasma triglyceriden. Aangezien genvarianten the effect van statine 
therapie kunnen be"invloeden, is tevens het effect van atorvastatine in dragers van 
genmutaties bestudeerd. Alleen de S447Stop mutatie veranderde het effect van 
atorvastatine therapie. De LPL activiteit na atorvastatine therapie is significant 
hoger in dragers van de S447Stop mutatie dan in patienten zonder genmutaties. 
In Hoofdstuk 5 is het effect van atorvastatine op apolipoproteine (apo)C-Ill 
beschreven. Een verhoogd apoC-III gehalte is een risico-indicator voor 
atherosclerose, met name vanwege de invloed op het catabolisme van 
triglyceriderijke deeltjes. Atorvastatine therapie verlaagd het apoC-III gehalte van 
HDL en non-HDL (de apoB-100 bevattende) lipoprote'inen. De resultaten 
suggereren een mogelijk mechanisme van triglyceriden verlaging door atorvastatine. 
De triglyceriden reductie die gevonden wordt tijdens atorvastatine behandeling zou 
mogelijk verklaard kunnen worden door verandering van apoC-III e:x.--pressie. Deze 
resultaten tonen een in potentie belangrijk anti-atherogeen effect van statine 
therapie aan. 
In Hoofdstuk 6 is de mogelijke verklaring van het verschil in het !age HDL gehalte 
tussen mannen en vrouwen met type 2 diabetes beschreven. Vrouwelijke diabetes 
patienten hebben een relatief lage LPL activiteit ten opzichte van vrouwen zonder 
diabetes. Mannen met type 2 diabetes daarentegen hebben een verhoogde HL 
activiteit ten opzichte van mannen zonder diabetes. Het relatieflage HDL-C gehalte 
bij vrouwen wordt zeer wel mogelijk veroorzaakt door een afgenomen HDL 
synthese, veroorzaakt door de !age LPL activiteit. Bij de DALI mannen lijkt er een 
toegenomen klaring van HDL en/of apoA-1 te zijn, vermoedelijk veroorzaakt door 
de hoge HL activiteit. Er lijkt dus een verschil in etiologie mbt het HDL gehalte bij 
vrouwen en mannen te bestaan. Ondanks het feit dat atorvastatine geen invloed 
heeft op de LPL activiteit en een vergelijkbare afname in HL activiteit veroorzaakt 
bij mannen en vrouwen, is er geen verschil in het lipiden profiel na behandeling. 
In Hoofdstuk 7 is het effect van atorvastatine op de LDL subfracties beschreven. In 
patienten met type 2 diabetes is het LDL-C gehalte vaak niet verhoogd, maar zijn de 
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LDL deeltjes we! kleiner en bevatten ze relatief meer cholesterol ("small dense 
LDL"), waardoor ze beduidend atherogener zijn. Atorvastine behandeling zorgt 
voor een vermindering van het cholesterol gehalte in aile LDL subfracties, maar 
veranderde de deeltjes niet qua grootte. 
In Hoofdstuk 8 is het effect van verbetering van het lipiden profiel door 
atorvastatine op het cognitief functioneren in patienten met 1ype 2 diabetes 
beschreven. Er is met name een verbetering van het verbale geheugen te zien na een 
verbetering van het lipid en pro fie!. Ondanks bet feit dat er slechts een gering aantal 
patienten bestudeerd zijn, kunnen deze resultaten dienen voor het opzetten van 
grotere studies, aangezien het verbeteren van de cognitieve functie bij patienten met 
type 2 diabetes zou kunnen bijdragen aan een belangrijke verbetering van de 
kwaliteit van Ieven. 
In Hoofdstuk 9 zijn de implicaties van de bovengenoemde DAL! studie resultaten 
voor de behandeling van diabetische dyslipidemie beschreven. 
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